Statement by the independent bid committee of Aixia Group AB (publ) in relation to White Pearl Technology Group AB (publ):s public takeover offer

Gothenburg                                                                               2026-06-01 Statement by the independent bid committee of Aixia Group AB (publ) in relation to White Pearl Technology Group AB (publ):s public takeover offer Background This statement is made by the independent bid committee of Aixia Group AB (publ) (“Aixia” or the “Company”) in accordance with the Takeover Rules for certain trading platforms issued by the Swedish Securities Market Self-Regulation Committee (the “Takeover Rules”). On 1 June 2026, White Pearl Technology Group AB (publ), reg. no. 556939–8752 (“WPTG” or the “Bidder”), announced a public takeover offer to the shareholders of Aixia to transfer all shares in Aixia to WPTG (the “Offer”). The shares in Aixia are admitted to trading on Spotlight Stock Market. The shareholders of Aixia are offered 5.33 newly issued shares in WPTG in combination with SEK 10.00 in cash for each share in Aixia. Based on the volume-weighted average price of SEK 18.11 per WPTG share on Nasdaq First North Growth Market during the 15 trading days immediately preceding the announcement of the Offer, the Offer corresponds to an implied value of SEK 106.53 per share in Aixia (the “Offer Price”). The Offer is made on the same terms and for the same consideration for both series Aixia shares and series B shares in Aixia. The Offer Price corresponds to a premium of: •          approximately 31.5 percent compared to the closing price of SEK 81 for the Aixia share on Spotlight Stock Market on 29 May 2026, which was the last trading day before the announcement of the Offer; •          approximately 58.5 percent compared to the volume-weighted average price of SEK 67.23 for the Aixia share during the 30 most recent trading days before the announcement of the Offer; and •          approximately 54.1 percent compared to the volume-weighted average price of SEK 69.12 for the Aixia share during the 90 most recent trading days before the announcement of the Offer. The Offer values all shares in Aixia at approximately SEK 168 million, based on all 1,576,000 shares in the Company, of which 100,000 are series A shares and 1,476,000 are series B shares. Prior to the announcement of the Offer, WPTG held no shares or votes in Aixia. Shareholders representing approximately 56.0 percent of the shares and approximately 70.5 percent of the votes in Aixia have irrevocably undertaken to accept the Offer. The acceptance period for the Offer is expected to commence on or about 13 July 2026 and to expire on or about 10 August 2026. The Bidder has reserved the right to extend the acceptance period. Completion of the Offer is conditional upon, among other things, all requisite regulatory approvals, including from competition authorities and foreign direct investment authorities, being obtained on terms acceptable to WPTG, no materially adverse changes to the Company’s position occurring, and no competing offer on terms more favourable to the shareholders being made. WPTG has reserved the right to waive, in whole or in part, the conditions for completion of the Offer. For further information, reference is made to WPTG’s press release published on 1 June 2026. For further information, please see WPTG's website here:https://whitepearltech.com/offer/ The independent bid committee In order to handle matters relating to the Offer, the board of directors has instructed the independent members of the board to form an independent bid committee, consisting of Ellen Reinhardt and Johan Ljungqvist. The Company’s chairman of the board, Leif Nord, the CEO and board member Mattias Bergkvist, and the board member Christian Gustavsson have been assessed to have conflicts of interest under section II.18 of the Takeover Rules. Mattias Bergkvist and Christian Gustavsson have undertaken, subject to completion of the Offer to join the group management of WPTG. Mattias Bergkvist och Christian Gustavsson and Leif Nord has given an irrevocable undertaking to accept the Offer in respect of his shareholding. Accordingly, Leif Nord, Mattias Bergkvist and Christian Gustavsson have not participated, and will not participate, in Aixia’s handling of, or decisions on, matters relating to the Offer. These circumstances also mean that section IV of the Takeover Rules applies to the Offer, which entails, among other things, that the acceptance period shall be at least four weeks and that Aixia shall obtain and make public a valuation statement (a so-called fairness opinion) from independent experts regarding the fairness of the Offer from a financial point of view for the shareholders of the Company. The independent bid committee will therefore, in accordance with section IV.3 of the Takeover Rules, obtain a valuation statement from a valuation institution. For the valuation statement, the valuation institution will receive a fee that is independent of the size of the offer consideration and the level of acceptance in the Offer, as well as of whether or not the Offer is completed. Impact on the Company and its employees Under the Takeover Rules, the independent bid committee shall, based on the Bidder’s statement in the announcement of the Offer, set out its view of the impact that completion of the Offer may have on Aixia, in particular on employment, and its view of the Bidder’s strategic plans for the Company and the effects these may be expected to have on employment and on the locations where Aixia conducts its business. In this respect, the Bidder has stated, among other things, the following: “As at the date of this press release, no decisions have been made regarding any material changes that may affect Aixia’s employees or management, or the Company’s current organisation and operations, including terms of employment, the number of employees and the locations where the Company conducts its business, other than that Mattias Bergkvist and Christian Gustavsson will be offered to join the group management of WPTG. WPTG values Aixia’s employees and their competence and intends to work constructively with the Company’s management in order to realise the full potential of the combined group.” The independent bid committee assumes that this description is correct and has, in relevant respects, no reason to take a different view. The independent bid committee’s statement on the Offer In evaluating the Offer, the independent bid committee has considered a number of factors that the committee has deemed relevant, including the Company’s current strategic and financial position, prevailing market conditions and the expected future development of the Company, as well as related opportunities and risks. The independent bid committee has applied methods customarily used in the assessment of public takeover offers, including how the Offer values Aixia relative to comparable listed companies and comparable transactions, bid premiums in previous public takeover offers, and the committee’s view of the Company’s value based on expected future cash flows. The independent bid committee wishes to highlight the following considerations in particular. Considerations regarding the bid premium The Offer represents a premium of approximately 31.5 percent compared to the closing price of the Aixia share on 29 May 2026, the last trading day before the announcement of the Offer, and a premium of approximately 58.5 percent and approximately 54.1 percent, respectively, compared to the volume-weighted average price of the Aixia share during the 30 and 90 most recent trading days, respectively, before the announcement of the Offer. Considerations regarding the composition of the consideration The consideration in the Offer consists predominantly of newly issued shares in WPTG and only to a minor part legal tender. Shareholders who accept the Offer consequence become shareholders in WPTG, whose shares are admitted to trading on Nasdaq First North Growth Market. The Offer Price of SEK 106.53 per share in Aixia corresponds to an implied (implicit) value, based on the combined exchange value of, on the one hand, the shares that the shareholder in Aixia receives in WPTG in the transaction and, on the other hand, the legal tender component paid in the transaction. It has been calculated by valuing the 5.33 newly issued WPTG shares at the volume-weighted average price of the WPTG share of SEK 18.11 during the 15 trading days immediately preceding the announcement, to which the cash component of SEK 10.00 has been added. The Offer thus implicitly values each share in Aixia at SEK 106.53 at that point in time. Since the majority of the consideration consists of WPTG shares, the value actually received by a shareholder depends on the price development of the WPTG share and may deviate from SEK 106.53, both upwards and downwards. The independent bid committee urges shareholders to take this into account, as well as their own view of WPTG and the combined group. Considerations regarding historical trading and liquidity The independent bid committee notes that, during certain periods of the past twelve-month period, the Aixia share has traded at prices exceeding the Offer Price of SEK 106.53, and that approximately 10.4 percent of the Company’s total number of shares were traded at these higher levels during that year. The committee emphasises, however, that these particular peak prices during the period occurred under structurally very low liquidity, and that the share has not at any time since 20 January 2026 exceeded the Offer Price. During this past year, the average daily trading volume amounted to only approximately 1,128 shares, with a median turnover of less than SEK 88,000 per trading day. The committee therefore concludes that the prices recorded above the Offer Price during the past year have not been representative of a liquid market in which larger blocks of shares could have been divested. Against this background, the committee assesses and highlights that the Offer provides a guaranteed and attractive opportunity for realisation for all shareholders, at a level that significantly exceeds what the open market has been able to offer over the preceding four-month period. Considerations regarding the long-term value of Aixia While the independent bid committee supports the Company’s strategy and has a fundamentally positive view of the Company’s future, the possibility of realising the long-term value of the Company’s future cash flows is associated with risks. The independent bid committee cannot assert that the risk-adjusted long-term potential value of the Company exceeds the value of the Offer. Considerations for shareholders The independent bid committee notes that the Bidder has secured irrevocable undertakings corresponding to approximately 56.0 percent of the shares and approximately 70.5 percent of the votes in Aixia. As set out in the Offer, if WPTG, in connection with the Offer or otherwise, acquires shares corresponding to more than 90 percent of the total number of shares in Aixia, WPTG intends to initiate compulsory acquisition under the Swedish Companies Act (2005:551) in order to acquire all remaining shares and to procure that Aixia’s shares are delisted from Spotlight Stock Market. In such a procedure, shareholders who do not accept the Offer are also expected ultimately to have their shares redeemed. The independent bid committee further notes that acceptance of the Offer during the acceptance period generally results in the shareholder receiving the consideration sooner than through a compulsory acquisition procedure. The independent bid committee’s preliminary position and intention to recommend Based on an overall and preliminary evaluation of the terms presented and the significant industrial synergies of the combination, the independent bid committee is very positive towards the Offer. It is the committee’s unanimous intention to recommend that the shareholders of Aixia accept the Offer. The committee wishes to emphasise, however, that a formal and final statement, in accordance with the Takeover Rules, is contingent upon a review of the independent valuation statement (a so-called fairness opinion) that is currently being procured from external experts. The complete and final statement will be published in good time, and no later than two weeks before the expiry of the acceptance period. Other This statement shall be governed by Swedish law and shall be construed in accordance therewith. Any dispute arising in connection with this statement shall be settled exclusively by the Swedish courts. This statement has been published in a Swedish and an English version. In the event of any discrepancy between the two versions, the Swedish version shall prevail. For more information, please contact: Johan Ljungqvist, chairman of the independent bid committee. Telephone: +46 70 582 20 50. Email: johan.ljungqvist@symetri.com. This information is information that Aixia Group AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation (EU) No 596/2014. The information was submitted for publication, through the agency of the contact person set out above, on 1 July 2026 at 07:02 CEST.

Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab

Oslo, Norway, 1 June 2026 - Lytix Biopharma ASA ("Lytix" or the "Company"), a clinical-stage immuno-oncology company developing novel intratumoral cancer therapies, today announced that clinical data evaluating intratumoral ruxotemitide (LTX-315) in combination with pembrolizumab in patients with advanced melanoma and metastatic triple-negative breast cancer (TNBC) has been  presented in a poster session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, USA. The poster, entitled "Safety and Efficacy of Intratumoral (IT) Ruxotemitide (LTX-315) in Combination with Pembrolizumab in Patients with Unresectable Advanced Melanoma or Triple Negative Breast Cancer (TNBC)," presents pooled data from two open-label Phase II studies of intratumoral ruxotemitide plus pembrolizumab in patients with advanced melanoma who had progressed following prior anti PD-1/PD-L1 therapy and in patients with metastatic TNBC. Key efficacy observations from the pooled analysis include: · Antitumor activity was observed in heavily pretreated patients with advanced melanoma and metastatic TNBC, two populations with limited therapeutic options. · Durable responses was obtained in melanoma patients in the context of prior PD-1/PD-L1-refractory disease. · Systemic activity was noted, including tumor regression in non-injected lesions, supporting the potential of ruxotemitide to induce broader immune activation following local intratumoral administration. · The safety profile observed across the studies was broadly consistent with the known effects of intratumoral immunotherapy and pembrolizumab, and the combination was manageable. The poster was presented by Prof. Aurélien Marabelle of Gustave Roussy, France, a senior clinical investigator in cancer immunotherapy with dedicated expertise in intratumoral treatment approaches. Prof. Marabelle leads clinical and translational work focused on immune-targeted therapies and intratumoral immunotherapy and serves on the Board of Directors of the Society for Immunotherapy of Cancer (SITC).  “The pooled Phase II data show that intratumoral ruxotemitide in combination with pembrolizumab was generally manageable and demonstrated antitumor activity in two difficult-to-treat patient populations: advanced melanoma after prior anti-PD-1/PD-L1 therapy and metastatic triple-negative breast cancer,” said Prof. Aurélien Marabelle of Gustave Roussy, France. “The observation of durable responses in melanoma, disease stabilization across both studies and activity in non-injected lesions supports further clinical evaluation of this intratumoral immunotherapy approach, including in earlier treatment settings.” “These Phase II data represent an important step in building the clinical rationale for ruxotemitide as a differentiated intratumoral immunotherapy,” said Øystein Rekdal, Chief Executive Officer of Lytix Biopharma. “Our ambition is to use local tumor destruction to initiate broader systemic antitumor immunity and thereby improve the depth and durability of responses to checkpoint inhibition. The ASCO findings strengthen our conviction that ruxotemitide should be advanced into earlier treatment settings, where immune activation may have the greatest potential to change patient outcomes.” About Ruxotemitide (LTX-315) Ruxotemitide (LTX-315) is a first-in-class oncolytic peptide designed for intratumoral administration. The molecule disrupts tumor cells locally, leading to the release of tumor antigens and danger-associated molecular signals that may activate systemic antitumor immune responses. This mechanism has the potential to convert immunologically "cold" tumors into "hot" tumors and enhance responses to checkpoint inhibitor therapies. About Lytix Biopharma Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with a highly differentiated oncolytic molecule platform based on world-leading research in host-defense peptide-derived molecules. Lytix Biopharma's lead product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule representing a new approach to maintaining durable anti-cancer immunity. Lytix Biopharma has a pipeline of molecules that work across multiple cancer indications and treatment settings, both as monotherapy and in combination therapy. Lytix is listed on Euronext Growth Oslo under the ticker LYTIX. For more information, visit www.lytixbiopharma.com.

Sinch appoints Sophie Cheng as Chief Marketing Officer

At Sinch, Sophie has led the company’s global product marketing and revenue enablement organization, helping strengthen market positioning, industry analyst relations and go to market execution. Prior to joining Sinch in 2024, she held senior leadership roles at ZoomInfo and Chorus.ai supporting rapid commercial growth and helping businesses improve how they engage with customers using AI-driven technologies. “Sophie brings a rare combination of strategic vision, operational excellence and deep understanding of both product and customer needs. She has already made a significant impact a Sinch through her leadership of our global product go-to-market organization. She is a modern marketing leader with a clear vision for how to elevate our market presence, strengthen customer relevance and position Sinch for continued growth,” says Laurinda Pang, CEO of Sinch. “I’ve seen firsthand the scale of Sinch’s ambition and the massive opportunity ahead as AI transforms how businesses communicate with consumers. I’m excited to expand my scope and turn customer and market intelligence into growth, innovation and more meaningful customer experiences. We’re only scratching the surface of what’s possible and I’m grateful for the trust as we continue building the future of customer communications,” says Sophie Cheng.           For more information, please contact: Fredrik Hallstan Director Corporate Communications Mobile: +46 761 15 38 30 E-mail: fredrik.hallstan@sinch.com Mia Nordlander SVP Investor Relations & Sustainability Mobile: +46 73 511 53 95 E-mail: mia.nordlander@sinch.com

Acquisitions of own shares in Evolution AB (publ)

The repurchase program, which Evolution announced on 18 May 2026, is being implemented in accordance with the EU Market Abuse Regulation No 596/2014 (“MAR”) and the Commission Delegated Regulation No 2016/1052 (“Safe Harbour Regulation”). During the period 25 May 2026 – 29 May 2026, shares in Evolution have been acquired as set out below. Date Aggregated daily Weighted average Transaction volume (number of price per day value per day shares) (SEK) (SEK)2026  137,560  703.1479  96,725,025.12-05-252026  136,992  699.9137  95,882,577.59-05-262026  135,025  690.7533  93,268,964.33-05-272026  139,974  684.5916 95,825,024.62-05-282026  142,634  693.2549 98,881,719.41-05-29 All acquisitions were carried out on Nasdaq Stockholm on behalf of Evolution by Citibank which makes its trading decisions concerning the timing of the purchases of shares independently of Evolution. Following the above acquisitions, Evolution’s holding of own shares amounted to 1,227,987 as of 29 May 2026. The total number of shares in Evolution is 199,226,613. Since 19 May 2026 up to and including 29 May 2026, a total of 1,227,987 shares have been acquired within the scope of the program. A maximum of 19,922,661 shares in total may be acquired. For further information, please contact:Joakim Andersson, CFO, ir@evolution.com. The information was submitted for publication, under the agency of the contact person set out above, on 1 June 2026, at 07:30 CEST.

Qlife enters fully funded feasibility agreement with global pharma company for Egoo Health biomarker application

The feasibility study represents a first step toward a potential collaboration focused on dedicated R&D and regulatory proceedings and future supply of Egoo Health systems for the targeted application. While the pharmaceutical partner remains undisclosed at this stage, the collaboration is anchored in a defined clinical and commercial use case where decentralized, high quality biomarker measurement is viewed as strategically important. “This feasibility program is designed to answer the technical and integration questions required to move into a long-term development and supply collaboration. Our partner has a clear strategic interest in this application, and the structure of the project reflects that ambition.” said Thomas Warthoe, CEO of Qlife. Strengthening Qlife’s partner driven growth model This announcement underscores Qlife’s continued strategic focus on partner‑led development, where global pharmaceutical and diagnostics companies leverage the Egoo platform as a scalable backbone for biomarker-driven therapeutic applications. The Company is increasingly focusing its R&D investments on co‑development models that: · Reduce time from feasibility to deployment · Enable application‑specific optimisation · Support long‑term supply and lifecycle collaboration This approach allows Qlife to concentrate resources on programs with clear commercial pull and defined downstream economics. Qlife will provide further updates as key milestones are achieved.

Latour strengthens its presence in the energy metering market through the acquisition of UK-based cThings

Investment AB Latour (publ) has, through its subsidiary Elvaco AB, part of business area Bemsiq Group, acquired 100 per cent of the shares in cThings Limited. cThings provides an end-to-end hardware and software solution primarily focused on energy usage. Founded in 2017, the company has 9 employees and is headquartered in Cambridge, United Kingdom. The company develops and markets a platform that enables property managers, energy suppliers and residents to easily monitor and optimize energy consumption in buildings and heat networks. cThings has an annual turnover of 2.5 MGBP (FY2025) with a profitability level well above Latour’s financial targets. In recent years, Elvaco has established a strong position in the market for the collection, processing and presentation of metering data. cThings will be established as Elvaco’s central unit in the United Kingdom, thereby strengthening Elvaco’s presence in the UK. "We continuously strive to identify innovative products and solutions that strengthen our customer offering. cThings is an exciting company with a strong software platform that complements our subsidiary Elvaco very well", says Anselmi Immonen, CEO of Bemsiq Group. "With Elvaco and Bemsiq as owners, we have an excellent opportunity to accelerate our growth journey, and we very much look forward to the next step together", continues Dominic Chapman, Founder and CEO of cThings. As a result of the acquisition, the Latour Group’s net debt (excluding IFRS 16) is expected to increase compared with the net debt level at the end of March 2026, to approximately SEK 15.4 billion, all else being equal. Gothenburg, 1 June, 2026 INVESTMENT AB LATOUR (PUBL)Johan Hjertonsson, President and CEO For further information, please contact:Anselmi Immonen, CEO Bemsiq Group, +358 50 911 8068Erik Wikström, CEO Elvaco AB, +46 705 35 79 95Fredrik Lycke, Investment Director, Investment AB Latour, +46 793 40 28 02 Bemsiq Group, with headquarters in Gothenburg, Sweden, has an annual turnover of SEK 2.1 billion SEK and employs about 700 persons. Bemsiq consists of a group of innovative and fast growing companies providing products in building automation and metering and is one of seven wholly-owned business areas within the Latour Group. Investment AB Latour is a mixed investment company consisting primarily of a wholly-owned industrial operations and an investment portfolio of listing holdings in which Latour is the principal owner or one of the principal owners. The investment portfolio consists of ten substantial holdings with a market value of SEK 81 billion as of 30 April, 2026. The wholly owned industrial operations have an annual turnover of approx. SEK 28 billion.

Traffic figures May 2026: Freetrailer delivers 198,248 rentals and breaks daily records multiple times

Freetrailer once again set a new monthly record, while the number of rentals over the trailing 12 months increased to 1,804,479, representing 18.3% growth compared to the same period last year. This development is supported by the continued expansion of the trailer fleet, new partnerships, and consistently high customer satisfaction levels, which together contribute to increased activity and stronger market positions across Freetrailer’s European markets.  Comment from the Group CEOThomas Zeihlund, Group CEO of Freetrailer Group A/S, states: “The strong performance in May confirms that the peak season is now fully underway, but also that our team is ready to deliver a great user experience through a well-functioning trailer fleet, high system uptime, strong marketing engagement, and excellent support for the relatively few customers who require assistance from our customer service team. In May, we launched a new initiative called Freetrailer on Tour, aimed at both potential and existing users, where we meet them directly at our partner locations. It is important for us to get closer to our customers and increase awareness of the Freetrailer concept where they already use our solution in their everyday lives. This direct dialogue provides valuable insights and strengthens our relationships.We are entering the summer season with strong momentum and a continued focus on scalable operations, high availability, and a simple, seamless user experience.”

TP Aerospace strengthen commercial focus with the appointment of Mike Humphreys as Chief Executive Officer (CEO)

The board of directors has appointed Mike Humphreys as the new CEO of TP Aerospace effective 1 June 2026.  Mike has up until now been a non-executive director of TP Aerospace and has been part of forming the existing strategy and will bring increased focus on commercial delivery. He has more than 35 years of experience from the commercial aviation aftermarket, having held C-suite roles in a number of companies such as FLS Aerospace, SR Technics and, most recently, as President of Airinmar.  Flemming Jensen, Chairman of the Board, said: “I am very pleased that Mike has agreed to take up the role as CEO of TP Aerospace. He brings significant experience from past CEO roles where he has demonstrated strong focus on commercial roll out. We believe that these skills will benefit TP Aerospace after a period of preparing the platform for future growth.”  Commenting on his new appointment, Mike said: “I am delighted to accept the role of CEO and join a company that I have been closely engaged with as a non-executive director. I am looking forward to working with the TP Aerospace leadership and the whole green team to lead the execution of our strategy”.  Flemming Jensen, Chairman of the board said: “On behalf of the company and all shareholders, I would like to thank Nikolaj Jacobsen, departing CEO for his contribution to TP Aerospace, where he has held the role as CEO since 2022. Nikolaj has been instrumental in preparing the business for future growth”.

Svalner Atlas joins forces with Ryan to create leading European tax and transaction advisory firm with global reach

Founded through the combination of leading independent advisory firms across Northern Europe, Svalner Atlas has established itself as one of the region's premier independent tax and transaction advisory groups, with over 450 professionals across multiple European markets. "Over the past years, we have built a highly respected firm with an exceptional team, a strong entrepreneurial culture, and a client offering that combines local expertise with international reach," said Viktor Sandberg, Group CEO of Svalner Atlas. "By joining Ryan, a firm that shares our entrepreneurial mindset, commitment to quality, and ambition to build a leading international advisory platform, we gain access to a stronger platform for continued growth, expanded capabilities, and broader international reach, while remaining true to our culture and client-centric approach." Headquartered in Plano, Texas, Ryan is widely recognized as a leading global tax services and software provider. With more than 7,100 professionals spanning multiple continents, Ryan combines deep tax expertise with innovative technology to help organizations manage complexity, reduce tax burden, and unlock capital for growth. The firm serves many of the world's largest multinational companies through a comprehensive suite of tax advisory, compliance, recovery, advocacy, and technology solutions.“This transaction is an important milestone in Ryan’s continued European growth strategy,” said G. Brint Ryan, Chairman and CEO of Ryan. “Svalner Atlas Advisors has built an exceptional reputation for delivering cross-border tax and transaction advisory services across the region. Their strong local presence, international reach, and client-focused culture align closely with Ryan’s values and strategic vision.” The transaction represents a successful exit for Consolid, the Stockholm-based private equity firm that backed Svalner Atlas at its formation in 2023 and supported the group's expansion across the Nordics and Benelux.This move creates a powerful platform for continued expansion across Europe, strengthening support for multinational clients, private equity firms, and large international businesses through highly specialized advisory services. The combination of Svalner Atlas' deep advisory expertise with Ryan's global scale and technology-enabled capabilities creates new opportunities for long-term value creation for clients and employees alike. Svalner Atlas will, for the time being, continue to operate under its existing brand with its current leadership team and organizational structure, ensuring continuity for clients and employees. Viktor Sandberg will continue as President of Northern Europe and take a seat on the Ryan Tax Holdings board.

Elkem ASA – Final results of the subsequent offering and allocation of offer shares

NOT FOR DISTRIBUTION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG OR JAPAN, OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. Oslo, 1 June 2026 Reference is made to the stock exchange announcement made by Elkem ASA (the "Company") on 15 May 2026 regarding the commencement on 18 May 2026 of the subsequent offering of up to 11,111,111 new shares in the Company (the "Offer Shares") at a subscription price of NOK 27 per Offer Share (the "Subsequent Offering"), and the stock exchange announcements made on 29 May 2026, informing of the last day of the subscription period in the Subsequent Offering and the preliminary results of the Subsequent Offering. The subscription period in the Subsequent Offering expired on 29 May 2026, at 16:30 hours (CEST). The final results show that the Company has received valid subscriptions for a total of 29,419,772 Offer Shares. Hence, 11,111,111 Offer Shares, will be issued in the Subsequent Offering. The Company raised approximately NOK300 million in gross proceeds through the Subsequent Offering. The allocations are expected to be made available through Euronext Securities Oslo, the central securities depositary in Norway (Nw. Verdipapirsentralen) (the ES-OSL) on or about 1 June 2026. The deadline for payment for the allocated Offer Shares is 3 June 2026, in accordance with the payment instructions set out in the Company's prospectus dated 15 May 2026 (the "Prospectus"). The Offer Shares may not be transferred or traded until they are fully paid and the share capital increase pertaining to the Subsequent Offering has been registered with the Norwegian Register of Business Enterprises (Nw.: Foretaksregisteret). Subject to timely payment of the Offer Shares subscribed for and allocated in the Subsequent Offering, the delivery of the Offer Shares is expected to be completed on or about 8 June 2026, and the Offer Shares are expected to commence trading on the Oslo Stock Exchange at the same date. The Managers (as defined below) may be contacted for information regarding allocation, payment and delivery of the Offer Shares. Information about the Subsequent Offering and the settlement procedures is also included in the Prospectus. Following the issuance of the 11,111,111 Offer Shares, the Company's share capital will be NOK 1,838,847,540, divided into 367,769,508 shares, each with a nominal value of NOK 5. ABG Sundal Collier ASA is acting as sole global coordinator and joint bookrunner and Danske Bank A/S, NUF, DNB Carnegie, a part of DNB Bank ASA, Nordea Bank Abp, filial i Norge and Skandinaviska Enskilda Banken AB (publ), Oslo branch are acting as joint bookrunners in the Subsequent Offering (together, the "Managers"). Advokatfirmaet Thommessen AS is acting as legal advisor to the Company in relation to the Subsequent Offering. For further information, please contact:Odd-Geir LyngstadVP Finance & Investor RelationsEmail: odd-geir.lyngstad@elkem.comTel: +47 976 72 806 This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. About Elkem ASA:Elkem is a global metals and materials company established in 1904. The company holds leading positions in silicon, ferrosilicon, foundry alloys and carbon solutions, supplying materials essential to modern society – from critical infrastructure and manufacturing to digitalisation, mobility and energy solutions. Elkem produces its materials by combining natural raw materials, renewable energy and advanced process technology, creating solutions that enable a more sustainable future. The company employs around 3,000 people, operates in more than 30 locations across Europe, Asia, the Americas and Africa, and is headquartered in Oslo, Norway where it is listed on the Oslo Stock Exchange (ELK). Driven by innovation. Powered by nature. Shaping the future. Important informationThis announcement is not and does not form a part of any offer of securities for sale, or a solicitation of an offer to purchase, any securities of the Company in the United States or any other jurisdiction. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. The securities referred to in this announcement have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and accordingly may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and in accordance with applicable U.S. state securities laws. The Company does not intend to register any part of the Subsequent Offering in the United States or to conduct a public offering of securities in the United States. Any sale in the United States of the securities mentioned herein will be made solely to "qualified institutional buyers" (QIBs) as defined in Rule 144A under the Securities Act, pursuant to an exemption from the registration requirements under the Securities Act, as well as to major U.S. institutional investors pursuant to an exemption under SEC Rule 15a-6 to the United States Exchange Act of 1934, as amended. This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the "EU Prospectus Regulation") (together with any applicable implementing measures in any Member State). The securities offered in the Subsequent Offering are offered on the basis of a Prospectus prepared by the Company and dated 15 May 2026, which is available on the website of ABG Sundal Collier ASA (www.abgsc.com/transactions), Danske Bank A/S, NUF (www.danskebank.com/elkem), DNB Carnegie, a part of DNB Bank ASA (www.dnb.no/emisjoner), Nordea Bank Abp, filial i Norge (www.nordea.com/en/issuances) and Skandinaviska Enskilda Banken AB (publ), Oslo branch (www.seb.no). Investors in the Subsequent Offering should not subscribe for any securities in the Subsequent Offering except on the basis of the Prospectus. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e. only to investors who can receive the offer without an approved prospectus in such EEA Member State. This communication is only being distributed to and is only directed at (i) persons in the United Kingdom, who have professional experience, knowledge and expertise in matters relating to investments and qualify as "investment professionals" for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the "Order"), (ii) persons who are outside the United Kingdom, and (iii) any other person to whom it can otherwise be lawfully distributed (all such persons being referred to as "relevant persons") and any investment or investment activity to which this communication relates is available only to and will be engaged in only with relevant persons, and any person other than a relevant person should not rely on it. The Offer Shares are being offered only in circumstances falling within the circumstances set out in Part 1 of Schedule 1 to The Public Offers and Admissions to Trading Regulations 2024 (the “POATRs”) (including, amongst other circumstances, the fact that the Offer Shares which are the subject of the Subsequent Offering are offered subject to a minimum subscription amount per UK applicant equivalent to at least GBP 100,000). Consequently, the Offer Shares may be offered only to “qualified investors” as defined in paragraph 15 of Schedule 1 to the POATRs, or otherwise to limited numbers of UK investors, or only where the minimum consideration required for the securities offered is GBP 100,000. Persons distributing this communication must satisfy themselves that it is lawful to do so. Matters discussed in this announcement may constitute forward-looking statements concerning future events, including possible issuance of equity securities of the Company. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this communication are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Actual events may differ significantly from any anticipated development due to a number of factors, including, but not limited to, changes in investment levels and need for the group's services, changes in the general economic, political, and market conditions in the markets in which the group operate, and changes in laws and regulations. Such risks, uncertainties, contingencies, and other important factors include the possibility that the Company will determine not to, or be unable to, issue any equity securities, and could cause actual events to differ materially from the expectations expressed or implied in this communication by such forward-looking statements. The Company does not make any guarantees that the assumptions underlying the forward-looking statements in this communication are free from errors. The information, opinions and forward-looking statements contained in this communication speak only as at its date and are subject to change without notice. Each of the Company, the Managers, and their respective affiliates expressly disclaims any obligation or undertaking to update, review, or revise any statement contained in this communication whether as a result of new information, future developments or otherwise, unless required by laws or regulations. The Managers are acting exclusively for the Company and no one else in connection with the Subsequent Offering and will not be responsible to anyone other than the Company for providing the protections afforded to its clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein. Neither the Managers nor any of their respective affiliates make any representation as to the accuracy or completeness of this announcement and none of them accepts any liability arising from the use of this announcement or responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Certain figures contained in this announcement have been subject to rounding adjustments. Accordingly, in certain instances, the sum or percentage change of the numbers contained in this announcement may not conform exactly with the total figure given. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction. Specifically, neither this announcement nor the information contained herein is for publication, distribution or release, in whole or in part, directly or indirectly, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia), Australia, Canada, Hong Kong, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction.

Buybacks of shares by H&M during week 22, 2026. The share buyback programme for the company’s long-term incentive program (LTIP) is now complete and has been closed.

Between 11 May 2026 and 29 May 2026 H & M Hennes & Mauritz AB (publ) (LEI code 529900O5RR7R39FRDM42) has repurchased in total 1,400,000 of the company’s own class B shares (ISIN: SE0000106270) as part of the share buyback programme initiated by the board of directors. Shares with a total value of SEK 228,094,341.09 have now been repurchased, and as a result the programme is being closed. The share buybacks in week 22 form part of the around SEK 280 million share buyback programme that H&M announced on 11 May 2026. The programme aims to secure delivery of class B shares to the participants in the company’s long-term incentive program (LTIP). The share buyback programme, which ran between 11 May 2026 and 29 May 2026, made its final purchases of shares on 29 May 2026 and is now closed. The programme has been carried out in accordance with Regulation (EU) No 596/2014 on market abuse (the Market Abuse Regulation – MAR) and Commission Delegated Regulation (EU) 2016/1052 (known as the Safe Harbour Regulation). H&M class B shares have been repurchased as follows: Date: Aggregated daily Weighted average Total daily volume (number of share price per day transaction value shares): (SEK): (SEK):25 May 2026 100,262 165.0218 16,545,415.7126 May 2026 104,616 162.0341 16,951,359.4127 May 2026 102,383 164.3888 16,830,618.5128 May 2026 120,000 164.8402 19,780,824.0029 May 2026 98,188 164.1615 16,118,689.36Total 525,449 164.1014 86,226,906.99accumulatedoverweek22/2026Total 1,400,000 162.9245 228,094,341.09accumulatedduring thebuybackprogramme All acquisitions have been carried out on Nasdaq Stockholm by Skandinaviska Enskilda Banken AB on behalf of H&M. Following the above acquisitions, H&M’s holding of treasury shares as at 29 May 2026 amounts to 2,500,000 class B shares (including 1,100,000 treasury shares that were acquired between 26 June 2025 and 17 July 2025 to secure delivery of class B shares to the participants in the company’s long-term incentive programme (LTIP)). The total number of shares in H&M, including treasury shares, is 1,598,873,003 and the number of shares outstanding, excluding treasury shares, is 1,596,373,003. Contact:Joseph Ahlberg, Head of Investor RelationsTelephone: +46 73 465 93 92E-mail: joseph.ahlberg@hm.com For more information from the H&M group and press images visit hmgroup.com/media. H & M HENNES & MAURITZ AB (PUBL) was founded in Sweden in 1947 and is listed on Nasdaq Stockholm. H&M’s business idea is to offer fashion and quality at the best price in a sustainable way. The group’s brands are H&M (including H&M HOME, H&M Move and H&M Beauty), COS, Weekday (including Cheap Monday and Monki), & Other Stories, ARKET, Singular Society and Sellpy. The group also includes several ventures. For further information, visit hmgroup.com.

Tieto completes the divestment of Tieto Indtech’s Edlevo and HR&Payroll software businesses to EG

Tieto Corporation       PRESS RELEASE        1 June 2026 12:45 p.m. EEST On 18 February 2026, Tieto announced an agreement to sell two of Tieto Indtech’s software businesses, Edlevo and HR& Payroll, to EG, an industry-specific software provider operating in the Nordics. Tieto has completed the transaction today 1 June 2026. The cash and debt free purchase price (enterprise value) for the divested operations amounts to EUR 95 million. As communicated at signing, Tieto intends to use the proceeds in accordance with the company’s capital allocation policy. For further information, please contact: Tieto Newsdesk, news (at) tieto.com, tel. +358 40 570 4072Tommi Järvenpää, Head of Investor Relations, tel. +358 40 576 0288, tommi.jarvenpaa (at) tieto.com Tieto Corporation DISTRIBUTION Principal Media Tietois a leading software and digital engineering services company with global market reach and capabilities. We provide customers across different industries with mission-critical solutions through our specialized software businesses Tieto Caretech, Tieto Banktech and Tieto Indtech, as well as our digital engineering business Tieto Tech Consulting. Our around 14 000 talented vertical software, design, cloud and AI experts are dedicated to empowering our customers to succeed and innovate with latest technology. Tieto’s annual revenue is approximately EUR 2 billion. The company’s shares are listed on the NASDAQ exchange in Helsinki and Stockholm, as well as on Oslo Børs.www.tietoevry.com

Vitrolife Group appoints Olivier Desmarets as Chief Operations Officer following Ermanno Sironi’s retirement

Vitrolife Group today announces the appointment of Olivier Desmarets as Chief Operations Officer (COO), effective 1 June 2026, following the retirement of Ermanno Sironi. In this role, Olivier Desmarets will be responsible for leading the company’s global operations, including Manufacturing, Labs, Supply chain & Procurement, Quality, Customer Care, IT and further strengthening operational performance across the organisation. Ermanno Sironi has played a key role in advancing Vitrolife Group’s operational capabilities and driving several important transformation initiatives over the past two years. His contributions have helped position the company for continued growth and improved efficiency. “On behalf of the company, I would like to extend my sincere gratitude to Ermanno for his strong leadership and valuable contributions, and I wish him all the best in his well-earned retirement,” says Bronwyn Brophy, CEO of Vitrolife Group. Olivier Desmarets brings more than 20 years of international leadership experience within MedTech and diagnostics companies. He joins the Vitrolife Group from miDiagnostics, where he served as Vice President Operations. Throughout his career, he has held senior roles across a range of organisations, including Johnson & Johnson and The Carlyle Group. His breadth of experience includes all areas of operations and he has worked in global environments spanning EMEA, APAC, and North America. “We are delighted to welcome Olivier to Vitrolife Group as our new COO. Olivier brings a strong track record of operational excellence and extensive international experience, which will be instrumental as we continue to execute our strategy, drive further efficiency and productivity and scale for future growth", says Bronwyn Brophy. In his role as COO, Olivier Desmarets will join the Executive Management Team and report to CEO Bronwyn Brophy.

Scania strengthens European capacity for electric truck production

The investment includes an extension of the existing facility and the adaptation of assembly lines for electric truck production. It will strengthen Scania’s industrial footprint in France and further develop the company’s capability to support the transition towards more sustainable transport solutions.Angers has been part of Scania’s industrial system for more than three decades and plays an important role in serving customers in France and across Europe. The site has consistently demonstrated strong industrial performance and adaptability, making it a recognised and reliable contributor within Scania’s production network. The planned investment builds on the site's existing capabilities and supports Scania’s long-term strategy to develop the technologies, industrial capabilities and partnerships needed for the future of transport.“This investment reflects our ambition to secure the long-term future of the Angers site while increasing its flexibility. We are preparing for the future, but we must remain able to adapt to changing volumes and market dynamics. The site will be capable of assembling both combustion engine and electric trucks, ensuring we can respond to evolving customer demand,” says Petrus Sundvall, President of Scania Production Angers.“The transition to electrified transport is not only about vehicles. It is about creating the conditions that enable transport operators to invest with confidence. Access to charging infrastructure, renewable electricity and predictable policy frameworks will be critical to accelerating the shift. Scania is investing to support this transition, but lasting progress will depend on how quickly the entire transport ecosystem can move forward together,” says Christian Levin, President and CEO of Scania.The transition of heavy transport is an important part of Europe’s climate ambitions. Reducing emissions from road transport will require action across the entire value chain, from vehicle manufacturers and transport operators to energy providers, infrastructure developers and policymakers.Scania continues to invest across its value chain to help enable this transition, including vehicle technology, battery systems, industrial capabilities and charging solutions. The investment in Angers is a concrete example of how Scania is building the capacity needed to support the future transport system.“Europe has set ambitious targets for reducing emissions from transport. Achieving those ambitions will require coordinated action across the entire value chain. Transport operators need the confidence to invest, infrastructure needs to be deployed at scale, and regulatory frameworks must support long-term planning. This investment demonstrates Scania’s commitment to contributing to that transition and helping create the conditions for a more sustainable transport system,” says Christian Levin.The investment in Angers represents another step in Scania’s broader commitment to driving the shift towards a sustainable transport system. By strengthening its production capacity for electric trucks, Scania is helping create the conditions for a transport system that is both more sustainable and more competitive.Explore Scania ’s battery-electric transport solutions .

Wyld Networks’ rights issue heavily oversubscribed – publishes preliminary outcome

Wyld Networks’ rights issue heavily oversubscribed – publishes preliminary outcome NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Wyld Networks AB ("Wyld Networks" or the "Company") hereby announces the preliminary outcome of the rights issue of shares, which was approved by the Extraordinary General Meeting on May 6, 2026 (the "Rights Issue"). The preliminary outcome indicates that 423,303,537 shares, corresponding to approximately 393 percent of the Rights Issue, have been subscribed for with and without support of subscription rights. The underwriting commitments will therefore not be utilized. The Rights Issue will preliminarily provide the Company with proceeds of approximately SEK 16.2 million before issue costs. Preliminary outcome of the Rights Issue The subscription period in the Rights Issue ends today, June 1, 2026. The preliminary outcome indicates that 98,002,008 shares, corresponding to approximately 91 percent of the Rights Issue, have been subscribed for with subscription rights in the Rights Issue. In addition, applications have been received to subscribe for 325,301,529 shares without subscription rights, corresponding to approximately 302 percent of the Rights Issue. Thus, the preliminary outcome indicates that the Rights Issue, with and without subscription rights, is subscribed to approximately 393 percent and that underwriting commitments will not be utilized. Allotment of shares subscribed for without subscription rights Allotment of shares subscribed for without subscription rights is made in accordance with the principles set out in the information document published by the Company on May 13, 2026, in connection with the Rights Issue. Notification of such allocation will be notified separately though a settlement note. Nominee-registered shareholders will receive notification of allotment in accordance with instructions from the respective nominee. Final outcome and trading in paid subscribed shares ("BTA") The final outcome of the Rights Issue is expected to be announced on June 2, 2026. The last day of trading in BTA is expected to be June 16, 2026. Trading in the new shares subscribed for with and without subscription rights is expected to commence on Nasdaq First North Growth Market on or about June 19, 2026. Advisor Mangold Fondkommission AB is financial advisor to the Company in connection with the Rights Issue. For further information, please contact: Kjell Olovsson, CEO Wyld NetworksE-mail: kjell.olovsson@wyldnetworks.com This information is information that Wyld Networks is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on June 1, 2026, at 16:20 CEST. About Wyld Networks Wyld Networks develop and sells innovative wireless technology solutions that enables affordable connectivity anywhere in the World, addressing the problems for businesses and people regarding the lack of global mobile network coverage. The solutions are mainly targeted to wireless connectivity for the Internet of Things (IoT) and people. Wyld Networks Ltd was formed in Cambridge, UK in 2016 and is a wholly owned subsidiary of Wyld Networks AB. The Wyld Networks share (WYLD) is traded on the Nasdaq First North Growth Market. Certified Adviser to Wyld Networks is Mangold Fondkommission AB. Read more on: www.wyldnetworks.com  Important information The information in this press release neither contains nor constitutes an offer to acquire, subscribe for or otherwise trade shares, warrants or other securities in Wyld Networks. No action has been taken and no action will be taken to allow an offer to the public in any jurisdiction other than Sweden. This press release is not a prospectus within the meaning of the Prospectus Regulation (EU) 2017/1129 ("Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. No prospectus will be prepared in connection with the Rights Issue. The Company has prepared and published an information document in the form prescribed in Annex IX to the Prospectus Regulation. This press release neither identifies nor purports to identify risks (direct or indirect) that may be associated with an investment in shares, warrants or other securities in the Company. The information in this press release is only intended to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance shall be given with respect to the accuracy or completeness of the information in this press release. This press release constitutes marketing in accordance with Article 2(k) of the Prospectus Regulation. The information in this press release may not be published, released or distributed, directly or indirectly, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require other actions than those following from Swedish law. Actions in violation of this instruction may constitute violations of applicable securities laws. No shares, warrants or other securities in Wyld Networks have been registered, and no shares, warrants or other securities will be registered, under the then-applicable United States Securities Act of 1933 (the "Securities Act") or securities legislation in any state or other jurisdiction in the United States, and may not be offered, sold or otherwise transferred, directly or indirectly, in or to the United States except in accordance with an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with securities legislation in the relevant state or other jurisdiction in the United States. In the United Kingdom, this document and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, “qualified investors” who are (i) persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as “relevant persons”). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it. Forward-looking statements This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is required by law or the regulations of the Nasdaq First North Growth Market for issuers.

Wärtsilä has completed the divestments of Water & Waste to Solix Group AB and Gas Solutions to Mutares SE & Co. KGaA

Technology group Wärtsilä has today completed two divestments: divesting the Gas Solutions business to Mutares SE & Co. KGaA, following the agreement announced  on 22 December 2025, and divesting Water & Waste business to Solix Group AB, following the agreement announced  on 5 February 2026. Gas Solutions, with the annual revenue of EUR 394 million in 2025, provides its customers with innovative systems and comprehensive lifecycle solutions for the gas value chain. Water & Waste, with annual revenue of EUR 54 million in 2025, focuses on environmental solutions across the full spectrum of water and waste management at sea. The financial performance of both businesses has been below Wärtsilä’s profitability targets. These business units with their employees will transfer to the respective new owners on 1 June 2026. By completing the divestments of the Gas Solutions and Water & Waste, Wärtsilä Portfolio Business will have no remaining business activities. “After establishing the Portfolio Business in early 2020, we have now divested of all the business units moved to Portfolio Business over the years and successfully executed on our strategy to accelerate performance improvements and unlock value to Wärtsilä through divestments. As a result of these divestments, Wärtsilä is becoming a more focused and profitable company. We wish our former colleagues and the new business owners the best of success,” says Håkan Agnevall, President & CEO, Wärtsilä. Media contact:  Anne Alarotu Head of External Communications Wärtsilä Mobile: +358 50 487 1308 media@wartsila.com   Wärtsilä in briefWärtsilä is a global leader in innovative technologies and lifecycle solutions for the marine and energy markets. We emphasise innovation in sustainable technology and services to help our customers continuously improve environmental and economic performance. Our dedicated and passionate team of 17,900 professionals in 199 locations in 78 countries shape the decarbonisation transformation of our industries across the globe. In 2025, Wärtsilä’s net sales totalled EUR 6.9 billion. Wärtsilä is listed on Nasdaq Helsinki.www.wartsila.com

Embla Medical hf: Transactions in relation to Share Buyback Program

Announcement no. 29/2026 1 June 2026 Reykjavik, Iceland/Copenhagen, Denmark, 1 June 2026. Embla Medical (Nasdaq Copenhagen: EMBLA), a leading global provider of innovative mobility solutions, today announced transactions in relation to its share buyback program (“Program”), see also Company Announcement no. 61/2025 dated 23 December 2025. During the period 26 May to 29 May 2026 Embla Medical has acquired 83,854 shares under the Program at the average price of DKK 27.04. Following the transactions below, the Company holds 1,684,311 shares, corresponding to 0.40% of the Company’s total share capital. Transaction No. of Avg. purchase price in DKK Transaction value in DKKdate shares26 May 2026 25,000 27.59 689,85027 May 2026 18,854 26.92 507,53728 May 2026 20,000 26.43 528,50229 May 2026 20,000 27.08 541,597Total 83,854 27.04 2,267,486 The purpose of the Program is to reduce the Company’s share capital and adjust the capital structure by distributing capital to shareholders in line with the Company’s Capital Structure and Capital Allocation Policy. The Program will end no later than 31 December 2026, but the Company is entitled to discontinue the Program at any time.   The Company may purchase up to 2,000,000 shares under the Program, corresponding to 0.46% of the current share capital. The total consideration for shares purchased under the Program shall not exceed USD 10 million. The Program on Nasdaq Copenhagen is carried out in accordance with Regulation No. 596/2014 of the European Parliament and of the Council on market abuse ("MAR"), and the Commission’s delegated regulation 2016/1052. Further information Klaus Sindahl, Head of Investor Relations, KSindahl@emblamedical.com, +45 5363 0134 Embla Medical press releases by e-mail If you wish to receive Embla Medical press releases by e-mail, please register at http://www.emblamedical.com/investors About Embla Medical Embla Medical (Nasdaq Copenhagen: EMBLA) is a leading global provider of innovative mobility solutions that help people live a Life Without Limitations[®]. Embla Medical is home to several leading brands renowned for positively impacting people's health and well-being. They include Össur, a leading global provider of prosthetics and bracing solutions; Fior & Gentz, an innovative developer of neuro orthotics; College Park, a provider of lower limb prosthetics; and ForMotion, a global network of Orthotic and Prosthetic (O&P) patient care facilities. Embla Medical is committed to sustainable business practices, is a signatory to the UN Global Compact and UN Women’s Empowerment Principles and contributes to the UN Sustainable Development Goals. The company's climate targets have been verified by the Science Based Targets initiative. Embla Medical operates globally and has around 4,500 employees. www.emblamedical.com

Camurus announces expansion of Lilly collaboration

Lund, Sweden — 1 June 2026 — Camurus (NASDAQ STO: CAMX) today announced that Eli Lilly and Company (“Lilly”) has exercised its option to include amylin receptor agonists (amylin) in the collaboration and license agreement entered in June 2025. The decision extends Lilly’s exclusive, global rights to Camurus’ FluidCrystal[®] technology for the development and commercialization of long acting cardiometabolic drug medicines to an additional compound class. The agreement comprises up to four proprietary Lilly drug compounds across three classes: dual GLP-1 and GIP receptor agonists, triple agonists for GLP-1, GIP and glucagon, and amylin receptor agonists. “Lilly’s decision to exercise the option validates our technology, broadens our partnership and extends FluidCrystal into the expanding field of amylin therapeutics”, said Fredrik Tiberg, President and CEO of Camurus. “We are very pleased with how the collaboration with Lilly is progressing.” Under the agreement, Camurus is eligible to receive up to 290 million USD in upfront development and regulatory milestone payments, as well as 580 million USD in sales-based milestone payments, in addition to tiered mid-single digit royalties on product sales. The option exercise triggers a 5 million USD initial payment to Camurus and is subject to milestone payments and the same royalty levels as the other compounds in the collaboration. For more informationFredrik Tiberg, President & CEOTel. +46 (0)46 286 46 92fredrik.tiberg@camurus.com   Fredrik Joabsson, Chief Business Development OfficerTel. +46 (0)70 776 17 37ir@camurus.com (mir@camurus.com) About FluidCrystalCamurus’ proprietary FluidCrystal technology is designed to deliver therapeutic levels of drug substance over extended periods – from days to months – with a single injection using a prefilled syringe or autoinjector pen. Upon contact with bodily fluids in the tissue, the lipid solution transforms into a liquid crystalline gel that quickly and effectively encapsulates the active ingredient. As the liquid crystalline matrix gradually degrades in the tissue, the drug is slowly released. The technology is commercially and regulatory validated by market approvals and product sales in Europe, the US, and Australia. About CamurusCamurus is an international, science-led biopharmaceutical company committed to developing and commercializing innovative, long-acting medicines for improving the lives of patients with severe and chronic diseases. New drug products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal[®] technology and its extensive R&D expertise. The R&D pipeline includes products for the treatment of dependence, pain, cancer, and endocrine diseases. Camurus has operations across Europe, the US, and Australia, with headquarters in Lund, Sweden. The company’s shares are listed on Nasdaq Stockholm under the ticker CAMX. For more information, visit www.camurus.com and LinkedIn . This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication, through the agency of the managing director, at 5.00 pm CET on 1 June 2026.

Elicera announces outcome of the rights issue

Elicera Therapeutics AB (publ) ("Elicera" or the "Company") announces the outcome of the partially guaranteed rights issue of approximately SEK 72.8 million (the “Rights Issue”). The subscription period in the Rights Issue ended on May 29, 2026. The outcome shows that 8,208,960 shares, corresponding to approximately 33.8 percent of the offered shares, have been subscribed for with the support of subscription rights in the Rights Issue. Additionally, applications for subscription of 604,169 shares without subscription rights, corresponding to approximately 2.5 percent of the offered shares, have been submitted. Subscriptions with and without subscription rights together correspond to approximately 36.3 percent of the shares offered in the Rights Issue. The Rights Issue was covered by subscription commitments and guarantee undertakings up to 75.0 percent, corresponding to approximately SEK 54.6 million. Consequently, approximately 38.7 percent of the Rights Issue will be allocated to parties who have entered into guarantee undertakings. The Rights Issue will provide the Company with approximately SEK 54.6 million before deduction of transaction costs related to the Rights Issue. The Rights Issue comprised 24,267,722 new shares, of which 8,208,960 shares, corresponding to approximately 33.8 percent of the offered shares, have been subscribed for with subscription rights. Additionally, applications have been submitted for the subscription of 604,169 shares without subscription rights, corresponding to approximately 2.5 percent of the offered shares. Consequently, 9,387,704 shares, corresponding to approximately 38.7 percent of the Rights Issue, will be allocated to parties who have entered into guarantee undertakings. The subscription price was SEK 3.0 per new share. Through the Rights Issue, the share capital will increase by SEK 764,434.99, from SEK 2,038,492.85 to SEK 2,802,927.83, through the issue of 18,200,833 new shares, meaning that the total number of shares will increase from 48,535,544 shares to 66,736,377 shares. The Rights Issue entails a dilution of approximately 27.3 percent of capital and votes. Allocation of shares subscribed for without subscription rights will be carried out in accordance with the principles outlined in the disclosure document regarding the Rights Issue published by Elicera on May 11, 2026. On or around June 2, 2026, a settlement note will be sent to those who have been allocated shares as confirmation of the allocation of shares subscribed for without subscription rights. No notification will be sent to those who have not received any allocation. Payment for subscribed and allocated shares shall be made in cash in accordance with the instructions on the settlement note sent to those who have received an allocation. Shareholders with nominee-registered holdings will receive notification of allocation in accordance with the procedures of their respective nominee. The last day of trading in paid subscribed shares (BTA) is June 4, 2026. The first day of trading in the new shares on Nasdaq First North Growth Market is expected to be around June 10, 2026. Comment from Jamal El-Mosleh, CEO“Through the rights issue, we have strengthened our financial position and secured capital to complete our ongoing CARMA study, including the recruitment and treatment of all planned patients. The proceeds from the issue also enable us to accelerate preparations for the planned Phase I/Ib study with our drug candidate ELC-401 in glioblastoma. Overall, this provides us with strong conditions to advance our clinical programs and continue creating long-term value. I would like to sincerely thank our existing shareholders for their trust and support in this share issue, and at the same time extend a warm welcome to our new shareholders.” Lock-up undertakings In connection with the Rights Issue, the Company has agreed to a lock-up undertaking, subject to customary exceptions, whereby the Company's Board of Directors may not propose or resolve on any new share issuances for a period of 180 calendar days after the announcement of the outcome of the Rights Issue. Furthermore, shareholding members of the Company's Board of Directors and management have undertaken, with certain exceptions, not to dispose of shares or other financial instruments in the Company for a period of 180 calendar days after the announcement of the outcome of the Rights Issue. Advisors DNB Carnegie Investment Bank AB acts as Sole Global Coordinator and Sole Bookrunner in connection with the Rights Issue. Advokatfirman Delphi KB is legal adviser to the Company. This press release has been approved by the board and the CEO for publication. The information was submitted for publication distributed through the contact person below at 17;46 CET on June 1, 2026. För For further information please contact: Jamal El-Mosleh, CEO, Elicera Therapeutics AB Phone: +46 (0) 703 31 90 51jamal.elmosleh@elicera.com Certified Advisor DNB Carnegie Investment Bank AB (publ) About Elicera Therapeutics AB Elicera Therapeutics AB (publ) has developed the patented gene technology platform iTANK that enables the arming of new and existing CAR T-cell therapies targeting aggressive and relapsing cancer forms. Elicera Therapeutics thereby addresses a well-defined and vast market. The company’s CAR T-cell therapies have shown a potent effect toward solid tumors which are recognized as particularly difficult to treat and constitute the majority of cancer cases. The company addresses a global multibillion market in cell therapy through its offering of non-exclusive licensing of the iTANK platform to companies in the pharmaceutical industry. Elicera Therapeutics has four internal development projects in immune therapy that separately have the potential to generate substantial value through out-licensing agreements. The company’s share is traded on Nasdaq First North Growth Market. For additional information, visit www.elicera.com. About the iTANK platform The iTANK technology platform has been developed for arming and enhancing CAR T-cells to meet two of the major challenges CAR T-cell therapies face in the treatment of solid tumors: a very diverse set of tumor antigen targets and a very hostile tumor microenvironment. The technology is used to incorporate a transgene into CAR T-cells encoding a neutrophil activating bacterial protein (NAP). NAP secreted from the CAR(NAP) T-cells has been shown to be able to enhance the function of CAR T-cells and importantly activating a parallel bystander immune response against the cancer via CD8+ killer T-cells. This is expected to lead to a broad attack against most antigen targets on cancer cells. The iTANK platform is used to enhance the company’s own CAR T-cells but can also be universally applied to other CAR T-cell therapies under development. Proof-of-concept data was published in Nature Biomedical Engineering in April 2022. The publication, titled “CAR T cells expressing a bacterial virulence factor triggers potent bystander antitumor responses in solid cancers” (DOI number: 10.1038/s41551-022-00875-5) can be found here: https://www.nature.com/articles/s41551-022-00875-5. More information about iTANK platform is available here: https://www.elicera.com/technology Important information Publication, release, or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where the press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Elicera Therapeutics AB (publ) in any jurisdiction, either from Elicera Therapeutics AB (publ) or from anyone else. This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. A disclosure document prepared in accordance with Article 1.4 db and Annex IX of the Prospectus Regulation regarding the Rights Issue described in this press release has been published and is available on Elicera’s website (www.elicera.com). This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“Securities Act”), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to USA, Australia, Hong Kong, Israel, Canada, Japan, South Africa, New Zealand, Russia, Switzerland, Singapore, South Korea or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation. Please note that an investment in the Company is subject to regulation under the Foreign Direct Investment Act (2023:560), which requires investors, under certain conditions, to notify and obtain approval from the Swedish Inspectorate for Strategic Products. Investors should make their own assessment of whether a notification obligation exists before making any investment decision. In the United Kingdom, this press release may only be distributed and is only directed at (i) persons who have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Financial Promotion Order" as amended), (ii) persons falling within Article 49 (2) (a) to (d) ("high net worth companies;  unincorporated associations etc.") of the Financial Promotion Order, (iii) persons that are outside the United Kingdom, or (iv) are persons to whom an invitation or incentive to engage in investment activities (within the meaning of Section 21 of the Financial Services and Markets Act 2000 ("FSMA")) in connection with the issue or sale of securities (all such persons together being referred to as "relevant persons"). This press release is only directed at relevant persons and persons who are not relevant persons must not act on or rely on the information contained in this press release. Any investment or investment activity to which this communication relates is only possible for relevant persons and will only be pursued with relevant persons. In all EEA Member States ("EEA"), other than Sweden, this communication is only addressed to and is only directed at qualified investors in the relevant Member State as defined in the Prospectus Regulation, i.e. only those investors to whom an offer may be made without an approved prospectus in the relevant EEA Member State. Forward-looking statementsThis press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes”, “expects”, “anticipates”, “intends”, “estimates”, “will”, “may”, “implies”, “should”, “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forward-looking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook for Issuers of Shares.

Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency

Inside information: Bioretec initiates new change negotiations in production to enhance operational efficiency Bioretec Ltd — Inside information — 1 June 2026 at 19:00 EEST Bioretec Ltd initiates change negotiations in accordance with the Finnish Act on Co-operation within Undertakings. The aim of the negotiations is to streamline operations and consequently to improve the company’s competitiveness and profitability. The negotiations will focus on Bioretec’s production function in Finland. The change negotiations will commence on 8 June 2026 and are estimated to last for approximately two weeks. A total of 12 employees from Bioretec’s staff in Finland are included in the scope of the negotiations. The negotiations may impact the employment terms of up to four individuals. Potential measures under negotiation may include terminations of employment. The objective of the negotiations is to achieve estimated annual cost savings of approximately EUR 0.2 million, separate from the EUR 0.4 million cost savings target communicated in connection with the previous change negotiations. As the company communicated on 12 November 2025, Bioretec’s investments in production have proven to be oversized in relation to the realized business development. Bioretec underwent change negotiations concerning its production function in November 2025, resulting in the termination of one production employee and the temporary layoff of five employees. Based on the company’s assessment, the measures implemented thus far are not sufficient on their own to adapt production to the current business volumes. Consequently, the company considers additional measures necessary to further adjust its cost structure. Bioretec will keep its personnel informed about the progress of the negotiations and will publicly announce the outcome once the negotiations have concluded. Further enquiries Tuukka Paavola, CFO, +358 50 386 0013 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients. Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions. To learn more about Bioretec, visit www.bioretec.com

The Board of Directors of Bioretec Ltd resolved on a new stock option plan

Bioretec Ltd Company Announcement 1 June 2026 at 19:05 p.m. EEST THE BOARD OF DIRECTORS OF BIORETEC LTD RESOLVED ON A NEW STOCK OPTION PLAN The Board of Directors of Bioretec Ltd has resolved to establish a new stock option plan for key personnel and selected consultants of the Group. There is a weighty financial reason for the Company to issue stock options, as they are intended to form part of the incentive and commitment program for the Group's key personnel and consultants. The stock options are intended to encourage the participants to work on a long-term basis to increase shareholder value and to commit the participants to the service of the Company. The stock option plan is directed to approximately 30 key persons and consultants. A maximum total of 182,970,807 stock options will be issued, entitling their owners to subscribe for a maximum total of 182,970,807 new shares in the Company or existing shares held by the Company. The stock options are issued gratuitously. Of the stock options, 96,059,674 are marked with the symbol 2026A and 86,911,133 are marked with the symbol 2026B. The shares to be subscribed for on the basis of the issued stock options correspond to a maximum total of 12 per cent of all the shares and votes in the Company after potential share subscriptions, should new shares be issued in the subscription. As a result of the share subscriptions, the number of shares in the Company may increase by a maximum total of 182,970,807 shares, should new shares be issued in the subscription. The stock options vest gradually over four years, subject to continued employment or service. After a 12-month cliff, 40 per cent of the 2026A options and 25 per cent of the 2026B options will vest. The remaining options of both classes will vest in equal quarterly instalments over the subsequent three years. The share subscription price for stock options 2026A and 2026B is the volume-weighted average share price (VWAP) of the Company's share during the period of one (1) month commencing on April 29, 2026, plus a 20 per cent premium. The share subscription price will be credited to the reserve for the Company's invested unrestricted equity. The share subscription price will be reduced by the amount of dividends and assets from reserves of unrestricted equity per share resolved after the Board’s resolution but before the share subscription. The share subscription period for the stock options starts when options vest and ends on May 31, 2032, for both stock options 2026A and 2026B. The theoretical market value of one stock option is EUR 0.0172 per stock option. The total theoretical market value of all stock options is approximately EUR 3,147,098. The theoretical market value of one stock option has been calculated using the Black & Scholes stock option pricing model, taking into account the exercise price of the stock option and the following assumptions: share price EUR 0.0226, risk-free interest rate 2.77%, time to maturity approximately six years, current dividend yield 0% and volatility approximately 89.60%. The Board of Directors resolved on the new stock option plan by virtue of an authorisation granted by the Extraordinary General Meeting of Shareholders on March 27, 2026. Contacts Kustaa Poutiainen, Chairperson of the Board, +358 40 042 4506 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients. Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions. To learn more about Bioretec, visit www.bioretec.com

Notice to the Annual General Meeting of Summa Defence Plc

Summa Defence Plc             Company announcement                1 June 2026 at 7:35 p.m. EEST The shareholders of Summa Defence Plc (the "Company") are invited to the Annual General Meeting to be held on Wednesday, 24 June 2026 at 10 a.m. at Valla Conference Centre, address Itämerenkatu 2, 00180 Helsinki, Finland. Entrance to Valla is via the Itämerenkatu-side entrance, opposite the Ruoholahti metro station. Registration of attendees and distribution of voting tickets will commence at 09:30 a.m. EEST. A. MATTERS ON THE AGENDA OF THE ANNUAL GENERAL MEETING The following matters will be considered at the Annual General Meeting: 1. Opening of the meeting 2. Calling the meeting to order 3. Election of persons to scrutinise the minutes and to supervise the counting of votes 4. Recording the legality and quorum of the meeting 5. Recording the attendance at the meeting and adopting the list of votes 6. Presentation of the financial statements for 2025, including the consolidated financial statements, the report of the Board of Directors, and the auditor's report 7. Adoption of the financial statements 8. Resolution on the use of the profit or loss shown on the balance sheet and on the payment of dividends The Board of Directors proposes that the loss of 21,355,491.37 euros shown in the financial statements for 2025 be recorded in the Company's profit/loss account and that no dividend be distributed to shareholders for the financial year 2025. 9. Resolution on the discharge from liability of the members of the Board of Directors and the Chief Executive Officers 10. Resolution on the remuneration of the members of the Board of Directors The Shareholders' Nomination Committee proposes to the Annual General Meeting that the following annual remuneration be paid to the members of the Board of Directors: · Chair of the Board of Directors: EUR 72,000 per year · Member of the Board of Directors: EUR 36,000 per year · Chair of the Audit Committee: EUR 15,000 as additional remuneration · Member of the Audit Committee: EUR 7,500 as additional remuneration Members of any other possible committees will be paid a meeting fee of EUR 300 per meeting. Of the annual remuneration, 60% would be paid in cash and 40% in shares of Summa Defence Plc. The share portion would be paid at the beginning of the board term and the cash portion monthly. No meeting fees would be paid. The proposed remuneration structure has been set at a level comparable to board remuneration paid by Finnish listed companies of similar size and takes into account the expertise and time requirements that the defence sector and the Company's growth phase place on board work. The share component (40%) aligns the financial interests of the board members with those of the shareholders. The overall cash-flow impact of the proposal on the Company's board remuneration is close to the current level. 11. Resolution on the number of members of the Board of Directors The Shareholders' Nomination Committee proposes that 6 members be elected to the Board of Directors for a term expiring at the end of the Annual General Meeting following the election. 12. Election of members of the Board of Directors The Shareholders' Nomination Committee proposes, in accordance with the consents received, that the following persons be elected to the Board of Directors for a term expiring at the end of the Annual General Meeting following the election: from among the current members, Arto Räty and Sirpa-Helena Sormunen, and as new members of the Board of Directors, Ville Jaakonsalo, Ville Heikkinen, Juha Pinomaa andTapani Kiiski. Information on the proposed members of the Board of Directors is available on the Company's website at https://summadefence.fi/en/investors/governance/general-meeting/. All proposed members of the Board of Directors are independent of the Company and its major shareholders. 13. Resolution on the remuneration of the auditor The Board of Directors proposes that the auditor's fee be paid in accordance with a reasonable invoice approved by the Company. 14. Election of the auditor The Board of Directors proposes that the audit firm KPMG Oy Ab be re-elected as the Company's auditor, having notified the Company that it will designate Authorised Public Accountant Henry Maarala as the principal responsible auditor. The auditor's term of office expires at the end of the first Annual General Meeting following the election. 15. Authorizing the Board of Directors to resolve a rights issue The Board of Directors proposes that the Annual General Meeting authorise the Board of Directors to resolve on a share issue against payment in accordance with the pre-emptive subscription rights of shareholders (rights issue) in one or more tranches so that a maximum of 3,000,000,000 new shares in the Company may be issued under the authorisation. The large maximum number of the authorisation is based on the fact that the final subscription price of the shares will only be determined at a later stage, and the Company wishes to ensure sufficient flexibility to implement the rights issue in all market conditions. The Board of Directors is authorised to decide on all other terms and conditions of the rights issue, and the Board of Directors shall have the right to decide to offer shares that shareholders have not subscribed for in accordance with their pre-emptive rights to other shareholders or to other parties determined by the Board of Directors, in the proportion and on the terms it deems best. The authorisation is proposed to be valid until 31 October 2026. The authorisation does not replace any other authorisations granted to the Board of Directors to resolve on the issuance of shares or special rights or option rights entitling to shares. 16. Authorising the Board of Directors to resolve on share issues and on the issuance of option rights and other special rights entitling to shares The Board of Directors proposes that the General Meeting authorise the Board of Directors to resolve, in one or more tranches, on share issues and on the issuance of option rights and other special rights entitling to shares referred to in Chapter 10, Section 1 of the Finnish Limited Liability Companies Act. The maximum number of new shares that may be issued and/or own shares held by the Company that may be delivered under the authorisation is 3,000,000,000 shares. The Board of Directors shall decide on all terms and conditions of the share issues and the issuance of option rights and other special rights entitling to shares. Share issues and the issuance of option rights and other special rights entitling to shares may be carried out in deviation from the shareholders' pre-emptive subscription rights (directed issue) if there is a weighty financial reason for doing so from the Company's perspective. In share issues, shares may be issued either against payment or without consideration. A directed share issue may be without consideration only if there is an especially weighty financial reason for doing so from the Company's perspective, taking into account the interests of all shareholders. The authorisation is proposed to be valid until the end of the Annual General Meeting to be held in 2027, however no later than 30 June 2027. 17. Authorising the Board of Directors to resolve on the acquisition and/or pledging of the Company's own shares The Board of Directors proposes that the General Meeting authorise the Board of Directors to resolve on the acquisition or pledging of a maximum of 4,500,000 own shares using the Company's distributable funds, representing approximately 9.85 per cent of all shares in the Company at the time of the notice to the Annual General Meeting. The acquisition may take place in one or more tranches. The maximum acquisition price per share shall be the highest price paid for the share in public trading at the time of acquisition. In implementing the acquisition of own shares, customary derivative, share lending or other agreements may be entered into in the capital markets within the limits of laws and regulations. The authorisation entitles the Board of Directors to resolve on the acquisition otherwise than in proportion to the shares held by the shareholders (directed acquisition). The shares may be acquired for use in connection with acquisitions or other arrangements related to the Company's business, for improving the Company's capital structure, or for further transfer or cancellation. The authorisation is proposed to include the Board of Directors' right to decide on all other matters relating to the acquisition of shares. The authorisation is proposed to be valid until end of the Annual General Meeting to be held in 2027, however no later than 30 June 2027. 18. Closing of the meeting B. ANNUAL GENERAL MEETING DOCUMENTS The proposals listed above on the agenda of the General Meeting, as well as the Company’s financial statements, which include the consolidated financial statements, the report of the Board of Directors  and the auditor's report (in Finnish), and this notice to the General Meeting are available to shareholders on the website of Summa Defence Plc at https://summadefence.fi/en/investors/governance/general-meeting/. Copies of these documents and this notice will be sent to shareholders upon request. The documents referred to above will also be available at the Annual General Meeting. The minutes of the Annual General Meeting will be available on the Company's website no later than 8 July 2026. C. INSTRUCTIONS FOR MEETING PARTICIPANTS 1. Shareholder registered in the shareholders' register Shareholders who are registered in the shareholders' register of Euroclear Finland Oy on the record date of the General Meeting 11 June 2026 are entitled to participate in the General Meeting. Any shareholder whose Company shares are recorded in their personal Finnish book-entry account is automatically included in the Company's shareholders' register. Changes in the shareholding after the record date of the General Meeting do not affect the right to participate in the General Meeting or the shareholder's voting rights. Registration for the General Meeting commences on 2 June 2026. A shareholder who is registered in the Company's shareholders' register and wishes to participate in the General Meeting must register for the Meeting no later than 16 June 2026 at 11:59 p.m. (Finnish time), by which time the registration must be received. A shareholder can register for the General Meeting: a. via the Company's website at https://summadefence.fi/en/investors/governance/general-meeting/. Electronic registration requires strong identification of the shareholder or their legal representative or proxy with a Finnish, Swedish, or Danish bank ID, or a mobile certificate. b. by e-mail to Innovatics Oy at agm@innovatics.fi. Shareholders registering by e-mail shall submit the registration form available on the Company's website at https://summadefence.fi/en/investors/governance/general-meeting/. c. by mail to Innovatics Oy at Innovatics Oy, General Meeting / Summa Defence Plc, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland. Shareholders registering by mail shall submit the registration form available on the Company's website at https://summadefence.fi/en/investors/governance/general-meeting/. Further information on registration is available by telephone during the registration period of the General Meeting by calling Innovatics Oy at +358 10 2818 909 on weekdays from 9:00 a.m. to 1:00 p.m. and from 1:00p.m. to 4:00 p.m. The shareholder and their representative are required to provide information, such as the shareholder's name, date of birth or business ID, phone number and/or e-mail, address, the name of any assistant or proxy representative and the proxy's date of birth, phone number and/or e-mail. The personal data provided by shareholders to Summa Defence Plc is only to be used in connection with the General Meeting and the processing of the necessary registrations related thereto. The shareholder, their representative or proxy must be able to prove their identity and/or right of representation at the meeting venue if necessary. 2. Holders of nominee-registered shares A holder of nominee-registered shares is entitled to participate in the General Meeting on the basis of the shares which would entitle them to be entered in the shareholders' register held by Euroclear Finland Oy on the record date for the General Meeting 11 June 2026. Participation also requires that the shareholder is temporarily registered in the shareholders' register held by Euroclear Finland Oy by 19 June 2026 at 10.00 a.m. at the latest. In the case of nominee-registered shares, this is considered as registration for the General Meeting. The holder of nominee-registered shares is advised to request well in advance the necessary instructions from their custodian bank regarding temporary registration in the register of shareholders, the issuing of proxies and registration and attendance at the General Meeting. For the avoidance of doubt, instructions for shareholders whose shares are nominee-registered in Sweden are set out below in subsection "3. Shareholders whose shares are registered with Euroclear Sweden AB in Sweden ". 3. Shareholders whose shares are registered with Euroclear Sweden AB in Sweden A shareholder whose shares are registered in the securities system of Euroclear Sweden AB and who intends to participate in the General Meeting and exercise their voting rights there must be registered in the owner register maintained by Euroclear Sweden AB no later than 11 June 2026. The Company will re-register the shares of such shareholders in the shareholder register maintained by Euroclear Finland Oy, provided that the shareholder has registered for the General Meeting in accordance with the instructions in section C.1 of this notice no later than 16 June 2026 at 11:59 p.m. Finnish time. A shareholder whose shares are nominee-registered in Sweden must request the nominee to re-register the shares in the shareholder's own name in the shareholder register maintained by Euroclear Sweden AB well before the re-registration deadline of 16 June 2026. 4. Proxy representatives and power of attorney A shareholder may attend the General Meeting and exercise their rights there through a proxy representative. The proxy representative must authenticate to the electronic registration service personally with strong authentication, after which they will be able to register on behalf of the shareholder who they represent. The shareholder’s proxy must present dated proxy documents, or otherwise in a reliable manner prove that they are entitled to represent the shareholder at the General Meeting. Proving the right to represent can be done by using the suomi.fi e-Authorizations service available in the electronic registration service. Shareholders can also use the electronic Suomi.fi authorization service instead of a traditional proxy document. In such cases, the shareholder authorizes a proxy that they nominate in the Suomi.fi authorization service at www.suomi.fi/e-authorizations using the mandate theme “Representation at the General Meeting”. At the service, the authorized person must identify themselves using strong electronic identification in connection with their registration, after which the electronic authorization will be checked automatically. Strong electronic identification can be done using online banking codes or Mobile ID. More information is available on the website www.suomi.fi/e-authorizations. If a shareholder participates in the General Meeting through several proxies representing the shareholder with shares held in different securities accounts, the shares on the basis of which each proxy represents the shareholder shall be identified in connection with the registration. Any proxy documents are requested to be submitted preferably as an attachment with the electronic registration or alternatively by mail to Innovatics Oy, General Meeting / Summa Defence Plc, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland or by e-mail to agm@innovatics.fi before the end of the registration period. In addition to submitting the proxy documents, the shareholder or their proxy shall register for the General Meeting in the manner described above in this notice. 5. Other instructions and information The main language of the meeting is Finnish, but discussion, questions, answers, and decisions will also be provided in English as needed. Shareholders present at the General Meeting have the right to ask questions about the matters discussed at the meeting in accordance with Chapter 5, Section 25 of the Finnish Limited Liability Companies Act. On the date of the notice to the General Meeting, Summa Defence Plc has a total of 45,681,664 shares and votes. In Raasepori, 1 June 2026 SUMMA DEFENCE PLC Board of Directors Summa Defence in brief Summa Defence Plc is a Finnish defence and security technology group whose mission is to create a strong industrial foundation of innovative defence and dual use SMEs for strengthening the comprehensive security of society. Summa Defence aims for both organic and inorganic growth across three focus areas: maritime technologies, land technologies and new technologies. The company’s vision is to be a forerunner in comprehensive security industry. The shares of Summa Defence Plc are listed on the Nasdaq First North Growth Market in Sweden (SUMMAS) and Finland (SUMMA). www.summadefence.fi/en/ The company’s Certified Adviser is Augment Partners AB, info@augment.se, tel. +46 8 604 2255.

Solstad Offshore ASA and SBM Offshore in partnership for a new installation vessel

Skudeneshavn, 1 June 2026 Solstad Offshore ASA (“Solstad Offshore”) and SBM Offshore have agreed to order a new-build multi-purpose deepwater installation and construction vessel, with targeted delivery in the first half of 2029. The parties have formed a joint venture company which has entered into a Letter of Intent with a selected shipyard for the construction of the vessel. The vessel will be owned by a newly established joint venture, in which Solstad Offshore will hold a 50.1% ownership interest and SBM Offshore 49.9%. Solstad will act as ship manager. The joint venture has entered into an initial 14-year charter agreement with SBM Offshore, securing a minimum utilization of 270 days per year, with options for SBM Offshore to extend the charter period within each year, and up to 11 additional years. When the vessel is not utilized for SBM Offshore, the joint venture may charter the vessel to third parties. The new vessel builds on the operational success of CSV Normand Installer that Solstad Offshore and SBM Offshore have owned and operated jointly since 2006. The existing frame agreement has been extended to give SBM Offshore access to the Normand Installer until 2034.  Lars Peder Solstad, CEO of Solstad Offshore ASA, commented: “This project represents an important strategic step for Solstad Offshore. Together with SBM Offshore, we are further developing a partnership that has evolved over more than two decades, building on the proven performance of Normand Installer and extending our installation capabilities into the future.” Contacts Lars Peder Solstad CEO, at +47 91 31 85 85 Kjetil Ramstad CFO, at +47 90 75 94 89 Solstad Offshore ASA www.solstad.com This information is considered to be inside information pursuant to the EU Market Abuse Regulation article 7 and is subject to the disclosure requirements pursuant to MAR article 17 and Section 5-12 the Norwegian Securities Trading Act. This announcement was published by Kjetil Ramstad, CFO of Solstad Offshore ASA, on 1 June 2026 at 21:00. 

Sivers & GlobalFoundries Advance AI Data Center Optical Solutions

Kista, Sweden –June 2,2026–Sivers Semiconductors  AB (STO:SIVE), a global leader in photonics and wireless technologies,today announced a strategic collaboration with GlobalFoundries (Nasdaq: GFS) (GF), to develop advanced silicon photonics solutions for the high-growth AI infrastructure market. Sivers Semiconductors’ laser arrays will be integrated into reference designs built on GF’s silicon photonics  platform. The collaboration supports a range of optical connectivity architectures, including co-packaged optics (CPO), linear pluggable optics (LPO), and other emerging data center interconnect solutions. Sivers’ laser arrays will also be available in GF’s Silicon Photonics Co-packaged Advanced Light Engine (SCALE™)  platform for next-generation optical sub-assemblies and light engine architectures. GF’s SCALE CPO solution combines integrated photonic devices, coarse and dense wavelength-division multiplexing (CWDM, DWDM) and advanced packaging enablement to improve bandwidth density and system scalability. “The rapid expansion of AI workloads and hyperscale data center architectures demand advanced photonics technologies that deliver higher bandwidth, improved energy efficiency, and scalable optical connectivity,” said Raymond Biagan, CRO at Sivers Semiconductors. “Our collaboration with GlobalFoundries positions both companies at the leading edge of silicon photonics innovation.” “GlobalFoundries continues to see strong momentum for silicon photonics solutions as AI data center architectures evolve toward higher bandwidth density and improved power efficiency,” said Vikas Gupta, Senior Fellow, Silicon Photonics Product Line at GlobalFoundries. “Pairing Sivers Semiconductors’ laser array technology with our silicon photonics and SCALE CPO platforms provides our customers with advanced, scalable optical engine solutions for high-bandwidth co-packaged optics and optical interconnects.” For more information, please visit https://www.sivers-semiconductors.com/.  About Sivers Semiconductors Sivers Semiconductors is a critical enabler of a greener data economy with energy-efficient photonics & wireless solutions. Our differentiated high-precision laser and RF beamformer technologies help our customers in key markets such as AI Datacenters, SATCOM, Defense and Telecom solve essential performance challenges while enabling a much greener footprint. For additional information, please visit us at:www.sivers-semiconductors.com. (SIVE.ST) About GF GlobalFoundries (GF) is a leading manufacturer of essential semiconductors, enabling AI at scale from the cloud to the physical world. Through deep partnerships with customers, GF delivers differentiated, power-efficientand high-performance solutions for automotive, aerospace and defense, datacenter, smart mobile devices,internet of thingsand other high-growth markets. With global manufacturing operations across the U.S., Europe and Asia, GF is a trusted and holistic technology partner for customers around the world. GF’s talented, global teamremainsfocused every day on security,longevityand sustainability. For more information, visitwww.gf.com . ###

Sweco acquires Finland’s leading nuclear expert company

Platom  is an expert company specialising in the nuclear industry, where it serves nuclear operators in the fields of nuclear and radiation safety, licensing, nuclear projects and nuclear technology. The company has more than 25 years of experience in expert services in the nuclear industry and employs approximately 30 specialists.“I am excited to welcome Platom’s specialists to be an important part of Sweco, which is one of Europe’s most experienced consultancies in nuclear infrastructure. Platom is Finland’s leading consultancy in the nuclear industry, and their expertise strengthens Sweco’s competitiveness both in lifecycle projects related to traditional nuclear power and in new-build nuclear power projects, such as small modular reactors (SMRs),” says Thomas Hietto, Business Area President of Sweco in Finland.As momentum across the nuclear sector continues to build, the industry is working through factors such as capital requirements, regulatory and permitting timelines, and supply-chain scaling. The rising investment is also driving strong demand for specialised engineering, technical and advisory expertise across Europe.“Expertise in nuclear projects is highly sought after by our clients, not only in Finland, but across Europe. Sweco has extensive experience from nuclear projects in various countries, including Sweden, Finland, Belgium, Lithuania and Norway. These projects are complex and require specialist skills in a range of fields over long periods of time, and through the addition of Platom, Sweco has further strengthened our capabilities to support clients in this sector,” says Thomas Hietto. Press photo:Thomas Hietto, Sweco Finland. Free use, please credit Mans Berg. About Sweco’s nuclear experience Sweco advises and is an expert in all areas of the energy transition, encompassing the production, transmission and storage of various energy types. A balanced mix of fossil-free energy types is essential for effectively addressing the challenges of the green transition, with nuclear power serving as one potential component of this mix. Sweco provides technical advisory services related to permitting procedures, project planning, construction, decommissioning and waste management. With extensive experience from nuclear power projects in various countries, such as Sweden, Finland, Belgium, Lithuania and Norway, Sweco is uniquely positioned to support clients at all stages of the nuclear lifecycle.  About Sweco’s acquisition agenda This acquisition aligns with Sweco’s acquisition strategy to grow the business by adding key skills that complement Sweco’s 23,000 experts and to expand the Group’s market position as Europe’s leading architecture and engineering consultancy. Sweco’s strategy is to grow through a combination of acquisitions and organic growth. The Group has completed close to 170 acquisitions over the past 20 years. In total, Sweco completed 13 acquisitions in 2025, adding approximately SEK 2.1 billion in annual net sales and more than 1,500 experts to Sweco. 

Alight and Lear expand solar partnership with carport in Spain, rooftop projects in Poland

The new projects further strengthen Alight’s growing portfolio of onsite solar solutions for industrial customers in Europe and will support Lear’s efforts to reduce emissions, manage energy costs and increase energy resilience across its operations. At Lear’s site in Valls, Alight has commissioned a new solar carport system covering approximately 400 parking spaces. The installation generates clean electricity for onsite operations while also providing shaded parking for employees and visitors. The carports also cover eight EV charging stations, adding further value to the site. The Valls project has expanded an existing solar installation delivered by Alight and has more than doubled the site’s solar capacity. The new 1.4-megawatt carport system has been added to the 1-megawatt rooftop solar installation that has been operating at the facility for the past three years. Carport solar installation in Valls, Spain. In Poland, Alight has developed and commissioned rooftop solar installations at Lear’s manufacturing facilities in Bieruń and Tychy. The systems supply renewable electricity directly to factory operations, helping Lear lower emissions and reduce exposure to long-term electricity price volatility. “Our partnership with Alight helps us integrate renewable energy directly into our operations,” said Josef Chrzanowski, vice president of global sustainability at Lear Corp. “The new carports in Valls, together with the rooftop projects in Poland, demonstrate how we can use our facilities to generate clean power, reduce costs, increase resilience and support our global sustainability commitments.” All three projects have been delivered through Alight’s Solar-as-a-Service model, under which Alight finances, builds, owns and operates the systems, and Lear purchases the electricity through long-term agreements. The model enables companies to adopt onsite solar without upfront investment while benefiting from predictable energy costs and reduced carbon emissions. “We are proud to expand our partnership with Lear through these new onsite solar projects in Spain and Poland,” said Rob Stait, managing director of Alight’s behind-the-meter division. “This is a strong example of how Alight helps industrial companies unlock the value of their real estate, reduce energy costs and carbon emissions, and build resilience with a long-term, reliable supply of clean electricity.” With these additions, Alight and Lear now partner at six sites across Europe, representing more than 6 megawatts of installed solar capacity. This expanded partnership reflects increasing demand for onsite solar from large, multi-site industrial companies seeking practical ways to decarbonize operations while improving long-term energy economics.

Governance and controls critical to successful deployment of AI to deliver pension reforms – Lumera

Trustees and providers will need robust approaches and strong governance to stay in line with best practice, emerging guidance and standards when deploying AI.  London, Tuesday 2nd June 2026 – Pension reforms will create a step change in what trustees and providers need to get from the data they hold with AI methods set to be a critical enabler of how data is analysed and managed in the best interest of members.However, the real challenge will be getting the governance and controls right, including use of human oversight and ‘humans in the loop,’ according to Lumera, a leading insurtech company. Trustees and providers will require robust approaches to AI, alongside clear governance frameworks with strong controls and human oversight, to stay in line with best practice, emerging guidance and standards when deploying AI, because the UK is taking a principles-based approach to AI regulation.This means that individual industry regulators will provide guidelines for firms but otherwise trustees and providers will need to establish their own robust operating models, which include human oversight, and governance approaches.This is significant given the centrality of AI reforms to implementing the swathe of pension reforms contained within the Pension Schemes Act, the newly launched Targeted Support regime and the further changes likely following the conclusion of the Pensions Commission. Default retirement pathways, Value for Money assessments and small pots consolidation will all increase the need for providers to make better use of their data to support automated decision making and matching as well as standardised benchmarking. This backdrop creates a clear expectation that providers will need to further their adoption of AI, but do so in a way that improves member outcomes while maintaining trust.To achieve this, providers will need to create their operating and governance models within the boundaries of data protection rules and regulations, and to have the flexibility to adapt their models as regulatory guidance evolves, such as the guidance on the responsible adoption of AI expected later in 2026 from the Pensions Regulator.Operating models will need to cover a range of AI techniques, such as clustering to identify patterns in data, classification to support consistent decisions, and ongoing monitoring to identify changes in behaviour and inform appropriate actions.These models will need to ensure that all uses of AI follow a well governed path where human involvement is clearly defined - whether in the form of oversight activities, or through the incorporation of ‘humans in the loop’ to regularly handle and review outputs. They will also include policy controls, routing decisions and guardrails to provide a tightly controlled governance framework with defined intervention points.Sami Saadaoui, Head of AI Architecture and Operations at Lumera, commented: “AI is set to become a critical enabler of the next phase of pension reform as the industry digests and begins to implement the Pension Schemes Act. “Schemes and providers will need to leverage AI to deliver more personalised member outcomes, support automated processes at greater scale and improve the consistency of decision-making across increasingly complex datasets.“However, the real challenge is not simply adopting AI, but deploying it within a robust governance and control framework. Pension providers and trustees will need clear accountability, strong human oversight and transparent decision-making processes to ensure AI is being used responsibly and in members’ best interests.“The UK’s principles-based approach to AI regulation means firms cannot rely on prescriptive rulebooks alone. Instead, they will need to demonstrate that their operating models, controls and governance frameworks are sufficiently robust to manage risks around bias, data quality, explainability and consumer outcomes.“The current swathe of reforms significantly increases the volume and complexity of data that needs to be processed and analysed. Firms need the scalable technology and human expertise to ensure that AI is unleashed to its full potential within defined guardrails.“Those that manage this best will be best placed to capitalise on a new era of pension saving and access in the UK, delivering better outcomes and maintaining trust with members.”For more information, please contact:Peter Roos, CCO, Lumera: +44 7552 861 411, peter.roos@lumera.comChristine Blinke, CMO, Lumera: +46 73 901 02 01, christine.blinke@lumera.com Temple Bar Advisory: Sam Livingstone (07769655437) and Juliette Packard (07425826161) lumera@templebaradvisory.com About LumeraLumera is an insurtech company driving digital transformation for the Life and Pensions industry in Europe. We provide technology solutions for insurance administration, data management and migration to a broad base of prominent clients. In addition, we have a wide range of expert services that combine our technology and industry expertise, tailored to each local market.Our mission – the Prudent Revolution – is about combining technology with partnerships to offer Life and Pensions companies the fastest and safest journey through complex change.Lumera is headquartered in Stockholm, with additional offices in the UK, the Netherlands, Norway, Sweden and Vietnam.The principal owner of Lumera is Monterro, a leading software investor in the Nordics.For more information, visit: www.lumera.com  Follow Lumera on LinkedIn .

Saab receives order for ground-based air defence solution from Sweden

The command-and-control and sensor systems continue to build on previous deliveries to FMV, strengthening Sweden’s ground-based air defence capability. This contract will provide the end-user with an improved ability to detect and counter advanced aerial threats. “We are very proud to contribute to strengthening the ground-based air defence capability of the Swedish Army brigades. It will enhance their capability to conduct air defence operations and represents an important recognition of our Giraffe AMB and GBAD command-and-control system, says Carl-Johan Bergholm, head of Saab’s business area Surveillance. Giraffe AMB delivers key capabilities for short to medium range Ground Based Air Defence (GBAD), creating time to secure freedom of manoeuvre and support air superiority. The combination of a powerful surveillance radar and integrated command-and-control functionality (LSS Lv) provide forces with swift understanding of the air situation, enabling immediate and effective responses to changing threats and new tactics in shifting operational conditions. Contact Saab Press Centre+46 (0)734 180 018presscentre@saabgroup.com  Saab is a leading defence and security company with an enduring purpose, to help nations keep their people and society safe. Empowered by its 28,000 talented people, Saab constantly pushes the boundaries of technology to create a safer and more sustainable world. Saab designs, manufactures and maintains advanced systems in aeronautics, weapons, command and control, sensors and underwater systems. Saab is headquartered in Sweden. It has major operations all over the world and is part of the domestic defence capability of several nations. 

ASSA ABLOY acquires Sentinel Dock & Door in Canada

ASSA ABLOY has acquired Sentinel Dock & Door (“Sentinel”), a commercial dock and door service company based in Canada. "I am very pleased to welcome Sentinel to ASSA ABLOY. This acquisition delivers on our strategy to strengthen our position in mature markets through adding complementary products and solutions to our core business,” says Nico Delvaux, President and CEO of ASSA ABLOY. "The acquisition of Sentinel significantly strengthens our direct channel presence, including service, and broadens our footprint across Canada. With their strong, service-oriented business and well-established operational platform, we are well-positioned to accelerate growth in the market," says Massimo Grassi, Executive Vice President of ASSA ABLOY and Head of Entrance Systems Division. Sentinel was founded in 1983 and has some 375 employees. The company is headquartered in Ontario with coverage across Canada. Sentinel will be part of the Business Segment Industrial within the Entrance Systems Division. Sales for 2025 amounted to about MCAD 137 (approx. MSEK 960) with a good EBIT margin. The acquisition will be accretive to EPS from the start. For more information, please contact:Nico Delvaux, President and CEO, tel. no: +46 8 506 485 82Erik Pieder, CFO and Executive Vice President, tel. no: +46 8 506 485 72Björn Tibell, Head of Investor Relations, tel. no: +46 70 275 67 68, E-mail: bjorn.tibell@assaabloy.com About ASSA ABLOYASSA ABLOY is the global leader in access solutions. Every day we help people feel safe, secure and experience a more open world. We operate worldwide with 64,000 employees and sales of SEK 152 billion, with leading positions in areas such as efficient door openings, trusted identities and entrance automation. Our innovations enable safe, secure and convenient access to physical and digital places.

Construction of Metso's technology center in Tampere, Finland, progresses to the second phase, investment approximately EUR 60 million

Metso has made an investment decision to proceed with the second phase of its Lokomotion technology center in Lahdesjärvi, Tampere, Finland. The second phase includes the construction of a new crusher factory as part of the overall technology center. The investment of the second phase is approximately EUR 60 million, to be distributed over three years. The investment in 2026 is estimated at approximately EUR 15 million. The Lokomotion technology center will form a modern and resource-efficient production and technology hub where technologies, equipment, and components for the production of aggregates and sand are designed, tested, and manufactured. The technology center is estimated to be fully completed in the early 2030s. “Starting the second phase of the Lokomotion project strengthens the overall Lahdesjärvi technology center and creates the foundation for starting crusher production in a new, modern facility. Altogether, this is a significant investment of over EUR 200 million, which will improve our global delivery capability and support our position as a market leader in aggregates solutions,” says Markku Simula, President of Metso’s Aggregates business area. “Metso has been a key part of Tampere’s industrial history for decades, and we continue to develop our operations in the area with a long-term perspective. The Lokomotion technology center is the largest industrial investment in Tampere in this century and plays an important role in developing the regional industrial ecosystem. The investment supports competence development, employment, and sustainable industrial growth,” Simula continues. Construction of the second phase to start in June The second phase of the Lokomotion project at Lahdesjärvi will expand the first phase’s assembly and logistics facilities currently under construction. Construction will begin with groundwork in June 2026, and crusher production at the new factory is expected to start in autumn 2028. Construction will proceed in parallel with the first phase, enabling a phased commissioning. The total building area of the technology center is approximately 66,000 m², of which the second phase accounts for about 12,000 m². First phase progressing on schedule Construction of the first phase began in June 2024 and is progressing according to the overall schedule. The first phase is scheduled to be completed in August 2027. It includes assembly and testing facilities for mobile crushers, as well as warehouse facilities. Work on interior building services and structural engineering is currently underway at the construction site. Production of Lokotrack® track-mounted crushing and screening equipment is scheduled to start at the new factory in Lahdesjärvi during the third quarter of 2027. The investment for the first phase is approximately EUR 150 million, of which approximately EUR 70 million had been spent by the end of April 2026. Metso’s current Lokomo site for its aggregates business in Hatanpää, Tampere, will be relocated gradually to the new technology center. Following the relocation, the company plans to divest the Hatanpää site and buildings it owns. Read more about Metso’s solutions for aggregates production and recycling on our website . Further information: Pasi Vuorinen, Vice President, Tampere plant, Aggregates business area, Metso, tel. +358 20 484 100, email pasi.vuorinen(at)metso.com Metso Media Desk, tel. +358 20 482 1930, email: media(at)metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Metso is headquartered in Espoo, Finland. At the end of 2025 Metso had close to 18,000 employees in around 50 countries, and sales in 2025 were about EUR 5.3 billion. Metso is listed on the Nasdaq Helsinki.  metso.com 

Freetrailer builds on global agreement and accelerates growth in Germany

The expansion builds on the global agreement previously entered into between Freetrailer and the home furnishing retailer, and marks an important step in Freetrailer’s continued scaling in the German market. With existing and upcoming rollouts, Freetrailer will exceed 800 trailers in Germany during the summer of 2026. For large furniture and home furnishing retailers, transport is a natural part of the customer experience. Freetrailer’s digital self-service solution makes it possible to offer customers a flexible transport option directly at the store, both for larger purchases and for everyday transport needs, while the trailers also create unique local brand visibility. “At IKEA, we want to make everyday life easier for the many people. That also means helping customers get their purchases home in a simple and flexible way. Freetrailer gives our customers an accessible transport option directly at our stores,” says Ingo Ronny Sellin-Wortmann, Services Experience Leader, IKEA Deutschland. “This is an important expansion for Freetrailer in Germany. When one of the world’s largest home furnishing retailers chooses to scale the solution significantly, it underlines the strength of our model. I am also pleased that the agreement gives us access to 10 major new locations in our focus region of North Rhine-Westphalia (NRW) in Germany,” says Thomas Zeihlund, Group CEO of Freetrailer Group A/S. North Rhine-Westphalia is one of Germany’s most important retail regions, with high population density and strong opportunities to build closer local coverage. 

TORM plc capital increase in connection with exercise of Restricted Share Units as part of TORM’s incentive program

TORM plc (Nasdaq: TRMD or TRMD A) has increased its share capital by 28,144 A-shares (corresponding to a nominal value of USD 281.44) as a result of the exercise of a corresponding number of Restricted Share Units (“RSUs”). A total of 7,089 new shares are subscribed for in cash at DKK 127.30 per A-share, 13,966 shares are subscribed for in cash at DKK 139.90, and 7,089 new shares are subscribed for in cash at DKK 195.50. Transfer restrictions may apply in certain jurisdictions outside Denmark, including applicable US securities laws. The capital increase is carried out without any pre-emption rights for existing shareholders or others. The new shares (i) are ordinary shares without any special rights and are negotiable instruments, (ii) give the right to dividends and other rights in relation to TORM as of the date of issuance and (iii) are expected to be admitted to trading and official listing on Nasdaq Copenhagen as soon as possible. After the capital increase, TORM’s share capital totals to USD 1,023,671.18 divided into 102,367,118 A-shares with a nominal value of USD 0.01 each. Each A-share carries one vote. Contact Mikael Bo Larsen, Head of Investor Relations Tel.: +45 5143 8002 About TORM TORM is one of the world’s leading carriers of refined oil products. TORM operates a fleet of product tanker vessels with a strong commitment to safety. environmental responsibility and customer service. TORM was founded in 1889 and conducts business worldwide. TORM’s shares are listed on Nasdaq in Copenhagen and on Nasdaq in New York (ticker: TRMD A and TRMD. ISIN: GB00BZ3CNK81). For further information, please visit www.torm.com. Safe Harbor Statement as to the Future Matters discussed in this release may constitute forward-looking statements. The Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are statements other than statements of historical facts. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation. Words such as, but not limited to, “expects,” “anticipates,” “intends,” “plans,” “believes,” “estimates,” “targets,” “projects,” “forecasts,” “potential,” “continue,” “possible,” “likely,” “may,” “could,” “should” and similar expressions or phrases may identify forward-looking statements. The forward-looking statements in this release are based upon various assumptions, many of which are, in turn, based upon further assumptions, including without limitation, management’s examination of historical operating trends, data contained in our records and other data available from third parties. Although the Company believes that these assumptions were reasonable when made, because these assumptions are inherently subject to significant uncertainties and contingencies that are difficult or impossible to predict and are beyond our control, the Company cannot guarantee that it will achieve or accomplish these expectations, beliefs, or projections. Important factors that, in our view, could cause actual results to differ materially from those discussed in the forward-looking statements include, but are not limited to, our future operating or financial results; changes in governmental rules and regulations or actions taken by regulatory authorities; inflationary pressure and central bank policies intended to combat overall inflation and rising interest rates and foreign exchange rates; general domestic and international political conditions or events, including “trade wars” and the war between Russia and Ukraine, the developments in the Middle East, including the war in Israel and the Gaza Strip, and the conflict regarding the Houthis’ attacks in the Red Sea; international sanctions against Russian oil and oil products; changes in economic and competitive conditions affecting our business, including market fluctuations in charter rates and charterers’ abilities to perform under existing time charters; changes in the supply and demand for vessels comparable to ours and the number of newbuildings under construction; the highly cyclical nature of the industry that we operate in; the loss of a large customer or significant business relationship; changes in worldwide oil production and consumption and storage; risks associated with any future vessel construction; our expectations regarding the availability of vessel acquisitions and our ability to complete acquisition transactions planned; availability of skilled crew members other employees and the related labor costs; work stoppages or other labor disruptions by our employees or the employees of other companies in related industries;  effects of new products and new technology in our industry;  new environmental regulations and restrictions; the impact of an interruption in or failure of our information technology and communications systems, including the impact of cyber-attacks, upon our ability to operate; potential conflicts of interest involving members of our Board of Directors and Senior Management; the failure of counterparties to fully perform their contracts with us; changes in credit risk with respect to our counterparties on contracts; adequacy of insurance coverage; our ability to obtain indemnities from customers; changes in laws, treaties or regulations; our incorporation under the laws of England and Wales and the different rights to relief that may be available compared to other countries, including the United States; government requisition of our vessels during a period of war or emergency; the arrest of our vessels by maritime claimants; any further changes in U.S. trade policy that could trigger retaliatory actions by the affected countries; the impact of the U.S. presidential and congressional election results affecting the economy, future government laws and regulations and trade policy matters, such as the imposition of tariffs and other import restrictions; potential disruption of shipping routes due to accidents, climate-related incidents, adverse weather and natural disasters, environmental factors, political events, public health threats, acts by terrorists or acts of piracy on ocean-going vessels; damage to storage and receiving facilities; potential liability from future litigation and potential costs due to environmental damage and vessel collisions; and the length and number of off-hire periods and dependence on third-party managers. In the light of these risks and uncertainties, undue reliance should not be placed on forward-looking statements contained in this release because they are statements about events that are not certain to occur as described or at all. These forward-looking statements are not guarantees of our future performance, and actual results and future developments may vary materially from those projected in the forward-looking statements. Except to the extent required by applicable law or regulation, the Company undertakes no obligation to release publicly any revisions or updates to these forward-looking statements to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events. Please see TORM’s filings with the U.S. Securities and Exchange Commission for a more complete discussion of certain of these and other risks and uncertainties. The information set forth herein speaks only as of the date hereof, and the Company disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this communication.

Fiskars Corporation: Record date and payment date of the second dividend instalment of EUR 0.21 resolved by the Annual General Meeting 2026

Fiskars CorporationStock Exchange ReleaseJune 2, 2026 at 11.15 a.m. EEST Fiskars Corporation: Record date and payment date of the second dividend instalment of EUR 0.21 resolved by the Annual General Meeting 2026 The Annual General Meeting of Fiskars Corporation held on March 11, 2026 resolved on a payment of dividend in four instalments of EUR 0.21 per share for the financial period that ended on December 31, 2025. The Annual General Meeting resolved that the first dividend instalment shall be paid in March, the second instalment in June, the third instalment in September and the fourth instalment in December of 2026. The first dividend instalment was paid on March 20, 2026. The Board of Directors of Fiskars Corporation has on June 2, 2026 resolved in accordance with the resolution of the Annual General Meeting that the dividend payment date for the second dividend instalment of EUR 0.21 per share shall be June 11, 2026. The record date for the dividend instalment shall be June 4, 2026. FISKARS CORPORATION Further information:Päivi Timonen, Chief Legal Officer, tel. +358 40 776 8264 Fiskars Group in brief Fiskars Group (FSKRS, Nasdaq Helsinki) is the global home of design-driven brands for indoor and outdoor living. Since 1649, we have designed products of timeless, purposeful, and functional beauty, while driving innovation and sustainable growth. In 2025, Fiskars Group’s global net sales were EUR 1.1 billion, and we had approximately 6,600 employees. We have two Business Areas (BA), Vita and Fiskars. BA Vita offers products in the high-end homeware segment as well as fine branded jewelry. Its desirable brands include Georg Jensen, Royal Copenhagen, Wedgwood, Moomin Arabia, Iittala and Waterford. In 2025, BA Vita’s reported net sales were EUR 613 million, and it had approximately 5,000 employees. BA Fiskars offers functional innovations in the gardening and outdoor categories, in addition to the scissors and creating, as well as cooking categories. The brands include Fiskars and Gerber. In 2025, BA Fiskars’ net sales were EUR 522 million, and it had approximately 1,300 employees. Read more: fiskarsgroup.com

ZINZINO AB (PUBL.): ANNOUNCEMENT FROM THE ANNUAL GENERAL MEETING

Zinzino AB (publ.) held its Annual General Meeting today, June 2, 2026, at which the following resolutions were adopted: · To adopt the income statements and balance sheets for the parent company and the Group, · To distribute SEK 6 per share for the 2025 fiscal year and to carry forward the remaining portion of retained earnings, · To discharge the Board of Directors and the CEO from liability, · To elect Hans Jacobsson as Chairman of the Board and Staffan Hillberg, Pierre Mårtensson, and Ingela Nordenhav as the other Board members,  · That Board fees shall total SEK 1,280,000, of which SEK 420,000 shall be paid to the Chairman, SEK 215,000 to each of the other Board members, SEK 85,000 to the Chair of the Audit Committee and SEK 50,000 to a member of the Audit Committee, as well as SEK 45,000 to the Chair of the Compensation Committee and SEK 35,000 to a member of the Compensation Committee, · To appoint BDO Göteborg AB as the auditing firm and Katarina Eklund as the lead auditor, · To adopt, in accordance with the Nomination Committee’s proposal, principles for the Nomination Committee ahead of the 2027 Annual General Meeting, · To issue 152,935 new Zinzino Class B shares with payment by set-off of a receivable to Enhanzz AG, · To issue 6,189 new Zinzino Class B shares with payment by set-off of a receivable to World Class Ventures LLC, · To issue 74,224 new Zinzino Class B shares with payment by set-off of receivables to the company’s distributors, · To issue 1,500,000 warrants to employees and others in accordance with the Board of Directors’ proposal, · To authorize the Board of Directors to decide on rights issues, · To authorize the Board of Directors to decide on directed offerings of a maximum total of 3,800,000 Class B shares, · To approve the remuneration report for 2025 presented by the Board, · The complete resolutions of the Annual General Meeting are available at the company’s head office in Gothenburg. · It was noted that the required majority of at least 9/10 of both the votes cast and the shares represented at the Annual General Meeting was achieved. Gothenburg, June 2, 2026 The Board of Directors of Zinzino For more information: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25700, dag@zinzino.com  Fredrik Nielsen CFO Zinzino +46 (0) 707 900 174, fredrik.nielsen@zinzino.com Pictures for publication free of charge: marketing@zinzino.com Certified Adviser: Tapper Partners AB

Bioretec Ltd – Manager’s transactions – Jordy Winters

Bioretec OyCompany release2 June 2026 at 13:25 p.m. EEST Bioretec Oy - Managers' Transactions ____________________________________________ Person subject to the notification requirement Name: Jordy Winters Position: Other senior manager Issuer: Bioretec Oy LEI: 7437008736AG7HY51K13 Notification type: INITIAL NOTIFICATION Reference number: 158959/6/4 ____________________________________________ Transaction date: 2026-05-29 Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME) Instrument type: SHARE ISIN: FI4000480454 Nature of transaction: ACQUISITION Transaction details (1): Volume: 50000 Unit price: 0.0224 EUR (2): Volume: 109000 Unit price: 0.0224 EUR (3): Volume: 82596 Unit price: 0.0224 EUR (4): Volume: 2849 Unit price: 0.0224 EUR (5): Volume: 200000 Unit price: 0.0224 EUR (6): Volume: 555555 Unit price: 0.0224 EUR Aggregated transactions (6): Volume: 1000000 Volume weighted average price: 0.0224 EUR Further enquiries Tuukka Paavola, CFO, +358 50 386 0013 Certified adviser Nordic Certified Adviser AB, +46 70 551 67 29 Information about Bioretec Bioretec is a globally operating Finnish medical device pioneer at the forefront of transforming orthopedic care with fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. The company's latest innovation, the RemeOs™ product line, is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The first RemeOs product market authorization was received in the U.S. in March 2023, and in Europe, the CE mark approval was received in January 2025. Bioretec's Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA both CE marked and FDA cleared for a wide range of indications in adult and pediatric patients. Bioretec is shaping the future of orthopedic treatment with a focus on healing through absorption, paving the way for more effective and patient-friendly solutions. To learn more about Bioretec, visit www.bioretec.com

Hansa Biopharma participating in Jefferies Global Healthcare Conference in New York

Lund, Sweden, June 2, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Renée Aguiar-Lucander, CEO, Hansa Biopharma, will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York, at 8:45 AM EDT on Thursday, June 4, 2026. If you are interested in meeting with Hansa’s management, please contact Hansa Biopharma at ir@hansabiopharma.com. Event: Fireside chat at Jefferies Global Healthcare Conference Date, Time, and Place: Thursday June 4, 8:45-9:15 AM EDT, at the Marriott Marquis in New York Speaker: Renée Aguiar-Lucander, CEO, Hansa Biopharma Link to Webcast  --- ENDS --- Contacts for more information: Evan Ballantyne, Chief Financial OfficerIR@hansabiopharma.com Kerstin Falck, VP Global Corporate Affairsmedia@hansabiopharma.com Notes to editors About Hansa Biopharma Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa’s proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases. The company’s portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS). Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at  www.hansabiopharma.com   and follow us on LinkedIn . ©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

LGBTQ Risk Map 2026: More Countries Report Higher Risk for Travelers

Most countries fall into the highest risk category Globally, the analysis classifies 91 countries as high risk for LGBTQ travelers. Another 62 countries are rated medium risk, and 80 are considered low risk. Compared with last year, conditions have worsened in several countries, including Belarus, Burkina Faso, India, Japan, Kazakhstan, Senegal, Slovakia, and the United States. The reasons vary but include restrictions on existing rights, legal rollbacks, harsher penalties, and new limitations on the recognition of gender identity and on travel documents. Regional differences continue to grow Western Europe remains the safest region for LGBTQ travelers, with all countries in the region classified as low risk in the latest analysis. By contrast, the Middle East and North Africa continue to include some of the world’s highest-risk destinations for LGBTQ travelers. Most countries in the region are classified as high risk, with Israel rated low risk and Lebanon rated medium risk. In Sub-Saharan Africa, the situation remains highly challenging. Approximately 80 percent of assessed countries in the region fall into the highest risk category. The deterioration is particularly evident in Burkina Faso and Senegal. Following the 2022 military coup, Burkina Faso enacted its first law criminalizing same-sex relations. In Senegal, prison sentences for same-sex relations have doubled. In Europe and Eurasia, new legal restrictions have led to lower ratings for individual countries. Kazakhstan has imposed restrictions on information about so-called “non-traditional sexual orientations,” while Slovakia has further limited the rights of same-sex couples. Belarus has adopted a law against so-called “LGBT propaganda,” which could result in fines or even arrests. Setbacks have also been recorded in Asia. In India, new legislation seeks to restrict transgender people’s ability to self-identify. In Japan, a court upheld the constitutionality of the country’s ban on same-sex marriage. In North America, the United States has tightened rules for travel documents. Passports will reflect only the sex assigned at birth, and the “X” gender marker will no longer be recognized. At the same time, the analysis also shows areas of progress. Botswana and St. Lucia have repealed laws criminalizing same-sex relations between men, resulting in improved ratings in this year’s map. “LGBTQ travelers face very different realities depending on where they travel. In some destinations, the risk may be primarily social. In others, it may be legal, with serious consequences,” said Magnus Hultman, CEO of Safeture. “For organizations, this makes it essential to understand destination-specific risks before travel and to ensure that travelers have access to relevant information, communication, and support if something happens.” The LGBTQ Risk Map 2026 is now available as a free download. It offers companies, travel managers, security teams, and travelers a practical overview to support safer international travel planning. The map can be downloaded here: 2026 LGBTQ Travel Safety Map - Safeture  For additional information, visit safeture.com or contact: Safeture CEO Magnus Hultman: +46 706 00 81 66. Magnus.hultman@safeture.com About Safeture ABSafeture is a Sweden-based SaaS company that provides a market-leading People Risk Management platform to help organizations protect their people anywhere in the world. By combining real-time risk intelligence, location awareness, and instant mass communication, Safeture enables faster response, stronger duty of care, and better decision-making for global operations. Trusted by medical assistance providers, security companies, insurers, and multinational organizations, Safeture supports travel, facility, and workforce safety through a scalable, partner-centric platform. Safeture AB is listed on Nasdaq First North Growth Market Stockholm (ticker: SFTR). Redeye Nordic Growth AB is the company’s Certified Adviser. About Riskline: Riskline is a Danish content provider and one of the world's leading companies for travel risk analysis. Professional analysts, supported by AI, process more than 100,000 data sources to produce accurate risk assessments in real time. Riskline and Safeture have been working together since October 2022. www.riskline.com

Getinge Launches Vasoview Hemopro 3, Advancing Endoscopic Vessel Harvesting

Endoscopic vessel harvesting is a minimally invasive technique used to obtain blood vessels, most commonly the saphenous vein or radial artery, for use in CABG surgery. Vessel harvesting plays a critical role in procedural success, as conduit quality and incision‑related complications can significantly impact outcomes and recovery. Compared with traditional open harvesting methods, EVH has been associated with reduced wound complications, less postoperative pain, faster recovery, and improved cosmetic results.[1,2] “For nearly three decades, the Vasoview family has helped set the standard in EVH,” said Elin Frostehav, President, Acute Care Therapies at Getinge. “Vasoview Hemopro 3 builds on that legacy with thoughtful design enhancements shaped by real‑world clinician experience, reinforcing our long‑standing commitment to innovation in EVH.”  Getinge has completed an Initial Launch of the Vasoview Hemopro 3 EVH System and has received valuable, positive customer feedback. Getinge has continuously refined EVH technology with a focus on preserving conduit quality while improving the patient and clinician experience. Through close collaboration with vessel harvesting specialists, Getinge has advanced EVH technology in a deliberate, user‑driven way, ensuring solutions evolve alongside clinical practice.  The Vasoview Hemopro 3 System incorporates targeted enhancements across ergonomics, energy control, visualization, and workflow efficiency, informed by input from more than 100 vessel harvesting specialists worldwide. A redesigned Harvesting Tool features an ergonomic, game‑controller‑style handle and a soft‑touch Activation Toggle that allows activation with minimal force and multiple hand positions, supporting clinician comfort and control throughout the procedure.  The system also introduces simplified connectivity through an integrated Harvesting Tool Power Cable, providing a one‑click connection to the new Vasoview Hemopro 3 Power Supply and eliminating the need for extension cable sterilization. The dedicated Power Supply is designed to deliver consistent energy and promote efficient cut‑and‑cautery performance with minimal downtime. Hemopro 3 includes features which support consistent visibility, safety, and workflow efficiency during EVH.  “With Hemopro 3, we focused on delivering meaningful improvements that enhance the patient experience and ultimately support better outcomes - safely, reliably, and consistently,” says Cynthia Hougum, Vice President, Cardiovascular Surgery at Getinge.  Vasoview Hemopro 3 is launching in the U.S., with a training supported rollout available for U.S. customers. Getinge plans a phased expansion outside the U.S., with availability in additional markets to follow based on regulatory approvals and market readiness. Vasoview Hemopro 2 will continue to be available as Getinge rolls out availability of Vasoview Hemopro 3. For more information on Vasoview Hemopro 3 and Getinge’s full portfolio of medical solutions, visit  Product Catalog - Getinge . 1. Ferdinand FD, MacDonald JK, Balkhy HH, et al. Endoscopic Conduit Harvesting in Coronary Artery Bypass Grafting Surgery: An ISMICS Systematic Review and Consensus Conference Statements. Innovations. 2017; 12(5): 301-319  2. Luckraz, H., et al., Endoscopic vein harvest in patients at high risk for leg wound complications: A cost-benefit analysis of an initial experience. Am J Infect Control, 2016. 44(12): p. 1606-1610.   Media contact:Caroline Örmgård, Head of Public & Media RelationsPhone: +46 (0)10 335 0041Email: caroline.ormgard@getinge.com About GetingeWith a firm belief that every person and community should have access to the best possible care, Getinge provides hospitals and life science institutions with products and solutions aiming to improve clinical results and optimize workflows. The offering includes products and solutions for intensive care, cardiovascular procedures, operating rooms, sterile reprocessing and life science. Getinge employs approximately 12,000 people worldwide and the products are sold in more than 135 countries.

District Reports PEA Results for the Viken Deposit that Strengthens Sweden’s Critical Raw Materials Future

[Blue text on a black background AI-generated content may be incorrect.] District Reports PEA Results for the Viken Deposit that Strengthens Sweden’s Critical Raw Materials Future Vancouver, B.C.June 2, 2026 June 2, 2026 – District Metals Corp. (TSX-V: DMX) (Nasdaq First North: DMXSE SDB) (OTCQX: DMXCF) (FRA: DFPP); (“District” or the “Company”) is pleased to announce the results of the Preliminary Economic Assessment (“PEA”) for the Viken Energy Metals Deposit (the “Viken Deposit”) within the Viken Property located in Jämtland County, central Sweden.  Through its wholly-owned subsidiary, Bergslagen Metals AB, the Viken Property is 100% owned by the Company and is also completely free of any net smelter returns royalty. Unless otherwise indicated, all dollar amounts are stated in United States dollars (“$”). Garrett Ainsworth, CEO of District, commented: “Today’s reported Viken Deposit PEA results mark a transformational milestone for District, and validates the immense scale, quality, and economic strength of this project. Delivering a robust after-tax NPV of $2.88 billion at an 8% discount rate and strong 45.9% IRR alongside initial CAPEX of $876 million. The low operating costs enable negative-cost uranium production of 3.3 million pounds of U3O8 per year, which meets the full uranium demand of Sweden’s current nuclear reactor fleet. These PEA results are globally significant and position the Viken Deposit amongst the most compelling development opportunities for important and critical raw materials in the mining sector today. These results underscore not only the project’s potential for profitability and resilience, but also our team’s vision and disciplined execution in advancing an asset we believe will be capable of generating substantial long-term value for shareholders, stakeholders, and the communities in which we operate.” Viken Deposit PEA Highlights · Strong financial metrics: After-tax net present value (“NPV8%”) of $2.88 billion, internal rate of return (“IRR”) of 45.9%, and payback period of 2.1 years. · Significant after-tax free cash1 flow: Initial capital cost of $876 million to generate average after-tax free cash flow of $531 million per year over the 13 years of life of mine (LOM) production. · Negative cost to produce uranium: Average cash cost1 (net of by-product credits) per pound of uranium of negative $121/lb U₃O₈ and an all-in sustaining cost2 (“AISC”) per pound of uranium of negative $118/lb U₃O₈ (net of by-product credits) over the life of mine. · Simplicity of mining: Conventional truck-and-surface miner open pit operation (no drill and blast) with an average strip ratio of 0.2 to 1.0 (waste to mill feed). · Enhanced metallurgical recoveries: Modified pug roast processing conceptually shows metallurgical recoveries of 90% for uranium, 70% for vanadium, 70% for sulphate of potash (SOP), 30% for nickel, and 50% for molybdenum and zinc. · Significant production profile: The Base Case scenario proposes mining at 10 million tonnes per annum (Mtpa) producing approximately: · 3.3 million pounds per year of U₃O₈ production capacity—enough to meet the uranium fuel requirements of all currently operating nuclear reactors in Sweden2. · 16 million pounds per year of vanadium pentoxide (V₂O₅) flake, further refined into downstream vanadium products including · 37 million litres per year of vanadium electrolyte and 6 million kilograms per year of ferrovanadium (FeV) at a ratio of 35:65, respectively. The world’s annual V2O5 flake supply is currently dominated by Russia and China3. · 250,000 tonnes per year sulphate of potash (SOP) by-product for sale as fertilizer capable of supplying 16% of Europe’s annual SOP demand that is currently import-dependent, and forecast to grow at a CAGR of 3.9% to 20344. · Mixed sulphide product for smelting to refined molybdenum (4.5 million pounds per year), nickel (1.6 million pounds per year), and zinc (2.1 million pounds per year) products. · Extraordinary optionality: The PEA outlines total life of mine production of 127 million tonnes sourced exclusively from within the 456 million tonne Indicated Mineral Resource Estimate published in April 20255. The additional 4.3 billion tonne Inferred Mineral Resource Estimate highlights the immense scale and optionality with planned life of mine production representing only a small fraction of the broader Mineral Resource base. The PEA does not include, nor is it based upon, the Inferred Mineral Resource Estimate. · Exceeding Environmental Regulations: New and proven technologies proposed for dust suppression, water management and protection, and dry stack tailings to reclaim the land back to its previous use. The Viken Deposit PEA was prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”) standards. The base case was completed at a uranium price of $85/lb, a vanadium electrolyte price of $9/L, a ferrovanadium price of $38/kg, a sulphate of potash price of $650/tonne, a molybdenum price of $27.22/lb, a nickel price of $7.71/lb, and a zinc price of $1.45/lb. Viken Deposit PEA Details District engaged P&E Mining Consultant Inc. and METS Engineering Group Pty Ltd who are independent consultants with a deep understanding of economic studies on Alum Shale deposits in Sweden. The study envisions a conventional open pit mining and processing operation with a low strip ratio that is amenable for a continuous mining system and truck transport.  The nominal initial nameplate processing capacity has been set to 27,400 tonnes per day (tpd) or 10 Mtpa, but the areal extent of the Viken Deposit provides significant scalability if desired. This PEA only considers a Phase 1 open pit mining operation, and it is expected that future phases of mining would benefit from reduced capital expenditures by using the existing mineral processing plant and infrastructure. The recovery of uranium, vanadium, sulphate of potash, and a mixed metal precipitate (molybdenum, nickel, zinc) has been evaluated through a pug roast mineral processing plant that includes crushing, pug roasting, grinding, flotation, and acid leaching. The resulting solution is run through a potassium salt crystalliser for recovery of SOP, followed by sulphide precipitation to produce a Mixed Sulphide Precipitate. The uranium and vanadium are recovered by solvent extraction. The vanadium (V2O5) flake product will be further refined into vanadium electrolyte (used in batteries for renewable energy storage) and ferrovanadium (used as alloy for strengthening steel) that have higher saleable value than the V2O5 flake product. The waste slurry will be de-watered and thickened for dry stack tailings placement that will be progressively rehabilitated. Table 1 - Viken Deposit Preliminary Economic Assessment Highlights +---------------------------------------+--------------------------+|After-Tax Net Present Value (NPV8) |US$2.88 billion |+---------------------------------------+--------------------------+|Initial Capital Costs (CAPEX) |US$876 million |+---------------------------------------+--------------------------+|Internal Rate of Return (IRR) |45.9% |+---------------------------------------+--------------------------+|Average Annual After-Tax Free Cash Flow|US$531 million ||(Life of Mine) | |+---------------------------------------+--------------------------+|Payback Period |2.1 years |+---------------------------------------+--------------------------+|Uranium Average Annual Production |3.3 million lbs U3O8 |+---------------------------------------+--------------------------+|Vanadium Average Annual Production |16 million lbs V2O5 |+---------------------------------------+--------------------------+|Vanadium Electrolyte (V Electrolyte) |37 million L V Electrolyte||Average Annual Production | |+---------------------------------------+--------------------------+|Ferrovanadium (FeV) Average Annual |6 million kg FeV ||Production | |+---------------------------------------+--------------------------+|Sulphate of Potash (SOP) Average Annual|250,000 t SOP ||Production | |+---------------------------------------+--------------------------+|Life of Mine (LOM) Production |13 years |+---------------------------------------+--------------------------+|Average Unit Operating Cost of U3O8 |(-) US$121/lb U3O8 ||(net of by-product credits) | |+---------------------------------------+--------------------------+|Uranium Price Assumption |US$85/lb U3O8 |+---------------------------------------+--------------------------+|Vanadium Price Assumption (35% vanadium|US$15.7/lb V2O5 ||electrolyte at $9/L, 65% FeV at $38/kg)| |+---------------------------------------+--------------------------+|SOP Price Assumption |US$650/t SOP |+---------------------------------------+--------------------------+|State Mineral Fee Paid to Landowners |US$22 million ||(0.15% for LOM) | |+---------------------------------------+--------------------------+|State Mineral Fee Paid to Sweden (0.05%|US$7 million ||for LOM) | |+---------------------------------------+--------------------------+|Corporate Taxes Paid to Sweden (20.6% |US$1.6 billion ||for LOM) | |+---------------------------------------+--------------------------+ Table 2 - PEA Sensitivity to Commodity Prices +---------------------------+-----+-----+-----+---------+-----+-----+-----+|Sensitivity |-30% |-20% |-10% |Base Case|+10% |+20% |+30% |+---------------------------+-----+-----+-----+---------+-----+-----+-----+|FeV Price (US$/kg) |27 |30 |34 |38 |42 |46 |49 |+---------------------------+-----+-----+-----+---------+-----+-----+-----+|V Electrolyte Price (US$/L)|6 |7 |8 |9 |10 |11 |12 |+---------------------------+-----+-----+-----+---------+-----+-----+-----+|U3O8 Price (US$/lb) |60 |68 |77 |85 |94 |102 |111 |+---------------------------+-----+-----+-----+---------+-----+-----+-----+|SOP Price (US$/t) |455 |520 |585 |650 |715 |780 |845 |+---------------------------+-----+-----+-----+---------+-----+-----+-----+|After-Tax NPV (8%) (US$M) |1,023|1,642|2,262|2,881 |3,498|4,115|4,732|+---------------------------+-----+-----+-----+---------+-----+-----+-----+|After-Tax IRR (%) |24.3 |32.2 |39.3 |45.9 |52.0 |57.8 |63.3 |+---------------------------+-----+-----+-----+---------+-----+-----+-----+|After-Tax Payback (years) |3.7 |2.9 |2.5 |2.1 |1.9 |1.8 |1.6 |+---------------------------+-----+-----+-----+---------+-----+-----+-----+ Capital Costs The LOM capital costs (CAPEX) for the contemplated conventional open pit mining, processing operation, vanadium refinement facilities and supporting infrastructure at the Viken Deposit are estimated at $1.0 billion including initial capital costs of $876 million as shown in Table 3 below.  The initial capital cost includes a contingency of approximately 22% or $159 million. P&E Mining and METS Engineering estimated the capital costs based on input and consultation with leading expert service providers who have experience with mine construction projects and cost estimation both in Sweden and globally. Table 3 - Summary Breakdown of Capital Cost Estimates +-----------------------------------------------+-------+----------+-----+|Capital Costs (US$ Millions) |Initial|Sustaining|Total|+-----------------------------------------------+-------+----------+-----+|Mine |  60 |  44 |105 |+-----------------------------------------------+-------+----------+-----+|Process Plant & Infrastructure & Indirect Costs|657 |  79 |736 |+-----------------------------------------------+-------+----------+-----+|Rehabilitation |    0 |    8 |    8|+-----------------------------------------------+-------+----------+-----+|Contingency |159 |  26 |185 |+-----------------------------------------------+-------+----------+-----+|Total Capital Costs |876 |158 |1,034|+-----------------------------------------------+-------+----------+-----+ Operating Costs The operating cost estimate (OPEX) is based on a conventional open pit mine using surface miners (cutting machinery that does not require drilling and blasting) and haul trucks to a conventional mineral processing plant, and a dry stack tailings facility. The Viken Deposit’s polymetallic endowment allows for the average cash cost (net of by-product credits) per pound of uranium of negative $121/lb U₃O₈ and an AISC per pound of uranium of negative $118/lb U₃O₈ (net of by-product credits) over the life of mine as further detailed below in Table 4. Table 4 - Summary of Viken PEA Production Profile Unit Annually Life of MineTonnes Processed million t 10 127.4Average Grade U3O8 ppm 197Average Grade V2O5 ppm 3,715Average Grade SOP % 4.12Total Pounds U3O8 million lbs 3.3 41.8Total Pounds V2O5 million lbs 16 203.9Vanadium Electrolyte (V Electrolyte) million litres 37 474.4Ferrovanadium (FeV) million kg 6 76.2Sulphate of Potash (SOP) thousand t 250 3,200Unit Operating CostOpen Pit Mining US$/t 3.50Processing US$/t 37.43Dry Stack Tailings US$/t 1.81General & Administrative US$/t 1.33SOP Freight US$/t 2.51Total Operating Cost US$/t 46.58Unit Operating Cost US$/lb U3O8 34.57US$/lb V2O5 2.64Operating Margin % 145 Mine Plan The PEA contemplates that the Viken Deposit mine will consist of a single open pit mining operation with surface miners capable of cutting 0.3 m deep into the Alum Shale, and conventional loading and hauling equipment. Open pit mining will be initiated in Year -1 (pre-stripping period) and mining will be completed by the end of Year 13. The mine plan consists of delivering 7.5 Mt of mill feed in Year 1, followed by 10 Mtpa thereafter, at a low LOM strip ratio of 0.2:1. An inter-ramp angle of 45° was used to design the open pit. The pit is planned to be mined in two phases, allowing for in-pit waste rock disposal. The Viken mining operation is envisioned to be owner operated. The Company will undertake all cutting, loading, hauling, and mine site maintenance activities. Drilling and blasting are not required. The anticipated truck size is 91 tonnes, similar to the CAT 777 truck, to be loaded by appropriately sized wheel loaders. The Company will provide mine management and technical services, and support equipment such as dozers, graders, and maintenance vehicles. The Main Waste Rock Storage Facility will be located to the west of the open pit. 127.4 Mt of mill feed will be mined, along with 23.4 Mt of waste rock (primarily limestone). Processing and Metallurgical The process feed is crushed, grinded and floated before being mixed with concentrated sulphuric acid in a pug mill and thermally roasted to convert vanadium, uranium, potassium and associated metals into water soluble sulphate species. This configuration targets high leach recoveries and allows a liberal flotation regime, which can enhance recovery of by-products such as mixed metal precipitate (MMP) and sulphate of potash (SOP). Approximately 35% of the total V₂O₅ production will be directed to vanadium electrolyte production, with the remaining V₂O₅ allocated to FeV production. The processing steps are: · Crushing · Grinding · Flotation · Pug Roasting · SOP Crystallisation · Ion Exchange · Solvent Extraction · Uranium and Vanadium Precipitation · Mixed Metals Precipitation · Residue Handling Next Steps The results for the PEA, using the base case assumptions, indicate that the Viken Deposit has both technical and financial merit. The project’s next steps include: · Drilling to convert Inferred Mineral Resources to the Indicated classification; · An extensive program of confirmatory, variability, and optimization testwork to improve confidence in the proposed process flowsheets, validate recovery assumptions, reduce technical uncertainty, and support future pre-feasibility level process design, engineering development, and cost estimation; · Geotechnical and hydrogeological drilling and studies; and · An environmental baseline study to characterize the existing features of the air, water and soil both on the Viken Property and in the surrounding area. A technical report prepared in accordance with NI 43-101 on the PEA will be filed within 45 days of this news release on District’s issuer profile on SEDAR+ at www.sedarplus.ca. Additional supporting details regarding the information in this news release, will be provided in the PEA technical report, including all qualifications, assumptions and exclusions that relate to the PEA. The PEA technical report is intended to be read as a whole, and sections should not be read or relied upon out of context. Viken Mineral Resource1 Estimate and Geology5 The Viken Mineral Resource Estimate (“MRE”) has been prepared in accordance with NI 43-101, has effective date of April 25, 2025, and takes into account the results from a total of 122 drill holes (by previous operators between 2006 and 2012) on the Viken Property, which consists of the Viken nr 1, Norr Viken, Lill Viken, Norra Leden, and Storviken mineral licenses that are 100% owned by the Company. The spacing of the drill holes ranges from 30 to 380 metres and averages approximately 300 metres. The mineralized Alum Shale extends under the entire Viken Property and beyond its boundaries. The principal assay laboratory, ALS Minerals in Piteå, Sweden, used three different certified reference materials to monitor the accuracy of copper, nickel, uranium and zinc analytical results. Two of the standards were certified for copper, nickel and zinc, whereas the third one was certified for copper, nickel, uranium and zinc. For QA/QC purposes, every 25th sample was sent to a second laboratory for re-analysis. Analyses were performed by ALS Chemex in Öjebyn and ALS Analytica in Luleå, Sweden. There were a total of 48 certified reference materials inserted by the lab for the drill programs. Table 5: 2025 Pit-Constrained Mineral Resource Estimate for the Viken Deposit(1-8) +---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+|Indicated|Tonnes|U3O8 |V2O5 |Mo |Ni |Cu |Zn |P2O5|Ce2O3|Y2O3|La2O3 |K2O|| | | | | | | | | | | | | || |M |ppm |ppm |ppm |ppm |ppm |ppm |ppm |ppm |ppm |ppm |% |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+|456 |175 |2,836 |257 |330 |113 |411 |2,461|88 |492 |7 |3.84 |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+| |Mlb |Mt |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+|Contained|176 |2,851 |258 |332 |114 |413 |1.12 |0.04|0.22 |0.00|17.53 || | | | | | | | | | | | ||Metal | | | | | | | | | | | |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+| | | | | | | | | | | | | |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+|Inferred |Tonnes|U3O8 |V2O5 |Mo |Ni |Cu |Zn |P2O5|Ce2O3|Y2O3|La2O3 |K2O|| | | | | | | | | | | | | || |M |ppm |ppm |ppm |ppm |ppm |ppm |ppm |ppm |ppm |ppm |% |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+|4,333 |161 |2,543 |240 |321 |118 |417 |2,541|88 |528 |7 |3.70 |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+| |Mlb |Mt |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+|Contained|1,538 |24,295|2,293|3,067|1,127|3,984|11.01|0.38|2.29 |0.03|160.27|| | | | | | | | | | | | ||Metal | | | | | | | | | | | |+---------+------+------+-----+-----+-----+-----+-----+----+-----+----+------+---+ Notes: (1)                 Mineral resources which are not mineral reserves do not have demonstrated economic viability. The estimate of mineral resources may be materially affected by environmental, permitting, legal, title, taxation, socio-political, marketing, or other relevant issues. (2)                 The Inferred Mineral Resource in this MRE has a lower level of confidence than that applied to an Indicated Mineral Resource and must not be converted to a Mineral Reserve. It is reasonably expected that the majority of the Inferred Mineral Resource could be upgraded to an Indicated Mineral Resource with continued exploration. (3)                 The Mineral Resource in this MRE was estimated using the Canadian Institute of Mining, Metallurgy and Petroleum (CIM), CIM Standards on Mineral Resources and Reserves, Definitions (2014) and Best Practices Guidelines (2019) prepared by the CIM Standing Committee on Reserve Definitions and adopted by the CIM Council. (4)                 The MRE was based on consensus economics forecast US$ metal prices of $72/lb U3O8, $5/lb V2O5, $17/lb Mo, $8.50/lb Ni, $4.25/lb Cu and $1.30/lb Zn with respective process recoveries of 80%, 80%, 70%, 70%, 50% and 75%. (5)                 Overburden, waste and mineralized US$ mining costs per tonne mined were respectively $2.00, $2.50 and $3.00. (6)                 Processing and G&A US$ costs per tonne processed were respectively $20 and $2. (7)                 Constraining pit shell slopes were 45 degrees. (8)                 The PEA does not include, nor is it based upon, the Inferred Mineral Resource Estimate. The Viken Deposit is hosted within the Cambrian Viken Shale, which is regionally extensive in Sweden and referred to as the Alum Shale. The Alum Shale is enriched in metals such as vanadium, uranium, molybdenum, zinc, copper and nickel. The stratigraphy across the Viken property consists of upper Middle and Upper Cambrian age Alum Shale occurring as both in situ and fault-detached blocks.  The latter having greater potential for economic mineralization, due to imbrication of mineralized blocks. The Alum Shale is mostly exposed at surface and is underlain by Proterozoic granites and gneisses thrust eastward over Archean granitoid basement rocks. The thickness of the Alum Shale host rock has been tectonically increased from 20 to 30 m to approximately 180 m by thrusting and folding during the Silurian. Mineralization of potential economic significance is hosted in Middle and Upper Cambrian Alum Shale, with the Upper Cambrian age strata more enriched in vanadium and uranium than the Middle Cambrian. Vanadium is held in the lattice of a mica mineral named roscoelite. Uranium values are predominantly associated with sub-micrometric uraninite crystals. Nickel, molybdenum, copper and zinc are present as sulphides. The previous technical report on the Viken Deposit recognized additional targets for further exploration with a potential range of 980 to 1,040 million tonnes at grade ranges of 140 to 180 ppm U3O8, 2,170 to 2,740 ppm V2O5 and 210 to 260 ppm Mo. These targets for further exploration are based on the estimated strike length, depth and width of the mineralization, as supported by intermittently spaced drill holes and observations of mineralized outcrops. The targets for further exploration are located adjacent to the margins of the current MRE. The potential quantities and grades of the targets for further exploration are conceptual in nature. There has been insufficient work done by a qualified person to define these estimates as Mineral Resources. The Company is not treating these estimates as Mineral Resources, and readers should not place undue reliance on these estimates. Even with additional work, there is no certainty that these estimates will be classified as Mineral Resources. In addition, there is no certainty that these estimates will prove to be economically recoverable. References 1 See “Cautionary Note Regarding Non-GAAP Financial Measures” below. 2 https://www.uniper.energy/sweden/power-supply-delivers/nuclear-power-sweden 3 https://min-met.com/blog/vanadium-production-and-supply-gaps/ 4 https://www.industryresearch.biz/fr/market-reports/sulphate-of-potash-sop-market-105211 5 Technical Report titled “Updated Mineral Resource Estimate and Technical Report on the Viken Energy Metals Project, Jämtland County, Sweden,” prepared for District Metals Corp., dated June13, 2025 with an effective date of April 25, 2025. Technical Information All scientific and technical information in this news release has been prepared by, or approved by Garrett Ainsworth, P.Geo, President and CEO of the Company and Eugene Puritch, P.Eng, FEC, CET, President of P&E Mining Consultants Inc. Messrs. Ainsworth and Puritch are each a Qualified Person for the purposes of NI 43-101. Mr. Puritch is independent of the Company. Mr. Puritch is responsible for reporting Mineral Resources for the Viken Deposit. Additional P&E independent Qualified Persons contributing to the PEA are Andrew Bradfield, P.Eng., William Stone, PhD, P.Geo., Fred Brown, P.Geo., David Burga, P.Geo., Jarita Barry, P.Geo. and D. Grant Feasby, P.Eng. The METS independent Qualified Person contributing to the PEA is Damian Connelly, FAusIMM (CP) Met. MMSA. FIEAust. Cautionary Note Regarding Non-GAAP Financial Measures Alternative performance measures in this news release such as “cash cost”, “AISC” “free cash flow” are furnished to provide additional information. These non-GAAP performance measures are included in this news release because these statistics are used as key performance measures that management uses to monitor and assess performance of the Viken Deposit, and to plan and assess the overall effectiveness and efficiency of mining operations. These performance measures do not have a standard meaning within International Financial Reporting Standards (“IFRS”) and, therefore, amounts presented may not be comparable to similar data presented by other mining companies. These performance measures should not be considered in isolation as a substitute for measures of performance in accordance with IFRS. Cash Costs Cash costs include site operating costs (mining, processing, site G&A), refinery costs and royalties, but excludes head office G&A and exploration expenses. While there is no standardized meaning of the measure across the industry, the Company believes that this measure is useful to external users in assessing operating performance. All-In Sustaining Cost Site level AISC includes cash costs and sustaining and expansion capital, but excludes head office G&A and exploration expenses. The Company believes that this measure is useful to external users in assessing operating performance and the Company’s ability to generate free cash flow from potential operations. Free Cash Flow Free cash flows are revenues net of operating costs, royalties, capital expenditures and cash taxes. The Company believes that this measure is useful to the external users in assessing the Company’s ability to generate cash flows from the Viken Deposit. About District Metals Corp. District Metals Corp. is led by industry professionals with a track record of success in the mining industry. The Company’s mandate is to seek out, explore, and develop prospective mineral properties through a disciplined science-based approach to create shareholder value and benefit other stakeholders. District is a 2025 TSX Venture 50 company, ranking among the top-performing issuers on the TSX Venture Exchange in the past year. District is a uranium polymetallic exploration and development company focused on its flagship Viken Property in Sweden. The Viken Property covers 100% of the Viken Deposit, which contains the largest undeveloped Mineral Resource Estimate of uranium in the world[i] along with significant Mineral Resource Estimates of vanadium, potash, molybdenum, nickel, copper, zinc, and other important and critical raw materials. For further information on the Viken Property, please see the technical report entitled “NI 43-101 Updated Mineral Resource Estimate and Technical Report on the Viken Energy Metals Project, Jämtland County, Sweden” dated effective April 25, 2025, which is available on SEDAR+ at www.sedarplus.ca . On Behalf of the Board of Directors “Garrett Ainsworth” President and Chief Executive Officer(604) 288-4430 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This is information that District Metals is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact persons set out above on June 2, 2026, at 9:56am ET. The Company’s certified advisor on Nasdaq First North Growth Market is Bergs Securities AB, +46 739 49 62 50, ca@bergssecurities.se (rutger.ahlerup@bergssecurities.se). Cautionary Statement Regarding “Forward-Looking Information” This news release contains certain statements that may be considered “forward-looking information” with respect to the Company within the meaning of applicable securities laws. In some cases, but not necessarily in all cases, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “targets”, “expects” or “does not expect”, “is expected”, “an opportunity exists”, “is positioned”, “estimates”, “intends”, “assumes”, “anticipates” or “does not anticipate” or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might”, “will” or “will be taken”, “occur” or “be achieved” and any similar expressions. In addition, any statements that refer to expectations, predictions, indications, projections or other characterizations of future events or circumstances contain forward-looking information. Statements containing forward-looking information are not historical facts but instead represent management’s expectations, estimates and projections regarding future events. Forward-looking information in this news release relating to the Company include, among other things, statements relating to uranium and Alum Shale mining regulation in Sweden; the economic parameters of the PEA and the Viken Deposit; potential of the Viken Deposit; targets for further exploration; the anticipated timeline for completion of the technical report; mineral resource estimates; the cost and timing of any development of the Viken Deposit; the proposed mine plan and mining methods; mining recoveries; processing method and rates; production rates; projected metallurgical recovery rates; infrastructure requirements; capital and operating cost estimates; the projected LOM and other expected attributes of the Viken Deposit; the NPV, IRR and payback period of capital; the uranium industry and uranium prices; government regulations and permitting; estimates of reclamation obligations and closure costs; requirements for additional capital; expectations with respect to project development and permitting, construction and operational processes; availability of services to be provided by third parties; future development methods and plans; and other activities, events or developments that are expected, anticipated or may occur in the future. These statements and other forward-looking information are based on opinions, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, as well as other factors that the Company believes are appropriate and reasonable in the circumstances, as of the date of this news release, including, without limitation, the reliability of exploration and drill results; reliability of data and the accuracy of publicly reported information regarding current, past and historic mines in the Bergslagen district and in respect of the Swedish properties; uranium and Alum Shale exploration and mining regulation in Sweden; the Company’s ability to raise sufficient capital to fund planned exploration activities, maintain corporate capacity; stability in financial and capital markets; the Company’s ability to complete its planned exploration programs; the absence of adverse conditions at mineral properties; no unforeseen operational delays; no material delays in obtaining necessary permits; the price of metals remaining at levels that render mineral properties economic. Forward-looking information is necessarily based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date such statements are made, are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information, including but not limited to risks associated with the following: the results of the inquiry into the mining of Alum Shale in Sweden and the possibility that it will be the subject of a municipal veto; uranium exploration and mining regulation in Sweden; the reliability of historic data on District’s properties; the Company’s ability to raise sufficient capital to finance planned exploration; the Company’s limited operating history; the Company’s negative operating cash flow and dependence on third-party financing; the uncertainty of additional funding; the uncertainties associated with early stage exploration activities including general economic, market and business conditions, the regulatory process, failure to obtain necessary permits and approvals, technical issues, potential delays, unexpected events and management’s capacity to execute and implement its future plans; the Company’s ability to identify Mineral Resources and Mineral Reserves; the substantial expenditures required to establish Mineral Reserves through drilling and the estimation of Mineral Reserves or Mineral Resources; the uncertainty of estimates used to calculated mineralization figures; changes in governmental regulations; compliance with applicable laws and regulations; competition for future resource acquisitions and skilled industry personnel; reliance on key personnel; title matters; conflicts of interest; environmental laws and regulations and associated risks, including climate change legislation; land reclamation requirements; changes in government policies; volatility of the Company’s share price; the unlikelihood that shareholders will receive dividends from the Company; potential future acquisitions and joint ventures; infrastructure risks; fluctuations in demand for, and prices of metals; fluctuations in foreign currency exchange rates; legal proceedings and the enforceability of judgments; going concern risk; risks related to the Company’s information technology systems and cyber-security risks; and risk related to the outbreak of epidemics or pandemics or other health crises. These factors and assumptions are not intended to represent a complete list of the factors and assumptions that could affect the Company. These factors and assumptions, however, should be considered carefully. Although the Company has attempted to identify factors that would cause actual actions, events or results to differ materially from those disclosed in the forward-looking information or information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. Also, many of such factors are beyond the control of the Company. Accordingly, readers should not place undue reliance on forward-looking information. The forward-looking information is made as of the date of this news release, and the Company assumes no obligation to publicly update or revise such forward-looking information, except as required by applicable securities laws. [i] S&P Global Market Intelligence - Market Intelligence Research

Scandinavian ChemoTech secures SEK 6 million Growth Loan from a larger Swedish Financial Institution

The financing forms part of ChemoTech’s long-term financial strategy and will support the Company’s commercial expansion within Animal Care in North America and Europe. By strengthening sales and marketing capacity, the loan is expected to contribute to increased revenues and accelerate the Company’s path toward profitability. It also enhances ChemoTech’s financial flexibility by enabling other funds to be reallocated toward the continued development of the TSE platform. The loan is being provided on highly competitive terms, with an interest rate considerably lower than the Company’s existing loans. The loan term is 36 months and is interest-only for the first eight months. It will be disbursed in two installments of SEK 3 million each. “We are entering a very exciting phase in ChemoTech’s development, where both our technology platform and business model are demonstrating strong progress and validation. This financing has become accessible to us as a result of our strong revenue growth over the past two years and represents an important step, giving us additional resources to accelerate key initiatives, strengthen our organization, and support the recruitment of critical talent as we scale our operations. The loan will enable us to expand our efforts to grow the installed base of TSE systems and increase the usability of TSE therapy among veterinarians. By duplicating best practices and helping clinics increase treatment frequency, we aim to support improved clinical outcomes while also contributing to stronger profitability for our clients,” says Mohan Frick, CEO of Scandinavian ChemoTech.

Norse Atlantic ASA – Updated key information relating to the Rights Issue

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, THE UNITED KINGDOM, CANADA, AUSTRALIA, HONG KONG, JAPAN OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. Arendal, Norway, 2 June 2026 – Reference is made to the stock exchange announcement published by Norse Atlantic ASA ("Norse Atlantic" or the "Company") on 14 April 2026, with key information relating to the fully underwritten rights issue in the Company raising gross proceeds of the NOK equivalent of approximately USD 110 million (the "Rights Issue"). Updated key information relating to the Rights Issue is set out below. Date on which the terms and conditions of the preferential rights issue were announced: 14 April 2026 and updated on 2 June 2026 Last day including right: 2 June 2026 Ex-date: 3 June 2026 Record Date: 4 June 2026 Date of approval: 2 June 2026 Maximum number of new shares: 2,039,664,000. The gross proceeds of the Rights Issue are fixed at the NOK equivalent of approximately USD 110 million. The final number of new shares has been determined based on the USD/NOK daily exchange rate published by Norges Bank on or about 16:00 CEST on the date of the extraordinary general meeting held on 2 June 2026 (the "EGM"), divided by the subscription price of NOK 0.50 per share. Subscription price: NOK 0.50 Ratio preferential rights: Each existing shareholder as of 2 June 2026 (and being registered as such in Euronext Securities Oslo, the Norwegian Central Securities Depository (the CSD) as at the expiry of 4 June 2026 (the Record Date)) will be granted 12.545397 subscription rights for each share registered as held by the shareholder. The number of subscription rights granted to each existing shareholder will be rounded down to the nearest whole subscription right. Subscription ratio: 1:1 (number of new shares per subscription right) Managers: Arctic Securities AS, Pareto Securities AS and SB1 Markets AS Will the rights be listed: Yes, the subscription rights are expected to be listed under ticker code "NORST" ISIN for the preferential rights: NO 0013752709 Other information: The extraordinary general meeting of the Company was held on 2 June 2026 and all required resolutions were adopted, including (i) to increase the share capital of the Company in connection with the Rights Issue, (ii) to grant an authorisation to the board of directors to increase the Company's share capital by issuance of new shares as settlement of fees to the underwriters of the Rights Issue, (iii) to grant an authorisation to the board of directors to increase the Company's share capital by issuance of new shares to bondholders of the Company's "USD 30,000,000 8.5 per cent. senior unsecured convertible bonds 2025/2027" who accept the Company's offer to convert their bonds into new shares in the Company at a conversion price equal to the subscription price of NOK 0.50 per share, and (iv) to grant an authorisation to the board of directors to increase the Company's share capital by up to NOK 3,000,000 by way of a private placement directed at the Company's CEO at a subscription price per share corresponding to the subscription price in the Rights Issue. The Rights Issue remains subject to publication of a prospectus for the offering and listing of the new shares as approved by the Norwegian Financial Supervisory Authority. Contacts: Investors: CFO, Anders Hall Jomaas, anders.jomaas@flynorse.com This information is published in accordance with the requirements of the Continuing Obligations and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. IMPORTANT INFORMATION This announcement does not constitute an offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. Copies of this document may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which such action is barred or prohibited by law. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States. Any offering of the securities referred to in this announcement will be made by means of the Prospectus. This announcement is not a prospectus for the purposes of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 on prospectuses to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71/EC (as amended) as implemented in any EEA Member State (the "Prospectus Regulation"). Investors should not subscribe for any securities referred to in this announcement except on the basis of information contained in the Prospectus. Copies of the Prospectus will, following publication, be available from the Company's registered office and, subject to certain exceptions, on the websites of the Managers. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. In the United Kingdom, this communication is only addressed to and is only directed at Qualified Investors as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading regulations 2024, and that are (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (the "Order") or (ii) persons falling within Article 49(2)(a) to (d) of the Order (high net worth companies, unincorporated associations, etc.) (all such persons together being referred to as "Relevant Persons"). These materials are directed only at Relevant Persons and must not be acted on or relied on by persons who are not Relevant Persons. Any investment or investment activity to which this announcement relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. Persons distributing this communication must satisfy themselves that it is lawful to do so. This document is not for publication or distribution in, directly or indirectly, the United States, Canada, Australia, the Hong Kong Special Administrative Region Of The People's Republic Of China or Japan or Any other jurisdiction in which such release, publication or distribution would be unlawful, and it does not constitute an offer or invitation to subscribe for or purchase any securities in such countries or in any other jurisdiction. In particular, the document and the information contained herein should not be distributed or otherwise transmitted into the United States or to publications with a general circulation in the United States of America. The Managers are acting for the Company in connection with the Rights Issue and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients or for providing advice in relation to the Rights Issue or any other transaction or arrangement referred to in this announcement. Matters discussed in this announcement may constitute forward-looking statements. Forward looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intends", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. Neither the Managers nor any of their respective affiliates makes any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. No reliance may be placed for any purpose on the information contained in this announcement or its accuracy, fairness or completeness. Neither the Managers nor any of their respective affiliates accepts any liability arising from the use of this announcement.

Saab presents first Gripen F

On 2 June Saab had a rollout of the first Gripen F fighter to the Brazilian Air Force during a ceremony held at Saab´s facilities in Linköping, Sweden. Gripen F is the two-seat variant of the Gripen E series and has been developed to meet the training and operational requirements of modern air forces by combining conversion training and combat capability on the same platform. As the launch customer, Brazil played an active role in the co development of the two-seat variant, enabling direct industrial participation and long-term cooperation. Through an extensive transfer-of-technology programme, Brazil has trained hundreds of engineers and technicians while strengthening the advanced design and development expertise within its national industrial base. “The rollout of Gripen F represents a shared achievement between Saab, Brazilian industry and the Brazilian Air Force, reflecting the deep trust we have built together over many years. Developing this aircraft together demonstrates the maturity of this collaboration. It represents not only a highly capable fighter for the Brazilian Air Force, but also the tangible outcome of sustained joint development and shared ambition,” says Lars Tossman, head of Saab’s business area Aeronautics.  Designed for an era of rapid transformation, Gripen F delivers world-class performance, sensors, and revolutionary architecture, mirroring Gripen E. The addition of a fully independent second cockpit enables instructor-guided missions in a fully operational fighter, giving trainee pilots realistic live mission conditions. Consequently, pilot conversion and preparatory training can be dramatically accelerated compared to conventional time, while enhancing operational effectiveness in high-threat environments through shared workload and improved mission command. Before final delivery to the Brazilian Air Force the aircraft will be transferred to Saab’s Flight Test Centre in Sweden, where it will start a dedicated flight test campaign. The 2014 contract with the Brazilian government covers the development and production of 36 fighter aircraft: 28 Gripen E and eight Gripen F. Deliveries began in 2020 and to date 11 aircraft have been handed over. Saab has also received Gripen F orders from Thailand and Colombia.  Contact Saab´s Press Center+46 (0)734 180 018presscentre@saabgroup.com Saab is a leading defence and security company with an enduring purpose, to help nations keep their people and society safe. Empowered by its 28,000 talented people, Saab constantly pushes the boundaries of technology to create a safer and more sustainable world. Saab designs, manufactures and maintains advanced systems in aeronautics, weapons, command and control, sensors and underwater systems. Saab is headquartered in Sweden. It has major operations all over the world and is part of the domestic defence capability of several nations.

Corr. of press release: ChemoTech secures 6 MSEK Growth Loan from a Swedish Financial Institution

The financing forms part of ChemoTech’s long-term financial strategy and will support the Company’s commercial expansion within Animal Care in North America and Europe. By strengthening sales and marketing capacity, the loan is expected to contribute to increased revenues and accelerate the Company’s path toward profitability. It also enhances ChemoTech’s financial flexibility by enabling other funds to be reallocated toward the continued development of the TSE platform. The loan is being provided on highly competitive terms, with an interest rate of 10 % per year, which is considerably lower than the Company’s existing loans. The loan term is 36 months and is interest-only for the first eight months. It will be disbursed in two installments of SEK 3 million each. “We are entering a very exciting phase in ChemoTech’s development, where both our technology platform and business model are demonstrating strong progress and validation. This financing has become accessible to us as a result of our strong revenue growth over the past two years and represents an important step, giving us additional resources to accelerate key initiatives, strengthen our organization, and support the recruitment of critical talent as we scale our operations. The loan will enable us to expand our efforts to grow the installed base of TSE systems and increase the usability of TSE therapy among veterinarians. By duplicating best practices and helping clinics increase treatment frequency, we aim to support improved clinical outcomes while also contributing to stronger profitability for our clients,” says Mohan Frick, CEO of Scandinavian ChemoTech.

Norse Atlantic ASA: IndiGo ACMI operations – redelivery of one aircraft

Arendal, Norway, 2 June 2026 -- Norse Atlantic ASA ("Norse Atlantic" or the "Company") was notified by Interglobe Aviation Limited ("IndiGo") of the redelivery of one out of six aircraft operated on ACMI charter due to the closure of a UK route.  The aircraft will be redelivered to Norse Atlantic 31 August 2026. IndiGo will continue to operate all its remaining aircraft leased from Norse Atlantic as planned. Following redelivery, the aircraft will be deployed by Norse Atlantic in its upcoming winter program for direct flights between Europe and Thailand. “With the additional aircraft, we look forward to deploying extra capacity on our successful and profitable Thailand routes. We also continue to strengthen our strong partnership with IndiGo and have jointly initiated a strategic collaboration project to assess new and deeper cooperation”, says Eivind Roald, CEO of Norse Atlantic. Abhijit Dasgupta, Senior Vice President - Network Planning & Revenue Management, IndiGo, says, “We inducted these leased wide-body aircraft to fast-track our connectivity to high potential long-haul destinations such as Manchester and witnessed very encouraging demand response. It is, therefore, unfortunate that longer flying times due to airspace constraints combined with dramatically escalating costs compelled us to take the decision to discontinue India – Manchester services. The response and support for these services have reinforced our belief in the opportunity for IndiGo’s long-haul ambitions, and we are convinced that this discontinuation is temporary. We look forward to serving this route again at the earliest viable opportunity and are exploring innovative solutions to continuing our collaboration with Norse Atlantic Airways.” Norse Atlantic commenced ACMI operations for IndiGo in March 2025, with a total of six Boeing 787-9 aircraft progressively deployed through early 2026. Contacts Investors: CFO, Anders Hall Jomaas, anders.jomaas@flynorse.comMedia: Bård Nordhagen, CCCO, baard.nordhagen@flynorse.com About Norse Atlantic ASA Norse Atlantic Airways is an airline committed to offering affordable fares on direct, long-haul flights to popular destinations, along with specialized charter and ACMI services for tailored travel needs and extensive cargo operations. Norse Atlantic operates a modern fleet of 12 fuel-efficient Boeing 787 Dreamliners, serving a network of destinations across North America, Europe, Africa and Asia. This information is considered to be inside information pursuant to the EU Market Abuse Regulation (MAR) and is subject to the disclosure requirements pursuant to MAR article 17 and section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Bård Nordhagen on the time and date provided.

The Board of Directors of Metacon has resolved on a capital raising of up to approximately SEK 144 million through a rights issue of shares and a directed issue of convertible debentures

Christer Wikner, CEO of Metacon, comments: "It is gratifying to announce that we have now secured resources for the continued development of Metacon. We do so at a time when the focus in the world around us, driven by powerful new forces, is rapidly turning towards hydrogen as a unique opportunity for national independence in critical sectors such as energy, steel manufacturing, food supply and fuel for various types of transport on road, at sea and in the air. I also note a strong confidence in the Company's future prospects, as all members of the Board of Directors and management intend to subscribe in the issue and collectively defend their existing ownership.” Background and rationale for the Capital Raising Metacon has undergone very rapid growth in recent years and is now involved, both in terms of sales efforts and deliveries, in the type of hydrogen projects that are the largest on the market. Throughout this journey, the Company has operated efficiently with, in context, limited resources compared to its competitors. The strength of this is that Metacon has today built a competitive and delivery capability with a low cost base, enabling the Company to compete for virtually all types of business within the field and allowing a small number of new projects to bring the Company into solid profitability. At the same time, it is evident that a business with a strategy targeting large-scale projects requires stronger finances in order to reach its full potential. In this context, it is the Company's assessment that the existing working capital is not sufficient for the current needs over the coming twelve months. Metacon sees an opportunity to, with a more robust sales organisation, convert more projects in its growing sales pipeline, which currently comprises over 150 active customer dialogues. The Company also strives to drive forward its innovative portfolio of various growth initiatives within both electrolysis and reforming in a more impactful manner. Taken together, an external injection of resources is therefore a logical and necessary step for the Company to take on its journey forward. In light of the above, the Board of Directors has, pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026, resolved to carry out the Capital Raising. Use of the proceeds from the Capital Raising Through the Capital Raising, Metacon may receive a maximum of approximately SEK 144 million before deduction of transaction costs, which amount to approximately SEK 16 million (including guarantee fee for the guarantee undertaking received). Given the Company’s current business plan and provided that the Rights Issue is fully subscribed, the proceeds from the Capital Raising are intended to finance the Company over the coming twelve months in accordance with the following order of priority: i. Repayment of temporary project financing – approximately 45 per cent. Repayment of previously incurred temporary debt financing, including interest. The financing was raised in January 2026 to cover the Company's working capital requirements in relation to ongoing customer projects. ii. Project financing and delivery capabilities – approximately 35 per cent. Supporting the Company's working capital requirements in connection with the execution of ongoing and future customer projects. This includes financing of project-related expenditures arising before payments are received from customers. In addition, part of the proceeds will be used to further develop the Company's delivery processes, systems, reference projects and organisation with the aim of improving execution efficiency, scalability, product demonstration capacity and profitability as the project portfolio grows. iii. Acceleration of marketing and commercial activities within the electrolysis business area – approximately 20 per cent. Strengthening the sales team for the broader European market, expansion into new geographic markets such as South America, and initiating work to establish a reference project to demonstrate the Company's products. The Rights Issue Terms of the Rights Issue Anyone who, on the record date of 10 June 2026, is entered in the Company's share register as a shareholder will receive one (1) subscription right for each share held in the Company. Five (5) subscription rights entitle the holder to subscribe for two (2) shares. The subscription price has been set at 0.20 SEK per share, which means that Metacon will receive gross proceeds of approximately 109 MSEK before deduction of issue costs, provided that the Rights Issue is fully subscribed. In addition, investors are offered the opportunity to apply for subscription of shares without the support of subscription rights. Shareholders who choose not to participate in the Rights Issue will, as a result of the Rights Issue, have their shareholding diluted by up to approximately 28.6 per cent (calculated on the total number of outstanding shares and votes in the Company following completion of the Rights Issue). However, these shareholders have the opportunity to compensate themselves financially for this dilution effect by selling their subscription rights. The last day of trading in the Company’s shares, including the right to receive subscription rights in the Rights Issue, is 8 June 2026. The shares will be traded excluding the right to receive subscription rights in the Rights Issue from 9 June 2026. The subscription period, with or without subscription rights, runs from and including 12 June 2026 until and including 26 June 2026. Trading in subscription rights will take place on the Nasdaq First North Growth Market during the period from and including 12 June 2026 until and including 23 June 2026, and trading in BTA (Swe. betald tecknad aktie) will take place on the Nasdaq First North Growth Market during the period from and including 12 June 2026 until and including around 8 July 2026. The full terms and conditions of the Rights Issue, as well as information about the Company, will be set out in an information document which is expected to be published on the Company’s website around 4 June 2026. Subscription commitments and guarantee undertaking Existing shareholders, all members of the Company's Board of Directors and all senior executives of the Company have entered into subscription commitments amounting to approximately SEK 2.4 million, corresponding to approximately 2.2 per cent of the Rights Issue. No consideration is payable for the subscription commitments entered into. In addition, Pareto Securities AS (the parent company of Pareto Securities AB, hereinafter "Pareto") has entered into a guarantee undertaking agreement totalling SEK 75.0 million, corresponding to approximately 68.8 per cent of the Rights Issue. Pursuant to the guarantee undertaking, Pareto shall subscribe for any shares not otherwise subscribed for up to approximately SEK 77.4 million. The guarantee fee is payable in cash and amounts to 8 per cent of the guaranteed amount. Pareto has entered into a put option agreement for a predetermined consideration with Fenja, pursuant to which Pareto is entitled to sell shares acquired in the Rights Issue to Fenja at a price corresponding to the subscription price in the Rights Issue. Pareto may terminate its guarantee undertaking before the Rights Issue is completed if certain termination events occur, including a material adverse effect on the Company, or if circumstances such as force majeure events or material trading restrictions occur which, in the assessment of Pareto, make it impossible, impracticable or inappropriate to complete the Rights Issue. In total, the Rights Issue is covered by subscription commitments and a guarantee undertaking of up to approximately SEK 77.4 million, corresponding to approximately 71.0 per cent of the Rights Issue. Neither the subscription commitments nor the guarantee undertaking are secured by a bank guarantee, blocked funds, pledges or similar arrangements. Further information regarding the parties that have entered into subscription commitments and guarantee undertaking will be available in the information document that the Company will publish prior to the commencement of the subscription period. Indicative timetable for the Rights Issue +--------------------------------------+---------------------------+|Estimated date for publication of the |4 June 2026 ||information document | |+--------------------------------------+---------------------------+|Last day of trading in the share, |8 June 2026 ||including subscription rights | |+--------------------------------------+---------------------------+|First day of trading in the share |9 June 2026 ||excluding subscription rights | |+--------------------------------------+---------------------------+|Record date for the rights issue |10 June 2026 |+--------------------------------------+---------------------------+|Trading in subscription rights |12 June 2026 - 23 June 2026|+--------------------------------------+---------------------------+|Subscription period |12 June 2026 - 26 June 2026|+--------------------------------------+---------------------------+|Trading in BTAs |12 June 2026 - 8 July 2026 |+--------------------------------------+---------------------------+|Estimated date for the announcement of|26 June 2026 ||the preliminary outcome of the Rights | ||Issue | |+--------------------------------------+---------------------------+ Information document In connection with the Rights Issue, the Company will prepare an information document (“Information Document”) in accordance with Article 1.4(db) of Regulation (EU) 2017/1129 of 14 June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market and repealing Directive 2003/71/EC (the “Prospectus Regulation”). The Information Document will be drawn up in accordance with Annex IX to the Prospectus Regulation. The Information Document relating to the Rights Issue is expected to be published around 4 June 2026. An Information Document and application form will be made available prior to the commencement of the subscription period on Metacon’s website, www.metacon.com, as well as on Pareto Securities AB’s website, www.paretosec.com. Agreement on convertible loan and issue of convertible debentures The Company has, today, 2 June 2026, entered into the Loan with the Lender. The Lender is entitled, at its sole discretion, to request the conversion of up to 35 MSEK of the Loan into shares in the Company at a conversion price corresponding to the subscription price in the Rights Issue, provided such request is notified no later than ten (10) banking days after registration of the Rights Issue with the Swedish Companies Registration Office. If the Lender does not request conversion after this time period, in whole or in part, the unconverted amount shall remain as a convertible loan under the terms of the loan agreement, with a conversion price of 0.25 SEK (the "Remaining Convertible Debt"). The arrangement fee for the Loan corresponds to SEK 1.75 million. The Company may repay the Loan (including accrued interest), in whole or in part, and at its sole discretion, at any time prior to the Loan’s maturity date without any additional cost. The Loan (including the Convertible Debentures) bears interest at an annual rate of STIBOR 3M, where STIBOR is set at a minimum of two per cent, plus an interest margin of nine per cent. Interest begins to accrue only when the Loan is released to the Company from a designated escrow account, which is expected to occur around two banking days after registration of the Rights Issue with the Swedish Companies Registration Office. Interest is calculated on a 360-day basis and is payable in cash quarterly on the last day of each quarter. The Loan matures on 30 November 2027, unless it has been converted or repaid prior to that date. If the outstanding loan amount at the time of an interest payment exceeds ten per cent of the Company’s market capitalisation (measured as the number of outstanding shares multiplied by the equally weighted daily volume-weighted average price during the twenty trading days preceding and including the relevant interest payment date), the Lender is entitled to demand that the Company repay the Loan so that the outstanding amount does not exceed ten per cent of the market capitalisation. This right of the Lender shall apply only from and including the interest payment date falling on 31 December 2026. In accordance with the Loan, the Board of Directors has, pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026, resolved on a directed issue of 35,000,000 Convertible Debentures with a total loan amount of SEK 35 million. Payment for the Convertible Debentures shall be made partly by set-off against the Lender's existing claim of SEK 1.75 million, in respect of the arrangement fee for the Loan, and partly through cash payment of the remaining amount. The subscription price for the Convertible Debentures corresponds to the nominal amount of the Convertible Debentures (SEK 1). The right to subscribe for the Convertible Debentures, in deviation from the shareholders' preferential rights, vests exclusively in the Lender. The Lender has subscribed for and been allotted all the Convertible Debentures. Payment for the Convertible Debentures to be paid in cash must be made no later than on 9 June 2026. The reason for the deviation from the shareholders’ preferential rights is that the Company has entered into the Loan with the Lender as an integral part of the Capital Raising, for the purpose of strengthening the Company's financial position through refinancing of existing debt, securing sufficient working capital for the execution of ongoing and future customer projects, and accelerating the Company’s commercial activities and sales efforts. The Convertible Debentures issue is directly linked to the Loan and enables the Lender, in accordance with the terms of the Loan, to convert all or part of the loan amount of SEK 35 million into shares in the Company, which reduces the Company’s indebtedness and strengthens its balance sheet. The issue of the Convertible Debentures to the Lender constitutes a prerequisite for the Company to benefit from the financing provided by the Loan and is thus necessary for the completion of the Capital Raising in its entirety. The Board of Directors considers that the terms of the Convertible Debentures issue have been set on market terms through arm’s length negotiations with the Lender, that the terms accurately reflect current market conditions and demand, and that the issue is in the best interests of the Company and its shareholders. The conversion price for the Convertible Debentures amounts to 0.20 SEK per share, corresponding to the subscription price in the Rights Issue, provided that the Lender requests conversion no later than ten (10) banking days after registration of the Rights Issue with the Swedish Companies Registration Office. In the event that the Lender does not request conversion within this period, in whole or in part, the conversion price for the Remaining Convertible Debt amounts to 0.25 SEK per share, corresponding to 125 per cent of the subscription price in the Rights Issue. Holders of Convertible Debentures of series 2026/2027 are entitled, from the date of registration of the Convertible Debentures with the Swedish Companies Registration Office up to and including 30 November 2027, to request the conversion of all or part of the loan amount into new shares in the Company. The convertible loan falls due for payment on 30 November 2027, insofar as repayment or conversion has not taken place prior to that date. The Convertible Debentures will not be admitted to trading and are subject to terms and conditions containing customary adjustment clauses. Undertaking to issue warrants The Company has undertaken to resolve on a directed issue of warrants issued free of charge to Fenja as part of the consideration for Fenja's undertakings in connection with the Capital Raising. The Board of Directors intends to resolve on the directed issue of the warrants, pursuant to the authorisation granted by the Annual General Meeting on 19 May 2026, no later than ten banking days after registration of the Rights Issue with the Swedish Companies Registration Office. The exercise price for the warrants shall amount to 140 per cent of the subscription price in the Rights Issue. The warrants are intended to be exercisable for the subscription of new shares in the Company from the date on which the warrants are registered with the Swedish Companies Registration Office until 31 May 2031. The warrants will not be admitted to trading. The warrants will be subject to terms and conditions containing customary adjustment clauses. The number of warrants to be issued to Fenja will correspond to three per cent of the total number of shares in the Company, based on the total number of outstanding shares in the Company immediately following the completion of the Rights Issue, including shares that may be issued through conversion of the Loan to the extent the Lender has requested conversion no later than ten banking days after registration of the Rights Issue with the Swedish Companies Registration Office, but excluding shares that may be issued through conversion of the Remaining Convertible Debt. Shares and share capital If the Rights Issue is fully subscribed, the number of shares will increase by 545,435,760, from 1,363,589,402 to 1,909,025,162 and the share capital will increase by SEK 5,454,357.60, from SEK 13,635,894.02 to SEK 19,090,251.62. For existing shareholders who do not participate in the Rights Issue, this entails, upon full subscription in the Rights Issue, a maximum dilution of approximately 28.6 per cent of the number of shares and votes in the Company. In the event that the Rights Issue is fully subscribed and the Lender exercises its right to conversion of 35 MSEK in full, the number of shares will increase by a maximum of 720,435,760, from 1,363,589,402 to 2,084,025,162, and the share capital will increase by a maximum of SEK 7,204,357.60, from SEK 13,635,894.02 to SEK 20,840,251.62. For existing shareholders who do not participate in the Rights Issue, this entails a maximum dilution of approximately 34.6 per cent of the total number of shares and votes in the Company. Lock-up undertakings Prior to the completion of the Capital Raising, all shareholding board members and senior executives of the Company have entered into lock-up undertakings which, among other things, mean that they have undertaken, with certain customary exceptions, not to dispose of shares in the Company. The lock-up undertakings will cease to apply on the date falling 180 days after the settlement date of the Rights Issue. Furthermore, the Company has undertaken towards Pareto, with customary exceptions and with the exception of issues attributable to the Loan and the Company's outstanding incentive programmes, not to issue additional shares or other equity-related instruments for a period of 180 days after the settlement date of the Rights Issue. Advisors Pareto Securities AB is Sole Manager and Bookrunner; BAHR Advokatbyrå AB is legal adviser to the Company; and Baker & McKenzie Advokatbyrå KB is legal adviser to Pareto Securities AB in connection with the Capital Raising. For further information, please contact: Christer Wikner, CEO & Group CEO, +46 707 647 389, christer.wikner@metacon.com Mattias Jansson, CFO, +46 722 316 862, mattias.jansson@metacon.com This information constitutes inside information which Metacon AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, on 2 June 2026 at 18:45 (CEST). About Metacon AB (publ) Metacon AB (publ) is a Swedish company that develops, manufactures and supplies systems for hydrogen production. The offering covers the entire chain from design and installation to service and maintenance. The company is listed on the Nasdaq First North Growth Market in Stockholm. In the field of electrolysis, Metacon develops and supplies complete electrolysis plants for large-scale hydrogen production. Operations are conducted in close collaboration with PERIC Hydrogen Technologies in Handan, China, one of the world’s leading players in pressurised alkaline electrolysis technology. In the field of reforming, the company develops solutions for hydrogen production based on patented catalytic reactor technology, HIWAR®. These are advanced, highly efficient systems that produce hydrogen through catalytic steam reforming. The systems can be fuelled by biogas, biomethane or other renewable feedstocks such as bioethanol and green ammonia and can be installed without connection to the electricity grid. For more information, see: www.metacon.com | X: @Metaconab | On LinkedIn: www.linkedin.com/company/metaconab Important information The information contained in this press release is not intended for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Belarus, Canada, Hong Kong, Japan, New Zealand, Russia, Singapore or South Africa, or in any other country or jurisdiction where this would be unlawful or would require a prospectus or additional information documents, registration or other measures in addition to those required under Swedish law. This press release is for information purposes only and does not constitute an offer to sell or issue, purchase or subscribe for, any of the securities described herein (collectively, the “Securities”) or any other financial instrument in Metacon AB (publ) (“Metacon”). Any offer relating to securities in connection with the Rights Issue will be made solely through the Information Document that Metacon intends to publish around 4 June 2026 on www.metacon.com. Before making an investment decision regarding securities in the Rights Issue, persons reading this press release should ensure that they fully understand and accept the risks that will be set out in the Information Document, if published. No reliance should be placed on the information in this press release or its accuracy or completeness. The offers are not being made to, and subscription forms are not being accepted from, subscribers (including shareholders), or persons acting on behalf of subscribers, in all jurisdictions where such subscription applications would contravene applicable laws or regulations or would require the preparation or registration of a prospectus or additional information documents or the taking of other measures beyond those required under Swedish law. Actions in contravention of the restrictions may constitute a breach of applicable securities legislation. None of the Securities have been or will be registered under the U.S. Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, pledged, sold, delivered or otherwise transferred, directly or indirectly, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with other applicable securities legislation. There will be no public offering of any Securities in the United States. In the UK, this press release is directed at and is being communicated only to persons who are “qualified investors” (as defined in paragraph 15 of Schedule 1 to the Public Offers and Admissions to Trading Regulations 2024) and who: (i) have professional experience in investment matters and fall within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), (ii) are high-net-worth entities falling within Article 49(2)(a)–(d) of the Order, or (iii) are persons to whom an invitation or inducement to participate in investment business (within the meaning of section 21 of the Financial Services and Markets Act 2000) may otherwise lawfully be communicated or caused to be communicated (all such persons being collectively referred to as “Relevant Persons”). Persons in the UK who are not Relevant Persons must not act on or rely on the information in this press release or use it as a basis for taking any action. In the UK, any investment or investment activity to which this press release relates is available only to, and will be undertaken only with, Relevant Persons. This press release contains certain information that reflects Metacon’s current views on future events and financial and operational developments. Words such as “intends”, "believes", “expects”, “may”, “plans”, “estimates” and other expressions that imply indications or predictions regarding future developments or trends, and which are not based on historical facts, constitute forward-looking information and reflect Metacon’s views and expectations and involve a number of risks, uncertainties and assumptions that may cause actual events and results to differ materially from any expected future events or performance expressed or implied by the forward-looking statement. The information in this press release is subject to change without prior notice and, except as required by applicable law, Metacon assumes no responsibility or obligation to publicly update or revise any of the forward-looking statements contained herein, nor does it intend to do so. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release. As a result of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise.

Smoltek has decided on a partially guaranteed rights issue of approximately SEK 60 million

Summary · The purpose of the Rights Issue is to accelerate commercialization and industrial scale-up, in accordance with the Company's strategy to enter into service and license agreements (SLA) and joint development agreements (JDA) with the objective of creating conditions for Smoltek to reach positive cash flow from 2027 onwards. · Anyone who, on the record date of 10 June 2026, is entered in the share register maintained by Euroclear Sweden AB has preferential rights to subscribe for Units in the Rights Issue. · For each existing share held on the record date, one (1) unit right is obtained. Nine (9) unit rights entitle you to subscribe for one (1) Unit. Each Unit consists of two (2) shares and one (1) warrant of series TO 9. The warrants are issued free of charge. · The subscription price has been set at SEK 3.00 per Unit, corresponding to SEK 1.50 per share. · Each warrant of series TO 9 entitles the holder to subscribe for one (1) new share in the Company at a subscription price corresponding to 80 percent of the volume-weighted average price for the Company's share during the period from and including January 18, 2027 to and including January 29, 2027, but at least SEK 1.75 and at most SEK 2.50 per share. Subscription of shares with the support of warrants of series TO 9 must take place in accordance with the terms of the warrants during the period from and including February 1, 2027, to and including February 15, 2027. · Provided that the Minimum Level is achieved, the Rights Issue is covered by subscription obligations and guarantee commitments which together aim for the Rights Issue to achieve a total subscription rate of 100 percent, corresponding to approximately SEK 60.4 million. · Existing shareholders, board members and senior executives have, through subscription obligations, undertaken to subscribe for Units in the Rights Issue for a total of approximately SEK 15.4 million, corresponding to approximately 25.6 percent of the Rights Issue. · Of the subscription commitments submitted, approximately SEK 8.0 million, corresponding to approximately 13.2 percent of the Rights Issue, is intended to be paid by offsetting loans. · Guarantee commitments have been provided for a total of approximately SEK 36.2 million, corresponding to approximately 60 percent of the rights issue. Of this, approximately SEK 24.1 million refers to a bottom guarantee from 40 percent up to 80 percent of the Rights Issue, while approximately SEK 12.1 million refers to a top guarantee from 80 percent to 100 percent of the Rights Issue. · If the rights issue is fully subscribed, Smoltek will receive issue proceeds of approximately SEK 60.4 million before issue costs, which are estimated to amount to SEK 8.1 million. In addition, the Company can receive an additional maximum of SEK 50.3 million (before issue costs) upon full exercise of warrants of series TO 9. · Through the rights issue, a maximum of 40,244,922 new shares can be issued, implying a dilution of approximately 18.2 percent. If the rights issue is fully subscribed and all warrants of series TO 9 are used for subscription of new shares, a maximum of 20,122,461 additional shares will be issued, which means a further dilution of approximately 8.3 percent. · In the event that the Rights Issue is oversubscribed, the board may decide, with the support of the authorization of the Annual General Meeting, on a directed issue of a maximum of 6,036,738 Units to a limited number of investors (Over-allotment issue). If the board decides on the Over-allotment issue, this means a further dilution of a maximum of approximately 5.2 percent attributable to the shares, and a further maximum of approximately 2.5 percent attributable to the warrants in the event that these are used to subscribe for new shares. The subscription price in the Over-allotment issue, if carried out, must be market-based and must at least correspond to the subscription price in the Rights issue. · The subscription period in the Rights Issue is estimated to run from and including 12 June 2026 to and including 26 June 2026. Background and motive Smoltek is a Swedish nanotechnology company that develops advanced material and component solutions based on its own patent-protected technology platform for the controlled growth of carbon nanofibers (Carbon Nanofibers, CNF). By controlling the growth of vertical carbon nanofibers on various materials, the company can create extremely thin, conductive and surface-efficient structures with properties that are particularly attractive in semiconductor and energy applications. The technology components with high performance, miniaturization and improved energy efficiency – areas where demand is driven by global megatrends such as AI, electrification and energy transition. Smoltek's technology platform is commercialized through two business areas. The subsidiary Smoltek Semi focuses on the semiconductor industry and develops ultra-thin capacitor solutions for the advanced chip architectures of the future. By using carbon nanofibres, the company can create capacitors with high capacitance on a very small surface area, which addresses critical needs in AI processors, mobile communication and advanced electronics, among others. The subsidiary Smoltek Hydrogen uses the same technology platform in hydrogen and electrochemical applications. Among other things, components for electrolysers are developed here, where carbon nanofiber technology can contribute to lower material consumption, higher efficiency and reduced costs by reducing the need for precious metals such as iridium. The ambition is to enable more cost-effective production of green hydrogen and thereby address a rapidly growing global market in sustainable energy. Smoltek's strategy is based on commercialization through industrial partnerships. In semiconductors, Smoltek Semi collaborates with Taiwanese ITRI for the production and customer validation of the Company's CNF-MIM capacitors, while Smoltek Hydrogen together with Heraeus Precious Metals develops and industrializes the Company's porous transport electrode (PTE) for PEM electrolysers. The company works continuously with prototypes, technical validations and customer dialogues with the aim of entering into service, license and joint development agreements (SLA/JDA) to accelerate the commercialization of the technology. The rights issue constitutes the last step in the financing plan of approximately SEK 100 million that the board presented in December 2024. The board assesses that the issue is necessary to strengthen the Company's financial position and enable continued technology development, investments in industrialization as well as intensified work in sales, business development and partner dialogues. The capital injection aims to finance the next phase of Smoltek's commercialization and create the conditions to reach a positive cash flow from 2027 onwards. The net cash of approximately SEK 52.3 million (of which approximately SEK 8.0 million will be added by offsetting loans) is intended to be used for the following purposes, in order of priority: · Customer-driven development, product adaptations and packaging · Research and development · Investments in fixed assets and equipment linked to industrialization and prototyping · Sales, business development and commercialization activities · Working capital for the Company's ongoing operations The rights issue Anyone who is registered as a shareholder in Smoltek with Euroclear Sweden AB on the record date of 10 June 2026 receives one (1) unit right for each existing share. Nine (9) unit rights entitle you to subscribe for one (1) Unit. Each Unit consists of two (2) newly issued shares and one (1) warrant of series TO 9. The warrants are issued free of charge. In addition, it will be possible to register for the subscription of Units without the support of unit rights. The Rights Issue comprises a maximum of 20,122,461 Units, corresponding to a maximum of 40,244,922 new shares and 20,122,461 warrants of series TO 9. If fully subscribed, the Rights Issue will bring the Company approximately SEK 60.4 million before issue costs. The subscription price has been set at SEK 3.00 per Unit, corresponding to SEK 1.50 per share. Each warrant of series TO 9 entitles the holder to subscribe for one (1) new share in the Company at a subscription price corresponding to 80 percent of the volume-weighted average price for the Company's share during the period from and including January 18, 2027 to and including January 29, 2027, but at least SEK 1.75 and at most SEK 2.50 per share. Subscription of shares with the support of the warrants must take place during the period from and including February 1, 2027, to and including February 15, 2027. The subscription period in the Rights Issue is estimated to run from and including June 12, 2026, to and including June 26, 2026. Unit rights that are not used during the subscription period will then expire and become worthless. Trading in unit rights will take place on the Spotlight Stock Market from and including 12 June 2026 to and including 23 June 2026. Trading in paid subscribed Units (BTUs) will take place, provided that the Minimum Level in the Rights Issue is achieved, from and including 1 July 2026 to and including around week 28 2026. If not all Units are subscribed with the support of unit rights, the board must, within the framework of the Rights Issue's maximum amount, decide on the allocation of Units subscribed without the support of unit rights. Allocation must then take place as follows: · in the first place, allocation must take place to those who subscribed for Units with the support of unit rights, regardless of whether the subscriber was a shareholder on the record date or not, pro rata in relation to the number of unit rights that were used for subscription and, to the extent that this cannot be done, by lottery, · in the second instance, allocation must take place to others who have registered for the subscription of Units without the support of unit rights. In the event that these cannot receive full allocation, allocation shall be made pro rata in relation to the number of Units that each has registered for subscription and, to the extent that this cannot be done, by lottery, · thirdly and lastly, any remaining Units must be allocated to the parties who undertook to guarantee the Rights Issue, in proportion to the guarantee commitments made. Special conditions regarding the rights issue's design Shareholders and other potential investors should note that the Rights Issue is subject to a minimum level for implementation. In order for the Rights issue to be carried out, the subscription, with or without the support of unit rights, must amount to at least 8,048,984 Units, corresponding to approximately 40 percent of the issue amount and approximately SEK 24.1 million. If the Minimum Level is not reached, the Rights Issue will not be carried out. If the Rights Issue is not carried out because the Minimum Level has not been reached, the issue proceeds paid will be refunded to the subscribers. Trading with BTU will only be started on the condition that the Company announces that the Lowest Level has been reached. Please note that cash paid for unit rights acquired on the market will not be refunded if the Rights Issue is not carried out. Investors who acquire unit rights on the market thus risk losing the entire amount paid for these rights. The chosen issue structure aims to create good conditions for both existing shareholders and new investors. Assuming that the Rights Issue is carried out according to plan, the issue proceeds are deemed to enable continued commercialization and industrial scale-up, including work linked to service and license agreements (SLA), joint development agreements (JDA) and other strategic initiatives in line with the Company's long-term strategy to achieve positive cash flow from 2027. Preliminary schedule for the Rights Issue +------------+-----------------------------------------------------------------+|June 8, 2026|Last trading day including the right to receive unit rights |+------------+-----------------------------------------------------------------+|June 9, 2026|First trading day excluding the right to receive unit rights |+------------+-----------------------------------------------------------------+|June 10, |Record date for obtaining unit rights. Shareholders who are ||2026 |registered in the share register maintained by Euroclear Sweden || |AB on this day receive unit rights for participation in the || |Rights Issue |+------------+-----------------------------------------------------------------+|12 June–26 |Subscription period in the Rights Issue ||June 2026 | |+------------+-----------------------------------------------------------------+|12 June–23 |Trading units on the Spotlight Stock Market ||June 2026 | |+------------+-----------------------------------------------------------------+|July 1 |Trading BTUs on the Spotlight Stock Market (provided that the ||through week|Minimum Level of the Rights Issue is reached) ||2026 | |+------------+-----------------------------------------------------------------+|Around June |Estimated date for publication of the outcome of the Rights Issue||29, 2026 | |+------------+-----------------------------------------------------------------+|June 9, 2026|Estimated date of publication of the information document |+------------+-----------------------------------------------------------------+ Underwriting obligations and guarantee commitments The rights issue is covered by subscription obligations and guarantee commitments which together aim to achieve a subscription rate of up to 100 percent of the rights issue, corresponding to approximately SEK 60.4 million. Existing shareholders, board members and senior executives have entered into subscription obligations totaling approximately SEK 15.4 million, corresponding to approximately 25.6 percent of the Rights Issue. Payment of Units corresponding to approximately SEK 8.0 million of the subscription commitments, corresponding to approximately 13.2 percent of the Rights Issue, is intended to be carried out by offsetting loans provided by, among others, David Gramnaes (through Gramtec Invest AB), Oskar Säfström (through Helm Properties AB) and Magnus Andersson (through Innocreate AS) under the loan agreements that the Company previously announced through press releases on February 11, 2026 and April 20, 2026. After that has taken place, the Company's remaining debt under the aforementioned loan agreement is estimated to amount to a total of approximately SEK 10.7 million. Furthermore, Mangold Fondkommission has provided guarantee commitments on customary terms, which in total amount to approximately SEK 36.2 million, corresponding to approximately 60 percent of the Rights Issue. Of this, approximately SEK 24.1 million refers to a bottom guarantee from 40 percent up to 80 percent of the Rights Issue, while approximately SEK 12.1 million refers to a top guarantee from 80 percent to 100 percent of the Rights Issue. Mangold Fondkommission has the necessary permission to act as an issue guarantor and has entered into separate put option agreements against a predetermined fee with a number of natural and legal persons according to which Mangold Fondkommission has the right to sell any Units that are allocated to Mangold Fondkommission in the Rights Issue within the framework of its guarantee commitment at a price corresponding to the subscription price in the Rights Issue. Guarantee compensation is paid in cash and amounts to 10 percent of the guaranteed amount within the framework of the bottom guarantee and 10 percent of the guaranteed amount within the framework of the top guarantee. No compensation is paid for the subscription obligations entered into. None of the above-mentioned subscription commitments or guarantee commitments are secured by bank guarantee, blocked funds, pledging or similar arrangements. Over-allotment issue In addition to the Rights issue, the board can decide on the Over-allotment issue as a directed issue with the support of the authorization from the Annual General Meeting on May 12, 2026. The over-allotment issue amounts to a maximum of 6,036,738 Units. The subscription price in the Over-allotment issue, if carried out, must be market-based and must at least correspond to the subscription price in the Rights issue. The over-allotment issue can be used if the Rights Issue is oversubscribed. The board may, at its discretion, use the Over-allotment Issue to enable further capital injections. Allotment in the Overallotment issue shall primarily be given to strategic and/or qualified investors. Change in number of shares and share capital and dilution Upon full subscription in the Rights Issue, the number of shares in the Company will increase by a maximum of 40,244,922 shares, from 181,102,155 shares to 221,347,077 shares, and the share capital will increase by a maximum of approximately SEK 4,794,307.23, from approximately SEK 21,574,383.24 to approximately 26,368 SEK 690.47, corresponding to a dilution of approximately 18.2 percent of the capital and votes in the Company. In the event of full exercise of all warrants of series TO 9 that can be issued within the framework of the Rights Issue, the number of shares may increase by a further maximum of 20,122,461 shares, to a total of a maximum of 241,469,538 shares, and the share capital may increase by a further maximum of approximately SEK 2,397,153.61, to a total maximum of approximately SEK 28,765,844.08. This corresponds to a further dilution of approximately 8.3 percent. The total dilution, assuming full subscription in the Rights Issue and full utilization of all warrants of series TO 9 that can be issued within the scope of the Rights Issue, thus amounts to approximately 25.0 percent of the capital and votes in the Company. In the event that the Rights issue is fully subscribed, and the board decides on the Over-allotment issue, a maximum of 6,036,738 Units can be issued, corresponding to a maximum of 12,073,476 shares and 6,036,738 warrants of series TO 9. This would mean that the number of shares in the Company increases by a maximum of 12,073,476 shares and that the share capital increases by a maximum of approximately 1 SEK 438,292.10, corresponding to a further dilution of approximately 5.2 percent of the capital and votes in the Company. In the event of full utilization of the warrants of series TO 9 issued within the framework of the Over-allotment issue, the number of shares may increase by a further maximum of 6,036,738 shares and the share capital may increase by a further maximum of approximately SEK 719,146.05, corresponding to a further dilution of approximately 2.5 percent of the capital and votes in the Company. The maximum dilution effect through the Rights issue and the Over-allotment issue thus amounts to approximately 22.4 percent excluding full exercise of all warrants of series TO 9, and to approximately 30.2 percent including full exercise of all warrants of series TO 9. Information document No prospectus will be drawn up in connection with the Rights Issue. The company will prepare and publish a simplified information document (the "Information Document") in accordance with Spotlight Stock Market's issuer regulations. The information document will be available on the Company's website no later than June 9, 2026. Advisor Redeye Corporate Finance and Mangold Fondkommission act as financial advisors and Fredersen Advokatbyrå acts as legal advisor to the Company in connection with the Rights Issue. Mangold Fondkommission also acts as issuing institution. For further information Magnus Andersson, CEO of Smoltek Nanotech Holding AB E-mail: magnus.andersson@smoltek.com   Phone: +46 317 01 03 05 Website: www.smoltek.com/investors   About Smoltek Smoltek Nanotech Holding is a public technology company that provides a technology that enables the production of conductive nanostructures on various materials. The company's technology multiplies the actual surface area for electrical and chemical processes and can be used in several industrial sectors. Customers are found in semiconductors and the global process industry. The products that the company develops are used as infrastructure components for stable power supply to microchips as well as electrodes and coating of surface structures in applications for the production and use of fossil-free hydrogen. The company protects its carbon nanotechnology through an extensive patent portfolio. Smoltek’s share is listed on the Spotlight Stock Market under the ticker symbol SMOL. Smoltek is a development company and forward-looking statements regarding time to market, production volume and price levels should be interpreted as forecasts and not commitments. Important information Publication, publication or distribution of this press release may be subject to restrictions by law in certain jurisdictions. Recipients of this press release in the jurisdictions where this press release has been published or distributed should inform themselves of and comply with such legal restrictions. The recipient of this press release is responsible for using this press release and the information contained herein in accordance with the applicable regulations of the respective jurisdiction. This press release does not constitute an offer to acquire or subscribe for shares or other securities issued by the Company, either from the Company or from anyone else, in any jurisdiction where such offer or such invitation would be contrary to applicable regulations or require additional registration or other measures. This press release is not a prospectus within the meaning of Regulation (EU) 2017/1129 (the “Prospectus Regulation”) and has not been approved by any regulatory authority in any jurisdiction. No prospectus has been drawn up or will be drawn up in connection with the Rights Issue. In each EEA Member State, this notice is addressed only to “qualified investors” in that Member State as defined in the Prospectus Regulation. This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States without registration, or without application of an exemption from registration, under the then-current U.S. Securities Act of 1933 (“Securities Act”), and may not be offered or sold in the United States without being registered, subject to an exemption from, or in a transaction not subject to the registration requirements of the Securities Act. There is no intention to register any securities mentioned herein in the United States or to make a public offering of such securities in the United States. The information in this press release may not be published, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, in or to the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa, South Korea or any other jurisdiction where such publication, publication or distribution of this information would be in conflict with current regulations or where such action is subject to legal restrictions or would require additional registration or other measures than what follows from Swedish law. Actions contrary to this instruction may constitute a violation of applicable securities legislation. In the United Kingdom, this document, and other materials relating to the securities referred to herein, are distributed and directed only to, and an investment or investment activity relating to this document is only available to, and will only be exercised by, “qualified investors” who are (i) persons who have professional experience in activities relating to investment and who fall within the definition of “professional investors” in section 19(5) of the UK Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (“The Order”); or (ii) high net worth persons referred to in Article 49(2)(a)-(d) of the Order (all such persons being collectively referred to as “relevant persons”). An investment or an investment measure to which this notice relates is available in the UK only to relevant persons and will only be carried out with relevant persons. Persons who are not relevant persons should not take any action based on this press release nor act or rely on it. This press release neither identifies nor purports to identify any risks (direct or indirect) that may be associated with an investment in new shares. The information in this press release is only intended to describe the background to the Rights Issue and does not claim to be complete or exhaustive. No assurance is given regarding the information in this press release regarding its accuracy or completeness. An investment decision to acquire or subscribe for shares in connection with the Rights Issue may only be made based on publicly available information regarding the Company and the Company's shares. Failure to follow these instructions may constitute a violation of the Securities Act or applicable laws in other jurisdictions. The company assesses that it conducts activities worthy of protection according to the Act (2023:560) on the review of foreign direct investments ("FDI Act"). In accordance with the FDI Act, the Company must inform prospective investors that the Company's operations may fall within the scope of the regulation and that the investment may be subject to notification. If an investment is subject to notification, it must be notified to the Inspectorate for Strategic Products (ISP) before it is carried out. An investment may be subject to notification if the investor, someone in his ownership structure or someone on whose behalf the investor acts, after the investment is carried out, holds votes corresponding to or exceeding any of the limit values of 10, 20, 30, 50, 65 or 90 percent of the total number of votes in the Company. The investor may be charged an administrative penalty fee if an investment that is subject to notification is carried out before the ISP either: i) decides to leave the notification without action, or ii) approves the investment. Each investor should consult an independent legal advisor regarding the possible application of the FDI Act in relation to the Rights Issue for the individual investor. Forward-looking statements This press release contains forward-looking statements that refer to the Company's intentions, assessments or expectations regarding the Company's future results, financial position, liquidity, development, prospects, expected growth, strategies and opportunities as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and can be identified by the inclusion of expressions such as "believes", "expects", "anticipates", "intends", "estimates", "will", "may", "anticipates", "should", "could" and, in each case, negations thereof, or similar expressions. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on additional assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will occur or that they are accurate. As these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, the actual result or outcome may, for many different reasons, differ materially from what appears in the forward-looking statements. Such risks, uncertainties, contingencies and other material factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not warrant that the assumptions underlying the forward-looking statements in this press release are correct and any reader of the press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements expressed or implied herein are provided only as of the date of this press release and are subject to change. Neither the Company nor anyone else undertakes to revise, update, confirm or publicly announce any revision of any forward-looking statement to reflect events occurring or circumstances occurring with respect to the contents of this press release, except as required by law or Spotlight Stock Market's issuer regulations.

Autoliv Strengthens Global Safety Innovation

The Innovation Center builds on more than 70 years of safety expertise rooted in Sweden, where Autoliv’s operations have played a pivotal role in advancing traffic safety on a global scale. Technologies developed here have been scaled worldwide and are today protecting road users across vehicle segments. With the Autoliv Innovation Center, Autoliv now takes the next step. By bringing research, system architecture, testing, prototyping and pilot production together in one environment, the center enables faster technical evaluation and shorter development cycles. Advanced digital tools are combined with physical labs and test environments to verify performance in realistic and measurable scenarios. A key foundation of the Innovation Center is Autoliv’s long‑standing triple‑helix approach, where industry, academia, and society collaborate to address complex safety challenges. The ambition is to create an arena for global cooperation that drives innovation across mobility and society, with the ultimate goal of Saving More Lives. “The Autoliv Innovation Center is a strategic development in how we advance safety going forward. By bringing the full innovation chain together, we can move faster from insight to real‑world impact and scale solutions globally. It is also the natural evolution of our long‑established operations in Vårgårda, building on decades of experience and capability. Sweden has played an important role in advancing traffic safety worldwide, and Vårgårda has been central to these accomplishments. What we are doing today is building on that heritage to accelerate the next generation of global safety innovation,” said Fabien Dumont, Executive Vice President & Chief Technology Officer, Autoliv. Over time, the operation in Vårgårda has been central to innovations for road safety including advanced motorcycle safety solutions, the development of Human Body Models (HBM) that improve injury assessment, Load Limit Management (LLM) technologies that enhance restraint performance, Pyrotechnic Safety Switch (PSS) solutions for electrical safety, and safety systems tailored for commercial vehicles. Autoliv’s safety solutions save approximately 40,000 lives and reduce around 600,000 injuries every year, a tangible demonstration of how innovation makes a real difference for society. With increased investment and an expanded platform for collaboration, the Autoliv Innovation Center is set to further accelerate the development of next‑generation safety solutions and help save even more lives in the future. Inquiries:  Media: media@autoliv.com Gabriella Etemad, Tel +46 70 612 64 24, Emelie Ericson, Tel +46 70 957 81 35 Investors & Analysts: ir@autoliv.com Anders Trapp, Tel +46 709 578 171 , Henrik Kaar, Tel +46 709 578 114 About Autoliv Autoliv, Inc. (NYSE: ALV; Nasdaq Stockholm: ALIV.sdb) is the worldwide leader in automotive safety systems. Through our group companies, we develop, manufacture and market protective systems, such as airbags, seatbelts, and steering wheels for all major automotive manufacturers in the world, as well as mobility safety solutions, such as commercial vehicles and electrical safety solutions. At Autoliv, we challenge and re-define the standards of mobility safety to sustainably deliver leading solutions. In 2025, our products saved approximately 40,000 lives and reduced around 600,000 injuries. We have operations in 25 countries, and we drive innovation, research, and development at our 13 technical centers. Our 64,000 employees are passionate about our vision of Saving More Lives and quality is at the heart of everything we do. Sales in 2025 amounted to $10.8 billion. For more information go to www.autoliv.com. Safe Harbor Statement This report contains statements that are not historical facts but rather forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those that address activities, events or developments that Autoliv, Inc. or its management believes or anticipates may occur in the future. All forward-looking statements are based upon our current expectations, various assumptions and data available from third parties. Our expectations and assumptions are expressed in good faith and we believe there is a reasonable basis for them. However, there can be no assurance that such forward-looking statements will materialize or prove to be correct as forward-looking statements are inherently subject to known and unknown risks, uncertainties and other factors which may cause actual future results, performance or achievements to differ materially from the future results, performance or achievements expressed in or implied by such forward-looking statements. Numerous risks, uncertainties and other factors may cause actual results to differ materially from those set out in the forward-looking statements, including general economic conditions and fluctuations in the global automotive market. For any forward-looking statements contained in this or any other document, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and we assume no obligation to update publicly or revise any such statements in light of new information or future events, except as required by law.

Metso launches new primary crushers for unmatched safety and availability in mining

Metso is strengthening its prominent position as a crushing solutions supplier with the launch of three new primary crushers – Metso Primarok™, Metso Optirok™ and Metso Durarok™. Engineered to address the diverse needs of modern mining operations, these high-performance crushers offer superior capacity, safer maintenance, as well as the lowest capital expenditure and total cost of ownership across a wide range of primary crushing applications and ore types. “Mining operations today require crushing solutions that are not only powerful, but predictable, safe, and optimized for the specific application. At the same time, primary crushing as the first stage in concentrate processing lays the foundation for overall recovery efficiency,” says Olli-Pekka Oksanen, Senior Vice President, Crushing at Metso. “Built on proven technologies complemented with major new features, including, for example, data-driven services and performance solutions, the new crushers take performance, availability, and maintainability to a totally new level, resulting in lower total cost of ownership. Primarok offers the highest capacity of any gyratory on the market, while Optirok is designed to address high-capacity primary crushing in compact footprints. Durarok, on the other hand, is a robust solution for materials with variability and moisture constraints and demanding operating conditions,” explains Oksanen. Primary crushing solutions for every application · Metso Primarok™ – engineered for unmatched performance and highest availabilityBuilt on more than a century of experience in gyratory crushing, the Metso Primarok can handle the most demanding primary crushing applications with ease. Its optimized kinematics, refined chamber design and ability to accept large feed sizes drive high efficiency and stable performance. On top of this, it allows for quick and secure shutdowns, as every maintenance task has been streamlined to maximize efficiency and safety.  · Metso Optirok™ – high capacity crushing in a compact footprintAs an evolution of the primary jaw crusher, Metso [AR2.1]Optirok takes crushing to a completely new level in applications with limited space and height. It delivers unmatched productivity, integrated scalping and a high reduction ratio, efficiently processing large volumes of run of mine material while enduring hard rock and abrasive applications. Its innovative features simplify maintenance, improving safety and reducing downtime.  · Metso Durarok™ – robust, simplified sizer designed for maximum enduranceThe Metso Durarok primary sizer combines a simplified, heavy duty design with high performance and durability. Its crushing rolls are engineered to withstand the heaviest loads and generate high crushing forces while maintaining low wear rates. Durarok enables higher utilization and uptime compared to conventional solutions, helping reduce operating costs and increase capacity. It is well suited for handling sticky materials, soft to medium hard ores, and demanding mining applications. Metso’s complete offering and support for crushing operations Metso has delivered thousands of crushers to mining and aggregates customers around the world, building a wide installed base across applications and commodities. The new primary crushers further strengthen Metso’s comprehensive crushing portfolio, which also includes well established jaw, cone, impact and gyratory crushers, which are available as stationary, semi-mobile and mobile solutions. As a leading provider of minerals processing solutions and services, Metso’s offering also covers lifecycle services and upgrades, as well as data-driven services and performance based service models. Read more about the new Metso crushers on our website . Register for the webinar To find out more about the new primary crushers, we invite you to attend the webinar scheduled for June 17, 2026, at 18:00 – 19:30 EEST. You can access the webinar through the registration LINK . Save the date: Metso Summit virtual launch event  A new chapter in minerals processing is about to begin. Join our upcoming Metso Summit virtual launch event on September 10, 2026, to experience our latest revolutionary technologies. Be the first one to discover how these innovations support the entire flowsheet with improved efficiency, sustainability, and customer value. More details will be available soon on our website . Further information:  Vinicius Vilela, Vice President, Mining Crushers, Metso, tel. +1 262 290 7567, email: Vinicius.vilela(at)metso.com  Metso Media Desk, tel. +358 20 482 1930, email: media(at)metso.com Metso is a frontrunner in sustainable technologies, end-to-end solutions and services for the aggregates, minerals processing and metals refining industries globally. We improve our customers’ energy and water efficiency, increase their productivity, and reduce environmental risks with our product and service expertise. We are the partner for positive change.  Metso is headquartered in Espoo, Finland. At the end of 2025 Metso had close to 18,000 employees in around 50 countries, and sales in 2025 were about EUR 5.3 billion. Metso is listed on the Nasdaq Helsinki. metso.com 

EQT Real Estate expands its growing UK logistics footprint with acquisition of six assets across key distribution hubs

EQT Real Estate is pleased to announce that the EQT Real Estate Europe Logistics Value Fund V has acquired a portfolio of six logistics assets totaling approximately 1.6 million square feet across Leamington Spa, Didcot, Peterborough and Kettering from Tritax Big Box REIT plc. The assets are fully leased following completion of the lease at Leamington I and are occupied by a diversified tenant base across e-commerce, logistics, publishing, healthcare and consumer industries. Strategically located near major transport routes including the M40, A14, and A1(M) which connect cities including London, Birmingham and Edinburgh, the properties provide access to key UK population centers and established distribution networks. The portfolio consists of modern Grade A properties featuring high clear heights, large loading yards and strong sustainability credentials, with most assets holding Energy Performance Certificate (EPC) A ratings. The acquisition further expands EQT Real Estate’s UK logistics footprint  and complements its broader European logistics portfolio across key distribution corridors and consumption hubs. The investment aligns with EQT Real Estate’s strategy of investing in high-quality logistics assets in supply-constrained markets that are supported by resilient occupier demand and long-term rental growth potential. Jonathan Mackie, Managing Director at EQT Real Estate, said: “We continue to see attractive long-term opportunities in European logistics, supported by structural trends including the  growth of online retail, supply chain optimization and increasing demand for efficient distribution space close to major population centers. This acquisition expands our growing UK logistics footprint and complements our broader European logistics portfolio across established distribution markets.”  ContactEQT Press Officepress@eqtpartners.com

Alleima responds to growing global demand for nuclear power – inaugurates Tube Mill 2026 in Sandviken

Photo: Alleima, Göran Björkman, CEO and President Alleima on stageThe inauguration of Tube Mill 2026 is a direct response to the growing global interest in nuclear power. The expansion includes the upgrade and reopening of one of Alleima’s production facilities for steam generator tubes. The new facility increases Alleima’s production capacity by approximately 60%, and the order base is solid, extending well into the future. The entire project has been completed according to plan and will be operational during 2026. “The opening of Tube Mill 2026 marks an important milestone for Alleima. By upgrading and reopening our tube mill, we strengthen our ability to meet the growing demand within the nuclear segment, both for conventional nuclear power plants and for small modular reactors. This is a central part of our strategy and demonstrates that we are a leading supplier of high-technology products based on quality, reliability, and long-standing industry experience,” says Göran Björkman, CEO of Alleima. For more than 60 years, Alleima has supplied critical components to the nuclear industry worldwide. The company already has around 300 employees directly involved in its nuclear operations, a number that is now increasing by nearly 100 employees. In addition to conventional nuclear power, the company sees strong potential for SMRs. Recently, major technology companies have also begun to show interest in nuclear power for their data centers driven by the need for large amounts of stable and fossil-free electricity around the clock. Among those present at the event were several key players in the nuclear industry, including Doosan Enerbility, NuScale Power, Rolls-Royce SMR, and Westinghouse. “Today, we have customers from all over the world here in Sandviken. This demonstrates that we have established ourselves as a reliable, stable, and long-term partner, manufacturing world-leading products for extremely demanding environments. Strong and close collaboration with our customers is essential for us, and we are therefore very pleased to celebrate this together,” says Carl von Schantz, President of the Tube Division at Alleima. Alleima supplies fuel cladding tubes, steam generator tubes, and nuclear-grade components, and also conducts research on tubing for future cooling technologies. Sandviken, Sweden, June 3, 2026 Alleima AB (publ) Contact detailsFrida Adrian, Head of Investor Relationsfrida.adrian@alleima.com+46 (0) 70 930 93 24 Yvonne Edenholm, Press and Media Relations Manageryvonne.edenholm@alleima.com+46 (0) 72145 23 42 Related LinksFotos from the event About AlleimaAlleima, is a global manufacturer of high value-added products in advanced stainless steels andspecial alloys as well as solutions for industrial heating. Based on long-term customer partnerships and leading materials technology, we develop products for the most demanding applications and industries. Our offering includes products likeseamless steel tubes for the energy, chemical and aerospace industries, precision strip steel for white goods compressors, air conditioners and knife applications, based on more than 900 active alloy recipes. It also includes ultra-fine wires for medical and micro-electronic devices, industrial electric heating technology and coated strip steel for fuel cell technology for cars, trucks, and hydrogen production. Our fully integrated value chain, from R&D to end-product, ensures industry-leading technology, quality, sustainability, and circularity. Alleima, with headquarter in Sandviken, Sweden, had approximately 6,800 employees and revenues of about 19 billion SEK in about 80 countries in 2025. Alleima is listed on Nasdaq Stockholm under the ticker ‘ALLEI’. Learn more atwww.alleima.com 

Volvo Cars reports rolling three-month sales for the period ending May 2026

The company's sales of electrified models – fully electric and plug-in hybrid models – accounted for 48 per cent of all cars sold during the three-month period. Fully electric cars comprised 23 per cent of all cars sold for the period, and plug-in hybrid models accounted for 25 per cent. The automotive industry, including the premium segment, continues to face intensifying headwinds across regions which reflected in the sales performance for the three-month period ending May 2026. Sales in China remain under pressure, as overall industry volumes continue to decline in double-digits for consecutive months. This is due to the highly competitive industry landscape and challenging macro environment. In the US, there are early signs of a recovery for both the industry and Volvo Cars, which is reflected in the gradual improvement in deliveries. However, the overall market still remains impacted by low customer sentiment and subdued demand for fully electric and plug-in hybrid cars post subsidy removal. “Despite all the external challenges, we continue to grow in Europe through electrification,” said Erik Severinson, Chief Commercial Officer at Volvo Cars. “Overall, deliveries of our fully electric cars grew for the eighth consecutive month driven by the strong demand for the EX30 and EX40 electric SUVs in Europe.  We have also seen sustained and strong increase in retail orders for our fully electric models in the region, which further reinforces our strategy to become a leader in premium electrification.” "Additionally, we are excited to receive overwhelmingly positive reviews of our new EX60 fully electric SUV from our customers and the media. Initial customer orders for the car have already surpassed our internal expectations. We are now gearing up to gradually ramp up the production of the car in the second half of the year.” March - May March - May y-o-y 2026 2025 Change (%) Electrified models 85,696 83,216 3% - Fully electric 41,435 37,502 10% - Plug-in hybrid 44,261 45,714 -3%Mild hybrids/ICE 93,284 106,224 -12%Total 178,980 189,440 -5.5%

Changes in UPM’s Group Executive Team: Joonas Rauramo appointed Executive Vice President, UPM Energy

UPM-Kymmene CorporationStock Exchange Release (Changes board/management/auditors)June 3, 2026 at 10:00 EEST Changes in UPM’s Group Executive Team: Joonas Rauramo appointed Executive Vice President, UPM Energy Joonas Rauramo has been appointed Executive Vice President, UPM Energy. He will be a member of UPM’s Group Executive Team and report to Massimo Reynaudo, President and CEO. He will assume his role on October 1, 2026 and will be based in Helsinki, Finland. Rauramo, born in 1983, will join UPM from Coolbrook Oy where he has served as CEO since 2022 and prior to that as Executive Vice President, Strategy & Industrial Partnerships. From 2007 to 2021, he held various roles at Fortum, most recently as Vice President, Wind and as Vice President, Solar & Wind Development. He serves as a board member at Korkia, and as a member of the IEA Technology and Innovation Advisory Board. Rauramo has Master of Science in Technology from Helsinki University of Technology and Master of Science in Economics from Aalto University School of Economics. He is a Finnish citizen. “I’m delighted to welcome Joonas to UPM. He brings extensive experience in power generation and industrial decarbonisation, as well as deep expertise in energy markets, project financing, M&A and building global partnerships. These are capabilities that are increasingly critical as demand for reliable, emission-free electricity continues to grow and the energy system undergoes profound transformation. With Joonas on board, we continue to develop our energy business further and contribute to the transition towards a sustainable and resilient energy future,” says Massimo Reynaudo. UPM, Media relationsMon-Fri 9:00–16:00 EESTtel. +358 40 588 3284media@upm.com UPMUPM is a material solutions company, renewing products and entire value chains with an extensive portfolio of renewable fibres, advanced materials, decarbonization solutions, and communication papers. Our performance in sustainability has been recognized by third parties, including EcoVadis and the Dow Jones Sustainability Indices. We operate globally and employ approximately 15,100 people worldwide, with annual sales of approximately €9.7 billion. Our shares are listed on Nasdaq Helsinki Ltd.UPM – we renew the everydayRead more: upm.com  Follow us onLinkedIn |YouTube |Instagram |#UPM #materialsolutions #WeRenewTheEveryday

ZINZINO AB (PUBL.): PRELIMINARY SALES REPORT MAY 2026

Zinzino group revenue increased with a total of 14 %, compared with the previous year. The revenue in May for Zinzino's sales markets increased by 14 % and amounted to SEK 312.2 (273.7) million. Faun Pharma's external sales amounted to SEK 3.9 (3.9) million. Overall, the Group increased revenues by 14 % to SEK 316.1 (277.6) million compared with the previous year. Accumulated revenue for January – May 2026 increased by 23 % to SEK 1,545.9 (1,254.0) million. Revenues were distributed as follows: Regions,MSEK 26-May 25-May Change YTD 2026 YTD 2025 ChangeThe Nordics 26.2 29.5 -11% 129.4 129.8 0%Central Europe 99.2 72.8 36% 464.4 333.9 39%East Europe 30.1 36.3 -17% 141.6 160.6 -12%South & West Europe 51.1 47.6 7% 258.5 216.4 19%The Baltics 9.2 11.3 -19% 48.1 48.6 -1%North America 66.6 46.1 44% 329.3 207.9 58%South America 3.6 0.8 350% 18.7 3.9 379%Asia-Pacific 24.1 27.4 -12% 117.2 118.4 -1%Africa 2.1 1.9 11% 10.5 8.4 25%Zinzino 312.2 273.7 14% 1,517.7 1,227.9 24%Faun Pharma 3.9 3.9 0% 28.2 26.1 8%Zinzino Group 316.1 277.6 14% 1,545.9 1,254.0 23% Countries in regions: -The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden -Central Europe: Austria, Germany, Switzerland -East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania -South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Portugal, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands -The Baltics: Estonia, Latvia, Lithuania -North America: Canada, USA, Mexico -South America: Peru, Colombia -Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines, South Korea -Africa: South Africa For more information: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25700, dag@zinzino.com  Fredrik Nielsen CFO Zinzino +46 (0) 707 900 174, fredrik.nielsen@zinzino.com Pictures for publication free of charge: marketing@zinzino.com Certified Adviser: Tapper Partners AB

Nobia appoints Jesper Gylling Olsen as CEO

Jesper Gylling Olsen is currently Executive Vice President at Nobia for HTH and has been employed by Nobia since 2019. Jesper Gylling Olsen succeeds Kristoffer Ljungfelt, who assumed the role of CEO having previously served as CFO and subsequently EVP for Nobia’s UK region."We are happy that Jesper Gylling Olsen has accepted the role of President and CEO of Nobia. Jesper brings impressive experience from the kitchen industry and has, within Nobia, successfully strengthened one of the Group's most significant businesses, delivering strong financial performance and high operational quality. Jesper will play a central role in the continued work to strengthen Nobia’s Nordic operations and realise the Company's priorities going forward. We also wish to thank Kristoffer for leading Nobia through a challenging period during which we first divested the UK business, and subsequently completed a new rights issue. Through Kristoffer’s efforts, we now have a focused Nordic Nobia ready for its next phase," says Jimmy Renström, Chairman of the Board of Nobia."I am proud and pleased that the Board has given me the opportunity to lead Nobia. Today, we have a clearer position in the Nordic kitchen market, with well-established brands and leading market positions. I have had the privilege of working with one of Nobia’s strong brands and look forward with confidence and great humility to driving the entire Group's continued focus on profitable growth," says Jesper Gylling Olsen, incoming President and CEO of Nobia. Jesper Gylling Olsen is Executive Vice President for HTH, one of Nobia’s strong brands, where he started working for the second time in 2019. During his time with Nobia, Jesper Gylling Olsen has been Head of International Brands (HTH and unoform), VP Director (HTH Kitchen), and Sales Director (HTH Kitchen). Before this, Jesper Gylling Olsen had more than 20 years’ experience from companies in the same market segment, with leading positions at e.g. JKE Design and Multiform/Ballingslöv. This information is information that Nobia is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person above, at 09:30 CET on 3 June 2026.

Cold Roads, Hot Marketing: How Iceland’s Clever ‘Hola’ Campaign Became a Global Masterclass in Public Relations

REYKJAVÍK – Infrastructure marketing is notoriously difficult to make exciting. Yet, a brilliant creative initiative out of Iceland has done the unthinkable: it turned pothole complaints into an award-winning, globally discussed marketing phenomenon.  The "¡Hola!" campaign, launched by the road-paving giant Colas Ísland in collaboration with advertising agency Pipar/TBWA, has caught the attention of international marketing circles after completely sweeping Iceland’s prestigious advertising awards (Lúðurinn) and winning Áran—the title for the most effective campaign of the year.  The Icelandic Context: A Brilliant Linguistic Twist Aired across Icelandic television, billboards, and digital media, the campaign capitalized on a genius linguistic coincidence. While the Spanish word "¡Hola!" is a cheerful greeting, phonetically it sounds identical to "hola", the Icelandic word for a pothole. Instead of hiding from public frustration regarding worn-down winter roads, Colas leaned directly into the problem. They introduced the world to Nicolas, a fictional, overly enthusiastic "pothole lover" who traveled across Iceland's rugged road networks, cheerfully saying "hello" (¡Hola!) to every crater he encountered on TV and social media.  Beyond the Screen: Driving Political and Civic Action What started as a humorous broadcast campaign quickly evolved into a massive public engagement project. The initiative featured several highly strategic pillars that turned viral laughs into real-world impact: · The Ruined Roads Guidebook (Ónýtuvegahandbókin): Colas published a comprehensive, tongue-in-cheek guidebook mapping out the worst road damage across the country, effectively pressure-testing local authorities to step up infrastructure budgets. · Interactive Civic Tracking: Icelandic drivers and cyclists were invited to actively participate by reporting road issues, transforming a public nuisance into a proactive community effort. · Humanizing the Crew: The ads cleverly shifted public perspective, turning road maintenance workers from an "inconvenience that causes traffic" into community heroes fixing the infrastructure. Why the International Marketing World is Watching International branding experts are pointing to the Icelandic campaign as a prime example of "flawpop" marketing—taking a company's most glaring industry challenge and turning it into their greatest asset. "Colas Iceland didn't just ask for patience; they created a shared cultural moment out of a universal frustration," noted an international creative director during an ad-industry review. "By using humor and local wordplay, they took the heat off their brand and put the focus on collaborative solutions." With its recent clean sweep at the 2026 Icelandic marketing awards, the "¡Hola!" campaign has proven that even the most mundane industries can achieve international creative acclaim. It stands as a reminder to companies worldwide that sometimes, the best way to fix a problem is to look it in the face and simply say hello. 

KONE Corporation’s Extraordinary General Meeting has approved the proposed resolutions related to the TK Elevator transaction

KONE Corporation, stock exchange release, June 3, 2026 at 11:45 a.m. EEST KONE Corporation’s Extraordinary General Meeting has approved the proposed resolutions related to the TK Elevator transaction KONE Corporation's Extraordinary General Meeting was held in Helsinki on June 3, 2026. The General Meeting approved the proposed resolutions related to the Transaction: an authorization to issue class B shares and the election of two new members to the Board of Directors. KONE Corporation ("KONE") announced on April 29, 2026 that KONE and Vertical Topco I S.A. (the "Seller") have entered into a share purchase agreement (the "Share Purchase Agreement"), pursuant to which KONE would acquire the entire issued share capital of Vertical Topco II S.A., which holds all of the assets of TK Elevator Group and is a wholly-owned direct subsidiary of the Seller (the "Transaction"). The rationale, details and terms of the Transaction are described in the stock exchange release concerning the Transaction published on April 29, 2026. Pursuant to the Share Purchase Agreement, the consideration to be paid by KONE to the Seller upon completion of the Transaction would consist of a combination of EUR 5 billion in cash (the "Cash Consideration") and a maximum share consideration of 270 million newly issued KONE class B shares (the "Share Consideration") as further described in the Transaction announcement of 29 April 2026. Both the Cash Consideration and the Share Consideration are subject to adjustments and will be finally determined in connection with completion of the Transaction, which is currently expected to take place at the earliest during the second quarter of 2027. Completion of the Transaction is subject to all conditions to completion under the Share Purchase Agreement and on the regulatory conditions to completion of the Transaction having been satisfied or waived. According to the Share Purchase Agreement, the Seller is from the date of completion of the Transaction entitled to appoint two of the members of the Board of Directors of KONE, one of whom would serve as co-vice chair. The Seller's board nomination right reduces to one director upon the ownership of the Seller in KONE, together with certain of its affiliates and direct and indirect shareholders, afforded by the class B shares received as Share Consideration as set out in the Share Purchase Agreement, falling below 15 per cent of the total shares in KONE, and terminates upon the ownership of the Seller in KONE, together with certain of its affiliates and direct and indirect shareholders, as set out in the Share Purchase Agreement, falling below 10 per cent of the total shares in KONE. Resolutions of the Extraordinary General Meeting on June 3, 2026 KONE Corporation’s General Meeting approved all resolutions as proposed in relation to the Transaction. The General Meeting authorized, in accordance with the proposal, the Board of Directors to resolve, on one or several occasions, upon the issuance of up to a maximum of 270,000,000 new class B shares in KONE in deviation from the shareholders' pre-emptive rights (directed share issue). The authorization may be used only for the issuance of the Share Consideration to the Seller in connection with the conveyance of all the shares in Vertical Topco II S.A. to KONE against the Share Consideration and the Cash Consideration, pursuant to the terms of the Share Purchase Agreement. The Board of Directors was authorized to decide on all other terms relating to the issuance of new class B shares in KONE pursuant to the authorization, including the issuance of class B shares against consideration in kind or set-off. The authorization is valid until June 3, 2031 and the authorization does not revoke the authorization to resolve upon a share issue granted to the Board of Directors by the Annual General Meeting held on March 5, 2026. Furthermore, as proposed, the General Meeting resolved to increase the number of members of the Board of Directors of KONE to ten (10), and elected Ranjan Sen and Bruno Schick as new members of the Board of Directors. The resolutions regarding increasing the number of members of the Board of Directors and election of the new members to the Board of Directors are conditional upon the completion of the Transaction, i.e., the resolutions will enter into force on the date on which completion of the Transaction occurs. The current eight (8) members of the Board of Directors elected by the Annual General Meeting on 5 March 2026, Banmali Agrawala, Matti Alahuhta, Susan Duinhoven, Marika Fredriksson, Anna Herlin, Antti Herlin, Jussi Herlin, and Timo Ihamuotila will continue in their positions until the conclusion of the next annual general meeting. For further information, please contact:Natalia Valtasaari, Head of Investor Relations, tel. +358 204 75 4705 Sender: KONE Corporation Niina VilskeSecretary to the Board Ilkka HaraCFO About KONE At KONE, our purpose is to shape the future of cities. As a global leader in the elevator and escalator industry, we move two billion people every day, making their journeys safe, convenient, and reliable with smart and sustainable People Flow®. In 2025, KONE had annual sales of EUR 11.2 billion, and at the end of the year over 60,000 employees in close to 70 countries. KONE class B shares are listed on the Nasdaq Helsinki Ltd. in Finland. www.kone.com

Fiskars Corporation increases bond maturing in 2028 by EUR 50 million

Fiskars CorporationStock Exchange ReleaseJune 3, 2026 at 12.30 p.m. EEST Fiskars Corporation increases bond maturing in 2028 by EUR 50 million On June 10, 2026, Fiskars Corporation will issue notes in an amount of EUR 50 million as a private placement (the "Notes") by way of a tap issue to its existing notes. The Notes will be further notes to its existing EUR 200 million 5.125 per cent senior unsecured sustainability-linked notes maturing in 2028 with ISIN FI4000561949. The issue price of the Notes is 101.611%. The proceeds from the issue of the Notes will be used to refinance existing indebtedness, balance the debt portfolio and for general corporate purposes. OP Corporate Bank plc acted as sole lead manager in the issue of the Notes. FISKARS CORPORATION Further information:Kaisa Vuorinen, VP, Group Treasury and Risk Management, tel. +358 50 327 9095 Fiskars Group in brief Fiskars Group (FSKRS, Nasdaq Helsinki) is the global home of design-driven brands for indoor and outdoor living. Since 1649, we have designed products of timeless, purposeful, and functional beauty, while driving innovation and sustainable growth. In 2025, Fiskars Group’s global net sales were EUR 1.1 billion, and we had approximately 6,600 employees. We have two Business Areas (BA), Vita and Fiskars. BA Vita offers products in the high-end homeware segment as well as fine branded jewelry. Its desirable brands include Georg Jensen, Royal Copenhagen, Wedgwood, Moomin Arabia, Iittala and Waterford. In 2025, BA Vita’s reported net sales were EUR 613 million, and it had approximately 5,000 employees. BA Fiskars offers functional innovations in the gardening and outdoor categories, in addition to the scissors and creating, as well as cooking categories. The brands include Fiskars and Gerber. In 2025, BA Fiskars’ net sales were EUR 522 million, and it had approximately 1,300 employees. Read more: fiskarsgroup.com Disclaimer The information contained herein is not for release, publication or distribution, in whole or in part, directly or indirectly, in or into any such country or jurisdiction or otherwise in such circumstances in which the release, publication or distribution would be unlawful. The information contained herein does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, any securities or other financial instruments in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration, exemption from registration or qualification under the securities laws of any such jurisdiction. This communication does not constitute an offer of securities for sale in the United States. The Notes have not been and will not be registered under the U.S. Securities Act of 1933 (the “Securities Act”), or under the securities laws of any state or other jurisdiction of the United States. The Notes may not be offered, sold, pledged or otherwise transferred directly or indirectly within the United States or to, or for the account or benefit of, U.S. Persons (as such term is defined in Regulation S under the Securities Act).

Corem achieves full letting at 1245 Broadway in New York – and repays construction loan

[1245 Broadway-kombinerad.jpg] Corem has now signed lease contracts for all spaces in the project property at 1245 Broadway in New York. The property is therefore fully leased. The final floor, comprising approximately 770 square meters, has been leased to an existing tenant in the building, which thereby expands its premises to a total of 2,140 square meters under a new five-year lease. The total annual contractual rental value for the property now amounts to approximately USD 20 million, and the occupancy rate stands at 100 percent. In connection with the completion of the project and the finalization of leasing, Corem has also fully repaid the construction loan of approximately USD 78.5 millon, that financed the development of the property. 1245 Broadway is an office property comprising approximately 17,500 square meters of leasable space, spread across 23 floors, located at the corner of Broadway and 31st Street in New York. The building is LEED Gold certified and offers modern office space with a high technical standard, including advanced solutions for air quality and touchless systems. The property was designed by Skidmore, Owings & Merrill and developed in collaboration with GDS Development Management (GDSNY). "We are very pleased to have now fully leased 1245 Broadway. It confirms the strength of the location, the quality of the product, and the demand for modern, sustainable office environments. At the same time, being able to repay the construction loan - which has been our most expensive loan in the portfolio - is an important milestone that further strengthens our financial position," says Sebastian Schlasberg, CEO of Property Operations at Corem. Corem Property Group AB (publ)FOR FURTHER INFORMATION, PLEASE CONTACTSebastian Schlasberg, CEO of Property Operations, +46 70 923 90 19, sebastian.schlasberg@corem.seEmelie Mörndal, Head of US operations, +46 10 482 70 38, emelie.morndal@corem.seCorem Property Group AB (publ)Address: P.O. Box 56085, SE-102 17 StockholmVisitors: Riddargatan 13 CReg.no: 556463-9440www.corem.se This press release is in all respects a translation of the Swedish original press release. In the event of any discrepancies between this translation and the Swedish original, the latter shall prevail.

Wärtsilä secures extensive U.S. power plant order and service agreement, showcasing end-to-end project expertise

Technology group Wärtsilä has secured a contract for 452 MW of power generation equipment and a long-term Operation and Maintenance (O&M) agreement with the Pecos Power Plant, owned by Mercuria Americas and Continental Resources. This milestone project, located in Pecos, Texas, USA, is designed to deliver flexible generation to maintain grid reliability in a power system with rapidly growing renewable penetration. Wärtsilä booked an initial order for 226MW in Q1 2025, increased the order by 226MW in Q3 2025, and the O&M agreement was signed in Q4 2025. The Pecos Power Plant, developed by Peak Reliability (a Mercuria Company) in partnership with Wärtsilä, combines proven development expertise with advanced power generation technology to deliver reliable and efficient energy to West Texas. The facility consists of 24 Wärtsilä 1850SG reciprocating engines that help meet the region’s growing electricity demand. Overall, the project highlights Wärtsilä’s capability in delivering comprehensive power plant solutions and underscores the company’s growing role as a lifecycle partner for large-scale independent power producers. “The flexibility of Wärtsilä’s technology will allow us to maximize our operational efficiency in an increasingly volatile power market. This further allows us to reliably serve our customers when they need power most. The region is experiencing record-breaking demand for electricity, and this project will play an important role in meeting this demand,” says Martin Parizek, Managing Director of Peak Reliability. The development effort led by the Peak Reliability team in strong collaboration with the Project Development team of Wärtsilä played a pivotal role in enabling the project to deliver power to the grid quickly. This natural gas plant will bring critical dispatchable energy generation to an area of ERCOT (Electric Reliability Council of Texas) that is situated in one of the world's largest pools of renewable energy. In addition to enhancing the reliability of the ERCOT grid, the power plant will also support west Texas industries and businesses through low cost, efficient, reliable power.   "Wärtsilä understands the pressing need to meet growing power demand with solutions that support energy supply, reliability and sustainability. By supporting delivery of end-to-end power supply projects from concept to execution, Wärtsilä is driving customer efficiency by reducing risks and time to market. Furthermore, our world-class expertise in operating and maintaining plants allows customers to focus on their core business, while we ensure optimal performance,” comments Risto Paldanius, Vice President, Americas at Wärtsilä Energy. The Operation and Maintenance agreement covers the full buildout of the project, forming a significant O&M power plant project for Wärtsilä Energy.  With this agreement, Wärtsilä will be responsible for ensuring the long-term performance, availability and reliability of the plant, supporting secure power supply in the ERCOT system.  The plant is expected to commence commercial operations in 2027. Media contact for more information on this release: Katri PehkonenCommunications ManagerWärtsilä EnergyMob: +358 50 591 6180katri.pehkonen@wartsila.com Image caption: Wärtsilä has secured a contract for 452 MW of power generation equipment and a long-term Operation and Maintenance agreement with the Pecos Power Plant, owned by Mercuria Americas and Continental Resources. © Wärtsilä Corporation All Wärtsilä releases are available at www.wartsila.com/media/news-releases and at news.cision.com/wartsila-corporation where also the images can be downloaded. Use of the image(s) is allowed only in connection with the contents of this press release. Wärtsilä images are available at www.wartsila.com/media/image-bank. Wärtsilä Energy in briefWärtsilä Energy is at the forefront of the transition towards a 100% renewable energy future. We help our customers and the power sector to accelerate their decarbonisation journeys through our market-leading technologies and power system expertise. Our solutions include flexible engine power plants, energy storage and optimisation technology, and services for the whole lifecycle of our installations. Our engines are future-proof and can run on sustainable fuels. Our track record comprises 81 GW of power plant capacity and over 130 energy storage installations in 180 countries around the world. About 35% of our operating installed base is under service agreements.www.wartsila.com/energy Wärtsilä in briefWärtsilä is a global leader in innovative technologies and lifecycle solutions for the marine and energy industries. We emphasise innovation in sustainable technology and services to help our customers continuously improve environmental and economic performance. Our dedicated and passionate team of 17,900 professionals in 199 locations in 78 countries shape the decarbonisation transformation of our industries across the globe. In 2025, Wärtsilä’s net sales totalled EUR 6.9 billion. Wärtsilä is listed on Nasdaq Helsinki.www.wartsila.com

Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments

VALBY, Denmark & AMSTERDAM, 03 June 2026 – H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company focused exclusively on brain health, and Cradle, a leading AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. It is estimated that more than half of the world’s population is impacted by brain disorders, and the effects are felt throughout society. Speeding up innovation time to develop high-quality biologics is a critical part of bringing effective new treatments to patients. As part of its aim to ease this burden and bring new treatments to patients in need, Lundbeck is deploying Cradle’s AI-powered protein design platform to develop multiple higher-performing candidates that can accelerate breakthroughs for neurological conditions. "Lundbeck is committed to becoming a bionic company, embedding AI into how we work to complement human expertise and bring faster results," said Tarek Samad, SVP, Global Head of Research and Corporate Patents at Lundbeck. "Our partnership with Cradle fits perfectly with this commitment as their platform provides our scientists with powerful AI that fits seamlessly into our processes, strengthening our ability to discover and optimize therapeutics.” The partnership is powering Lundbeck's first end-to-end AI-guided protein engineering workflow, where experimental results are continuously fed back into the model, enabling each iteration to improve prediction accuracy and accelerate convergence toward viable candidates. The platform will initially be used to advance two antibody programs targeting CNS diseases. Lundbeck's protein engineers and computational biologists will use Cradle's generative AI platform to engineer higher-quality antibody candidates while reducing the number of wet-lab iterations required to reach lead candidates. "Lundbeck has a strong biotherapeutic pipeline in CNS and is now strengthening that position with the power of AI across their research and development organization," said Stef van Grieken, CEO and Co-Founder of Cradle. "The Cradle platform has been shown in internal and partner programs to accelerate design cycles significantly. By closing the loop between computation and the lab, we can help Lundbeck reach high-quality antibody candidates faster and with fewer iterations.” The Cradle partnership builds on Lundbeck’s systematic embrace of AI to accelerate its Focused Innovator strategy. It complements a recently announced partnership with the Danish Centre for AI Innovation, which provides Lundbeck access to Denmark's Gefion AI supercomputer with advanced AI computing power for large-scale scientific modelling and discovery. Together, the two partnerships will strengthen Lundbeck’s end-to-end AI discovery capabilities, from expanding the scientific search space to improving and accelerating specific biologic candidates. Across the organization, Lundbeck estimates AI-driven initiatives are already contributing more than 12,000 hours saved per week through efficiency gains. In drug discovery specifically, AI-enabled structural insights and predictions that once took months can now be generated in under 24 hours, while expanding the searchable scientific space by approximately 50,000x.  About H. Lundbeck A/S Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com  and connect with us via LinkedIn . Contacts     Anders Crillesen Jens HøyerSenior Director, Corp. Communication Vice President, Head of Investor RelationsAECE@lundbeck.com JSHR@lundbeck.com+45 27 79 12 86 +45 30 83 45 01   About Cradle Cradle’s mission is to make engineering biology easier, quicker and more cost-effective. Its enterprise-grade AI software platform currently serves eight out of the top 25 global pharma companies, and is used across over 50 R&D programs. With Cradle, scientists can engineer better proteins, faster and more successfully, speeding up the development cycle of new therapeutics and bio-based products such as, antibodies, enzymes, and bio-based materials by 2-12x. Cradle is based in Amsterdam, The Netherlands; Zurich, Switzerland and the United States with a team of machine learning and biotech research specialists with experience at many of the world’s leading technology and biotech companies, including Google, Novartis, Meta, Zymergen, Uber, Deepmind and Generate Biomedicines. Cradle is backed by IVP as well as Index Ventures and Kindred Capital. For more information, visit cradle.bio . Contacts     press@cradle.bio 

Zinzino AB (publ.): 250 International chefs and sommeliers recognize Zinzino’s BalanceOil+ with 2026 Superior Taste Award

Award-winning omega-3 supplement earns international recognition for taste in one of the world's most respected blind sensory evaluations More than 250 internationally renowned chefs and sommeliers have evaluated thousands of products from over 100 countries in one of the world's most respected blind tasting competitions. Among the recipients of the 2026 Superior Taste Award is BalanceOil+ Orange Lemon Mint, Zinzino's flagship omega-3 supplement. Presented by the International Taste Institute in Brussels, the Superior Taste Award is widely regarded as one of the food and beverage industry’s most respected certifications for taste and sensory quality. Products are evaluated anonymously through a rigorous, blind-tasting process by an independent jury that includes Michelin-starred chefs, award-winning sommeliers, and leading culinary experts from around the world. For Zinzino, the recognition is particularly significant because taste remains one of the biggest challenges within the omega-3 category. “Consumers increasingly understand the importance of omega-3 nutrition, but taste continues to be a critical factor in long-term product use,” said Emmalee Gisslevik, Senior Research & Development Specialist at Zinzino. “Receiving this recognition from an independent international jury of chefs and sommeliers validates our commitment to combining scientific excellence with an enjoyable consumer experience.” “Consumers today expect more from nutrition than ever before. They are looking for solutions that are personalized, scientifically grounded, and enjoyable to use every day,” said Chief Marketing Officer Gabriele Helmer. “Operating in more than 100 markets worldwide, Zinzino has helped pioneer the field of test-based personalized nutrition. This international recognition reinforces our belief that scientific innovation, premium quality, and an exceptional consumer experience will define the next generation of personalized nutrition.” Where science meets consumer experience As the global nutritional supplement market continues to evolve, consumer expectations are changing. Today’s consumers are looking not only for scientifically developed products and premium ingredients, but also for products they enjoy incorporating into their daily routines. Industry experts increasingly recognize consumer experience as an important factor in long-term product usage. Products that successfully combine nutritional value with consumer enjoyment are becoming increasingly important across the wellness and nutrition sectors. BalanceOil+ Orange Lemon Mint was developed to meet these expectations through a unique combination of sustainably sourced fish oil, extra virgin olive oil, and vitamin D. The formulation delivers high levels of EPA and DHA while providing a fresh citrus flavor profile, designed for everyday use. Continued recognition for product excellence The 2026 Superior Taste Award marks the second consecutive year that products from Zinzino’s BalanceOil family have been recognized by the International Taste Institute. In 2025, both BalanceOil+ Premium and BalanceOil Tutti Frutti received Superior Taste Awards, further reinforcing the consistent sensory quality across the product range. The latest recognition reflects Zinzino’s continued focus on combining scientific innovation, product quality, and consumer experience within the growing personalized nutrition market. About the Superior Taste Award Presented by the International Taste Institute in Brussels, Belgium, the Superior Taste Award is one of the world’s leading certifications dedicated exclusively to taste evaluation. Since 2005, the Institute has assessed thousands of products from more than 100 countries through independent blind sensory evaluations. In 2024 alone, more than 2,600 products received Superior Taste Awards after rigorous judging. Products are evaluated on criteria including first impression, aroma, taste, texture, and overall sensory experience. Only products achieving high overall sensory scores receive certification. About Zinzino Zinzino is a global direct sales company based in Scandinavia and a pioneer in test-based, personalized nutrition. Operating in more than 100 markets worldwide, the company develops, markets, and sells scientifically based nutritional supplements, skincare, and lifestyle products designed to help individuals better understand and optimize their nutritional habits through personalized nutrition solutions. For more information: Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25700, dag@zinzino.com  Fredrik Nielsen CFO Zinzino +46 (0) 707 900 174, fredrik.nielsen@zinzino.com Pictures for publication free of charge: marketing@zinzino.com Certified Adviser: Tapper Partners AB

Hemsö acquires district court in Hamburg

The district court building was completed in 1878 and has been used continuously as a courthouse ever since. The property has been listed as a protected historic building since 1981 and has undergone ongoing renovations through to 2026. The court handles a broad range of cases within its jurisdiction, including civil and criminal matters, family and youth cases, as well as general legal and administrative proceedings. “Over the past 15 years, Hemsö has built a high-quality portfolio of social infrastructure properties in Germany. At the same time, we have expanded our portfolio within both the education and justice sectors. In the Hamburg acquisition, we were able to leverage our strong balance sheet and high level of transaction certainty. We look forward to the partnership with our tenant,” says Jens Nagel, Head of Region Germany at Hemsö. Hamburg has a population of approximately two million people, while around five million people live in the wider metropolitan region. The acquisition of the district court, Hemsö’s first property in Hamburg, further strengthens the company’s German portfolio within the justice sector. Hemsö already owns five police properties in Germany. For more information, please contact: Jens Nagel, Head of Region Germany                                       +46 8-501 170 70Åsa Thoft, Head of Communications                                         +46 8-501 170 57

Crunchfish CEO to Speak at Digital Euro Association Webinar

More than 30 years ago, the internet achieved communication resilience through decentralization and packetized communications. Payments and most digital applications still depend on continuous access to authorization, infrastructure and centralized systems. Offline payments provide a unique lens through which to explore a broader architectural transition toward survivable digital systems. The session will explore a fundamental question facing digital systems: How can digital applications remain functional and trustworthy even when the underlying system itself is unavailable? The webinar will be structured around three complementary discussions: 1. Resilient Digital Money and Institutional Alignment The first part will examine the three fundamentally different approaches to offline payments: •         Immediate offline payments (portable money) •         Deferred offline payments (portable risk) •         Governed offline payments (portable authorization) •         Where do money and risk reside? •         Institutional Alignment: Bankable, Implementable, Governed The discussion will focus on why different offline architectures produce very different institutional outcomes for central banks, system operators, banks, and wallets. 2. Trust, Authorization and Governed Execution The second part will explore how survivability can be achieved while maintaining governance and settlement integrity. Topics include: •         Reservation-backed governed execution •         Portable authorization •         Trusted sessions and trusted intent •         The role of authorization in resilient digital systems •         Why governance, not survivability, is the key design challenge 3. Industry Trends: Agentic AI, Interoperability and Programmable Money The final section broadens the discussion beyond offline payments. Emerging developments such as: •         Agentic AI payments •         Programmable money •         Interoperability •         CBDC initiatives •         India’s payments architecture all point toward a future where authorization may become increasingly portable while execution remains centrally governed. Joachim Samuelsson, CEO of Crunchfish, commented: “Offline payments are often viewed as a niche payments problem. I believe they are much more than that. They provide a glimpse into how digital systems can remain trustworthy and operational even when parts of the underlying infrastructure become unavailable. The same principles are beginning to emerge in areas such as agentic AI, programmable money and interoperable digital ecosystems.” The webinar is hosted by the Digital Euro Association and moderated by DEA Executive Director Tamara Ferreira Schmidt. It will be possible to ask questions during the webinar. Registration is free and open to all: Date: 9 June 2026 Time: 17:00–18:00 CEST Online Event Free Registration: https://luma.com/c7rseywq For more information, please contact: Joachim Samuelsson, CEO of Crunchfish AB +46708 46 47 88 joachim.samuelsson@crunchfish.com This information was provided by the above for publication on June 3rd, 2026, at 14:30 CEST. Västra Hamnen Corporate Finance AB is the Certified Adviser. Email: ca@vhcorp.se. Telephone +46 40 200250. About Crunchfish –crunchfish.com  Crunchfish is a deep fintech company developing governed offline payments technology for payment systems, banks, and payment applications. The company enables offline payments as a Layer-2 solution on top of existing payment systems, allowing transactions to be executed without connectivity while ledger authority and settlement remain unchanged. Through a reservation-based model, resilience is achieved without creating parallel forms of money or unmanaged credit risk. Crunchfish’s architecture is patented and enables interoperability across multiple payment systems and markets. The solution strengthens system stability while also supporting economic incentives by ensuring that liquidity backing offline payments remains within the regulated financial system.

Smoltek sees opportunities in Japan’s big investments in semiconductors for AI and High-Performance Computing

Japan has launched an ambitious strategy to re-industrialize its semiconductor industry, supported by major government funding, strategic industrial policy, and global technology partnerships. The Japanese government has committed over JPY 3.9 trillion (≈ EUR 24–26 billion) in direct subsidies and support measures for semiconductor manufacturing, R&D, and ecosystem development through the late 2020s. Japan has several companies, such as Kyocera-AVX, Murata, Taiyo Yuden, TDK, that have global ambitions and investment plans.   For Smoltek Semi, this is a strong commercial opportunity. Japanese companies are now investing in new capacity and technologies to secure materials and supply chain capacity needed for next-generation logic, AI, and advanced packaging, and Smoltek’s CNF-MIM capacitor technology fits directly into that need. “Smoltek Semi has had dialogues with several Japanese semiconductor companies and capacitor manufacturers in recent years. We have also had technology evaluation agreements with a large Japanese capacitor manufacturer. With the renewed contract with Business Sweden, we can reconnect with leading Japanese technology companies,” explains Magnus Andersson, President of Smoltek Semi. Smoltek Semi sees the Japanese market as an opportunity to close technology agreements with companies seeking differentiated capacitor technology for future semiconductor platforms. Japan has long held global strength in semiconductor materials, equipment, and precision manufacturing, and the current industrial policy push creates new momentum for companies that can add value to this ecosystem. Smoltek’s technology may therefore become a useful enabler for Japanese players aiming to strengthen competitiveness in AI, advanced packaging, and high-performance computing applications. “Smoltek Semi’s engagement in Japan reflects the company’s ambition to bring disruptive capacitor technology to one of the world’s most strategically important semiconductor markets,” Magnus Andersson elaborates.

Veidekke: Acquires Danish technical installation company

The acquisition supports Hoffmann’s strategy of strengthening its expertise in technical building installations – an area of increasing customer demand and important for the execution of Hoffmann’s projects – through targeted acquisitions of smaller companies. – We are very pleased to bring the business of Installatøren A/S into Hoffmann. Installatøren is a highly professional company that will further strengthen an already well-functioning organisation, says Torben Bjørk Nielsen, Managing Director of Hoffmann. As a long-standing partner, Installatøren A/S is already well acquainted with Hoffmann’s solution-oriented approach and model for early contractor involvement with customers, making the companies a strong strategic and operational fit. Both companies are also based in Glostrup outside Copenhagen. For more information, contact: Jørgen Wiese Porsmyr, EVP/CFO Veidekke ASA, +47 907 59 058 Veidekk press photos Subscribe to notices from Veidekke  Veidekke is one of Scandinavia's largest contractors. In addition to undertaking all types of building and civil engineering assignments, the group also maintains roads and produces asphalt and aggregates. Veidekke emphasises stakeholder involvement and local experience. Its annual turnover is approximately NOK 43 billion, and half of its 8,000 employees own shares in the company. Veidekke is listed on the Oslo Stock Exchange, and has posted a profit every year since its inception in 1936.

OssDsign Catalyst® outperforms earlier-generation bone graft as a standalone treatment in trauma study

In the study, published in JBMR, researchers compared the bone healing response of two synthetic bone graft materials – one with a nano-scale structure (OssDsign Catalyst) and one with a micron-sized structure typical of earlier-generation grafts. The materials were implanted into critical-sized bone defects in the knee joints of rabbits and evaluated at 4, 8, 12 and 26 weeks. OssDsign Catalyst achieved full healing of the defect at the earliest timepoint of 4 weeks, as opposed to the earlier-generation graft which took twice as long. OssDsign Catalyst also showed continuous, progressive biological resorption and replacement with host bone throughout the study, with graft material decreasing by 60% over 26 weeks. In contrast, the earlier-generation graft showed minimal remodeling, remaining largely unchanged from week four onwards. Importantly, the coupled remodeling of OssDsign Catalyst was not only visible in histology but supported by statistically significant quantitative data — providing strong scientific evidence for one of the key advantages of fourth-generation synthetic bone grafts. "While many earlier-generation synthetic grafts have failed to match traditional bone graft options in clinical outcomes, OssDsign Catalyst is now closing that gap. Preclinical research remains essential to deepen understanding and strengthen the scientific foundation for clinical adoption, and we are pleased to see these standalone results published in one of the leading journals in our field," comments Mark Waugh, CEO of OssDsign. The study is published in the latest issue of The Journal of Bone and Mineral Research and is accessible here: https://onlinelibrary.wiley.com/doi/abs/10.1002/jbm.b.70103

Paradox Interactive’s shares have been approved for admission to trading on Nasdaq Stockholm

Nasdaq Stockholm’s Listing Committee has today approved the application by Paradox Interactive AB (publ) (“Paradox” or the “Company”) for admission of the Company’s shares to trading on Nasdaq Stockholm Main Market. The approval is conditional upon the fulfilment of customary conditions, including that a prospectus is approved and registered by the Swedish Financial Supervisory Authority (Sw. Finansinspektionen). The first day of trading on Nasdaq Stockholm is planned for Tuesday, 9 June 2026. In connection with the listing on Nasdaq Stockholm Main Market, the Company’s shares will be delisted from Nasdaq First North Growth Market and the expected last day of trading on Nasdaq First North Growth Market is Monday, 8 June 2026. “Being admitted to Nasdaq Stockholm's Main Market is a natural next step. It is a validation of the fantastic company that so many people have helped build. The move strengthens our position and gives additional momentum to our long-term efforts to build one of the world's leading developers and publishers of strategy and management games. We hope that our players, employees, and everyone interested in our future will continue to be part of this journey,” says Fredrik Wester, CEO of Paradox. There will be no offering or issuance of new shares in connection with the admission of the Company’s shares to trading on Nasdaq Stockholm Main Market. The shares will retain their ticker symbol (PDX) as well as ISIN code (SE0008294953). Shareholders of Paradox do not need to take any action in connection with the admission to trading on Nasdaq Stockholm. For complete information regarding the admission to trading on Nasdaq Stockholm, reference is made to the prospectus that will be published (in Swedish only) in connection with the listing, which is expected to be approved by the Swedish Financial Supervisory Authority and published on the Company’s website (www.paradoxinteractive.com) around 5 June 2026. Legal adviserGernandt & Danielsson is the Company’s legal adviser in relation to the listing on Nasdaq Stockholm.

ATP and EQT Announce Global Partnership

The ATP has signed a multi-year partnership with leading global investment organisation EQT, which will be the first official private markets partner of the ATP Tour through 2030. As a governing body of men's professional tennis, ATP stages premier tournaments across six continents and showcases the world’s greatest players. This represents EQT’s first-ever global sports sponsorship at a pivotal time in the firm’s growth. As EQT adds new strategies and products, enters new markets, and broadens access to private markets, building global brand recognition is becoming increasingly critical. This partnership provides access to a global platform across major markets with a broad, high-value audience. The partnership with the ATP coincides with EQT’s global brand relaunch, “Better Never Ends”, linking its belief in continuous improvement with the pursuit of progress at the heart of professional tennis. The agreement supports the ATP’s strategy to build deeper, multi-market partnerships that drive growth and deliver value across the Tour. A dedicated activation programme will create opportunities for players to participate in partner-led moments, while integrating some of the sport’s leading athletes into EQT’s brand campaigns. As a Platinum Partner, EQT will activate across ATP Masters 1000, ATP 500 and ATP 250 tournaments throughout the season, connecting with a global audience of more than one billion fans. The partnership includes prominent brand visibility, alongside access to premium hospitality and stakeholder engagement opportunities across key international markets. Per Franzen, EQT’s Managing Partner & CEO, said: "An ever-larger share of value creation in the global economy is happening in private markets, and individual investors want access to that opportunity. As the largest private markets firm outside the U.S., EQT has both the scale and responsibility to help make that a reality. That is why we decided to partner with the ATP, which has the right platform to build EQT's brand recognition among our target audiences around the world. We are proud to partner with an organization that, like EQT, is defined by long-term thinking, high performance, and a truly global ambition." Andrea Gaudenzi, ATP Chairman, said: “The scale of this partnership and its global footprint reflect EQT’s commitment to the ATP Tour. It’s an exciting moment for both organisations and another step in our focus on working with brands that share our values and are invested in the long-term future of tennis. EQT is a natural fit, with a shared emphasis on long-term performance, active growth and sustainable value creation for players, fans and commercial partners.” The announcement builds on a period of record sponsorship growth for the ATP, underlining the strength of the Tour as a premium platform for brand visibility, business engagement and international expansion. ContactEQT Press Office, press@eqtpartners.com

Notice of Telia Company’s Extraordinary General Meeting 2026

The shareholders of Telia Company AB (publ), reg. no. 556103-4249, are hereby given notice of the Extraordinary General Meeting to be held on Thursday, July 2, 2026, at 10.00 a.m. CEST at Telia Company's head office, Stjärntorget 1 in Solna, Sweden. Registration for the Extraordinary General Meeting will commence at 9.00 a.m. CEST on the same day. The shareholders may also exercise their voting rights at the Extraordinary General Meeting by postal voting in accordance with the provisions of Telia Company's Articles of Association. Participation Shareholders who wish to participate in the Extraordinary General Meeting must: · be recorded as a shareholder in the presentation of the share register prepared by the Swedish Central Securities Depository Euroclear Sweden AB concerning the circumstances on Wednesday, June 24, 2026, and · give notice of participation no later than Friday, June 26, 2026. Participation at the meeting venue Shareholders who wish to attend the meeting venue in person or by proxy must give notice of participation no later than Friday, June 26, 2026, on Euroclear Sweden AB's website https://www.euroclear.com/sweden/generalmeetings/, by telephone +46 (0) 8 402 90 50, or by post to Telia Company AB, "Telia Company EGM 2026", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. Shareholders shall, in their notice of participation, state their name, personal identification number or company registration number, address, telephone number and advisors, if applicable. Shareholders represented by a proxy or a representative should send documents of authorization to the address above well in advance of the Extraordinary General Meeting. A template proxy form is available on Telia Company's website www.teliacompany.com. Participation by postal voting Shareholders who wish to participate in the Extraordinary General Meeting by postal voting in advance must give notice of participation by casting their postal vote so that the postal vote is received by Euroclear Sweden AB (administering the forms on behalf of Telia Company) no later than Friday, June 26, 2026. A special form shall be used for postal voting. The postal voting form is available on Telia Company's website www.teliacompany.com. The postal voting form can be submitted either by e-mail to GeneralMeetingService@euroclear.com or by post to Telia Company AB, "Telia Company EGM 2026", c/o Euroclear Sweden AB, P.O. Box 191, SE-101 23 Stockholm, Sweden. Shareholders may also cast their postal votes electronically through BankID verification via Euroclear Sweden AB's website https://www.euroclear.com/sweden/generalmeetings/. If a shareholder postal votes by proxy, a power of attorney shall be enclosed with the postal voting form. A template proxy form is available on Telia Company's website www.teliacompany.com. If a shareholder is a legal entity, a certificate of incorporation or a corresponding document shall be enclosed with the postal voting form. Further instructions are included in the postal voting form and on Euroclear Sweden AB's website https://www.euroclear.com/sweden/generalmeetings/. Please note that shareholders who wish to attend the meeting venue in person or by proxy must give notice of participation in accordance with the instructions under the heading "Participation at the meeting venue" above. This means that a notice of participation only through postal voting is not sufficient for shareholders who wish to participate in the Extraordinary General Meeting by attending the meeting venue. Shareholding in the name of a nominee To be entitled to participate in the Extraordinary General Meeting, shareholders whose shares are registered in the name of a nominee (including Finnish shareholders that are registered within the Finnish book-entry system at Euroclear Finland Oy) must re-register such shares in their own name so that the shareholder is recorded in the presentation of the share register as of Wednesday, June 24, 2026. Such re-registration may be temporary (voting rights registration) and can be requested from the nominee in accordance with the nominee's procedures in such time in advance as the nominee determines. Voting rights registrations effected by the nominee no later than Friday, June 26, 2026, will be considered in the presentation of the share register. Proposed agenda 1. Opening of the Extraordinary General Meeting 2. Election of the Chair of the Extraordinary General Meeting 3. Preparation and approval of the voting list 4. Approval of the agenda 5. Election of two persons to check the minutes 6. Determination of whether the Extraordinary General Meeting has been duly convened 7. Determination of the number of Board members 8. Resolution to determine the remuneration for new Board member 9. Election of new Board member10. Closing of the Extraordinary General Meeting Resolutions proposed by the Nomination Committee The composition of the Nomination Committee is based on the ownership structure in Telia Company as of July 31, 2025, in accordance with the instruction for the Nomination Committee. The Nomination Committee comprises Magnus Johansson, Chair (the Swedish state), Katarina Hammar (Nordea Funds), Sussi Kvart (Handelsbanken Fonder) and Emilie Westholm (Folksam). In addition, the Chair of the Board of Directors, Lars-Johan Jarnheimer, has been appointed as co-opted member of the Nomination Committee. The Nomination Committee presents the following proposals: · Item 2 – The Nomination Committee proposes that the Chair of the Board of Directors, Lars-Johan Jarnheimer, is elected to be the Chair of the Extraordinary General Meeting. · Item 7 – The Nomination Committee proposes that the Board of Directors, for the period until the end of the next Annual General Meeting, shall consist of seven members elected by the General Meeting. · Item 8 – The Annual General Meeting on April 9, 2026 approved the yearly remuneration to the Board of Directors as follows: SEK 2,170,000 to the Chair of the Board of Directors, SEK 730,000 to each other member of the Board elected by the General Meeting, SEK 375,000 to the Chair of the Audit Committee, SEK 215,000 to each other member of the Audit Committee, SEK 75,000 to the Chair of the Remuneration Committee and SEK 75,000 to each other member of the Remuneration Committee. The Nomination Committee proposes that the proposed new Board member be remunerated pro rata for the period from the Extraordinary General Meeting until the end of the Annual General Meeting 2027, at the same annualized levels as resolved by the Annual General Meeting 2026 (including any applicable committee fees). · Item 9 – The Nomination Committee proposes the election of Susanne Blanke as a new Board member. Information about the proposed new Board member, as well as the Nomination Committee's motivated statement, is available on Telia Company’s website www.teliacompany.com. Susanne Blanke is VP AI Strategy & Transformation at Husqvarna Group, where she leads the company's AI-driven transformation of its operating model and business. She has previously held the roles of VP Customer Experience and VP Strategy at Husqvarna. Prior to joining Husqvarna in 2021, Susanne held senior positions at H&M and eBay/Tradera. At H&M, she led global digital growth as Global Head of Growth, and before that, global store development as Global Head of Store Development. She has previously worked as a management consultant at Boston Consulting Group and in strategy at Ericsson. Susanne holds an MSc in Media Technology from KTH Royal Institute of Technology and an MSc in Business & Economics from Stockholm University. Susanne is a Board member of engineering consultancy company Rejlers, where she serves on the audit committee. Resolutions proposed by the Board of Directors · Item 3 – Preparation and approval of the voting list The voting list proposed to be approved is the voting list prepared by Euroclear Sweden AB on behalf of Telia Company, based on the Extraordinary General Meeting’s register of shareholders, postal votes received and shareholders having given notice of participation and being present at the meeting venue. Other information Number of shares and votes The total number of shares and votes in Telia Company amounts to 3,932,109,286 at the date this notice is issued. Shareholders' right to request information At the request of any shareholder, the Board of Directors and the Chief Executive Officer shall provide information on any circumstances that may affect the assessment of a matter on the agenda, provided that the Board of Directors believes it would not be of significant detriment to Telia Company. Documentation The Board of Directors' and the Nomination Committee's proposals to the Extraordinary General Meeting are set out in this notice. Information about the proposed new Board member, as well as the Nomination Committee's motivated statement, is available on Telia Company's website www.teliacompany.com. Authorization The Board of Directors, or such person that the Board of Directors may appoint, shall be authorized to make the minor adjustments in the resolutions adopted by the Extraordinary General Meeting as may be required in connection with registration at the Swedish Companies Registration Office and Euroclear Sweden AB and to take such other measures required to execute the resolutions. Processing of personal data For information on how your personal data is processed, please refer to: www.euroclear.com/dam/ESw/Legal/Privacy-notice-bolagsstammor-engelska.pdf. If you have questions regarding Telia Company’s processing of your personal data, you can contact us by emailing dpo-tc@teliacompany.com. Telia Company AB has the company registration number 556103-4249 and the Board’s registered office is in Stockholm. Stockholm, June 2026 Telia Company AB (publ) The Board of Directors NOTES TO EDITORS For more information, contact Tobias Gyhlénius, Head of Group Communications, on +46 (0)771 77 58 30, visit our newsroom  and follow us on LinkedIn . To download our logo, high-resolution images of Telia leaders, offices and solutions, or B-roll footage for editorial use, visit our media bank . ABOUT TELIA Telia Company (STO: TELIA) is a leading telecommunications operator in the Nordic and Baltic regions. Every day, we deliver world-class connectivity and communications services to millions of customers through our sustainable and secure networks – enabling people, businesses and societies to thrive and grow. Our unique position at the center of digitalization shapes our ambition to be a trusted and progressive partner and gives us our purpose: to reinvent better connected living. Find out more at www.teliacompany.com/en.

Statement from the board of directors of Formpipe Software AB (publ) in relation to Tabellae BidCo's public offer

This statement is made by the board of directors[1] of Formpipe Software AB (publ)[2] (“Formpipe” or the “Company”) pursuant to Rule II.19 of the Stock Market Self-Regulation Committee’s Takeover rules for Nasdaq Stockholm and Nordic Growth Market NGM (the “Takeover Rules”). Summary of the Offer On 4 June 2026, Tabellae HoldCo ApS[3], Mission Trail Partners, LP (“Mission Trail”) and Aktiebolag Grenspecialisten (“Grenspecialisten”) (together the “Consortium“), acting through Tabellae BidCo ApS (“Tabellae BidCo” or the “Offeror”), announced a public offer to the shareholders of Formpipe to tender all outstanding shares in the Company to Tabellae BidCo at a price per share of SEK 30 in cash (the “Offer”). Mission Trail and Grenspecialisten, both being members of the Consortium, currently hold 5,456,446 and 3,136,432 shares and votes in Formpipe, respectively. Consequently, the Consortium currently controls 8,592,878 shares and votes in Formpipe, which corresponds to approximately 29.3 percent of the outstanding shares and votes in Formpipe. All shares held by Mission Trail and Grenspecialisten will be contributed to Tabellae BidCo upon completion of the Offer. The total value of the Offer, based on the 20,720,037[4] outstanding shares in Formpipe not directly or indirectly held by Tabellae BidCo or its closely related parties, amounts to approximately SEK 622 million. The Offer values Formpipe, based on all 29,312,915 shares in Formpipe, at approximately SEK 879 million. The offered consideration in the Offer represents a premium of: · approximately 53.8 percent compared to the closing share price of SEK 19.50 on Nasdaq Stockholm on 3 June 2026, being the last trading day prior to the announcement of the Offer; · approximately 34.5 percent compared to the closing share price of SEK 22.30 on Nasdaq Stockholm on 26 March 2026, being the last trading day prior to Formpipe’s publication of the notice convening its 2026 annual general meeting (the “AGM Notice”), which included a proposal to implement a voluntary share redemption program pursuant to which shareholders would be offered the right to redeem shares for a cash consideration of SEK 30 per share (the “Redemption Program”); · approximately 29.4 percent compared to the volume weighted average trading price of SEK 23.18 for the shares on Nasdaq Stockholm during the last 30 trading days ended 26 March 2026, being the last trading day prior to Formpipe’s announcement of its AGM Notice; · approximately 25.6 percent compared to the volume weighted average trading price of SEK 23.88 for the shares on Nasdaq Stockholm during the last 90 trading days ended 26 March 2026, being the last trading day prior to Formpipe’s announcement of its AGM Notice; and · approximately 18.0 percent compared to the volume weighted average trading price of SEK 25.43 for the shares on Nasdaq Stockholm during the last 180 trading days ended 26 March 2026, being the last trading day prior to Formpipe’s announcement of its AGM Notice. If, prior to settlement of the Offer, Formpipe distributes dividends or in any other way distributes or transfers value to its shareholders, the consideration in the Offer will be reduced accordingly. An offer document regarding the Offer is expected to be made public on or around 18 June 2026. The acceptance period of the Offer is expected to commence on or around 22 June 2026 and expire on or around 22 July 2026. Completion of the Offer is conditional upon, among other things, the Offer being accepted to such extent that Tabellae BidCo becomes the owner of shares representing more than 90 percent of the total number of outstanding shares in Formpipe (on a fully diluted basis) and the receipt of all necessary clearances, approvals, decisions and other actions from authorities or similar, required for the Offer and the completion of the acquisition of the Company, in each case which, in Tabellae BidCo’s opinion, are acceptable. Tabellae BidCo has reserved the right to waive, in whole or in part, these and the other conditions for completion of the Offer. The board of directors has, upon written request from the Offeror, allowed Tabellae BidCo to conduct a due diligence review of the Company in connection with the preparations for the Offer. Tabellae BidCo has not received any inside information in connection with such due diligence review, that has not subsequently been made public by Formpipe. For further information about the Offer, please see Tabellae BidCo's website, https://designingthefuturetogether.se. The board of directors' evaluation of the Offer For the purpose of this statement and the handling of the Offer, the board of directors has consisted of the board members Annikki Schaeferdiek, Jim Bretschneider and Johan Stakeberg. Board member Erik Ivarsson is an analyst and portfolio manager at Grenspecialisten and board member Martin Bjäringer has, through his company Julnie S.A., undertaken to accept the Offer on certain conditions (see below). Erik Ivarsson and Martin Bjäringer are therefore deemed to have a conflict of interest pursuant to Rule II.18 of the Takeover Rules and have for that reason not participated, and will not participate, in the board of directors' handling of, or decisions on, matters related to the Offer. In evaluating the Offer, the board of directors has considered a number of factors which the board of directors considers relevant. These factors include, but are not limited to, the Company's current strategic and financial position, prevailing market conditions, the Company’s expected future development and the opportunities and risks related thereto. The board of directors has also evaluated the Offer using valuation methods normally used to evaluate public offers for listed companies, including how the Offer values Formpipe in relation to comparable listed companies and comparable transactions, bid premiums in previous public offers, the stock market’s expectations regarding the Company and the board of directors' view of the Company’s value based on its expected future cash flows. The board of directors notes that the Offer represents a premium of approximately 53.8 percent compared to the closing share price of  SEK 19.50 for Formpipe's share on Nasdaq Stockholm on 3 June 2026 (which was the last trading day prior to the announcement of the Offer), a premium of approximately 34.5 percent compared to the closing share price of SEK 22.30 on the last trading day prior to the announcement of the AGM Notice, and a premium of approximately 29.4 percent, approximately 25.6 percent and approximately 18.0 percent, respectively, compared to the volume weighted average trading price for Formpipe's share during the last 30 trading days, 90 trading days and 180 trading days, respectively, prior to the announcement of the AGM Notice. In evaluating the Offer, the board of directors has considered that Mission Trail and Grenspecialisten, which own and control in total approximately 29.3 percent of all outstanding shares in the Company, are part of the Consortium and will contribute such shares in the Company to Tabellae BidCo in connection with the completion of the Offer. In addition, the board of directors has considered that the Company’s shareholders ALCUR Fonder AB, Julnie S.A. and Jofam AB, representing in total 7,331,625 shares, representing approximately 25.0 percent of all outstanding shares in the Company, have undertaken to accept the Offer, subject to certain conditions. Please refer to the Offeror’s announcement of the Offer for further information about the undertakings. As part of its evaluation of the Offer, the board of directors has also investigated other opportunities in light of the discussions with Tabellae BidCo and taken into account interest from other potential offerors. In accordance with Rule III.3 of the Takeover Rules, the board of directors has obtained a valuation opinion (a so-called fairness opinion) regarding the Offer from Astelia Advisory AB (“Astelia”). The fairness opinion, which is attached as an appendix to this statement, concludes that Astelia considers the Offer to be fair from a financial point of view for the shareholders of the Company, subject to the assumptions and considerations set out in the fairness opinion. For the fairness opinion, Astelia receives a fixed fee which is not dependent on the size of the consideration in the Offer, the extent to which acceptances of the Offer are received or whether the Offer is completed. The board of directors has engaged ABG Sundal Collier AB as financial advisor and Cirio Advokatbyrå as legal advisor in connection with the Offer. The board of directors' recommendation Based on the above, the board of directors unanimously recommends the shareholders of Formpipe to accept the Offer. Effects on the Company and its employees Under the Takeover Rules, the board of directors is required to, based on what Tabellae BidCo has stated in its announcement of the Offer, present its opinion regarding the impact that implementation of the Offer will have on the Company, particularly in terms of employment, and its opinion regarding Tabellae BidCo's strategic plans for the Company and the effects it is anticipated that such plans will have on employment and on the locations where the Company conducts its operations. In its announcement of the Offer, Tabellae BidCo states: “The Offeror values the skills and talents of Formpipe’s employees and intends to continue to safeguard the excellent relationship that Formpipe has with its employees. Given the Offeror’s current knowledge of Formpipe’s business and in light of current market conditions, the Offeror does not intend to materially alter the operations of Formpipe following the implementation of the Offer, save that the Offeror intends to pursue the operational and commercial integration of Formpipe and Tabellae. The Offeror intends to determine what measures, if any, will be taken to integrate the two organizations and realize synergies following a thorough assessment, to be undertaken together with Formpipe, of the combined business following completion of the Offer. The Offeror will only be in a position to specify its intentions with respect to the employees and management of Formpipe and the Offeror upon completion of such assessment. There are currently no decisions on any material changes to Formpipe’s or the Offeror’s employees and management or to the existing organization and operations, including the terms of employment and locations of the business.” The board of directors assumes that this statement is correct and has in relevant respects no reason to take a different view. ____________________ This statement shall in all respects be governed by and construed in accordance with substantive Swedish law. Disputes arising from this statement shall be settled exclusively by Swedish courts. Stockholm, 4 June 2026 Formpipe Software AB (publ) The Board of Directors [1] Board member Erik Ivarsson is an analyst and portfolio manager at Aktiebolag Grenspecialisten and board member Martin Bjäringer has, through his company Julnie S.A., undertaken to accept the Offer on certain conditions. Erik Ivarsson and Martin Bjäringer are therefore deemed to have a conflict of interest pursuant to Rule II.18 of the Takeover Rules and have for that reason not participated, and will not participate, in the board of directors' handling of, or decisions on, matters related to the Offer. [2] The annual general meeting held on 29 April 2026 resolved on a change of name to Lasernet Group AB. The name change has not yet been registered with the Swedish Companies Registration Office. [3] Tabellae HoldCo ApS is controlled by Valedo Partners IV AB, which, together with its co-investors, hold approximately 62.4 percent of the shares and votes in Tabellae HoldCo ApS. The remaining shares in Tabellae HoldCo ApS are held by Tabellae A/S’s (an operational subsidiary wholly-owned by Tabellae BidCo ApS) founders, board members and management. [4] Excluding, as per the date of the announcement of the Offer, (i) 5,456,446 shares held by Mission Trail, and (ii) 3,136,432 shares held by Grenspecialisten.

IONCOR Selects Epec PDUs to Support Next-Generation Battery System Deliveries

The partnership supports IONCOR’s continued growth and development of high-performance battery systems for demanding applications. By integrating Epec Flow PDUs into its deliveries, IONCOR further enhances the reliability, safety, and scalability of its solutions. “Together with Epec we are representing more than system integration, it’s a joint effort to push electrification forward to scale operations and deliveries,” says Roberts Abele, CEO of IONCOR. “Epec’s role in our system deliveries reflects their strong capabilities and supports our work in delivering reliable electrification solutions.” The cooperation combines IONCOR’s battery system expertise with Epec Flow power distribution technology to support reliable and efficient electrification solutions for demanding applications. “We are proud to support IONCOR’s growth journey and to be selected as part of their system deliveries,” says Jyri Kylä-Kaila, CEO of Epec. “This cooperation reflects the increasing demand for smart and reliable electrification technologies in the industry.” The companies share a commitment to advancing sustainable and intelligent electrification solutions and see strong potential for future collaboration in the rapidly evolving battery and electric vehicle market. The collaboration will also be highlighted during The Battery Show Europe in Stuttgart, Germany, on June 9-11, 2026. 

Eye Health New E-Book Initiative from AstaReal

[AstaReal Vision Ebook.png] The e-book, Astaxanthin and the Evolution of Vision Care in a Screen-Centric World , describes how high screen time, reduced outdoor activity, and an ageing population are affecting vision health worldwide. It also highlights research on ocular nutrition and how different nutrients, including astaxanthin, may help support eye function. The book also explores research related to digital eye strain, or Computer Vision Syndrome, a growing issue associated with prolonged screen use. Among the studies highlighted is the 2025 study  in which children aged 10 to 14 showed reduced eye fatigue and improved stereoscopic vision after daily intake of AstaReal’s natural astaxanthin. “Research on eye health in general, and digital eye strain in particular, has developed rapidly in recent years. At the same time, we see a growing need for more knowledge about how today’s screen use affects younger generations and the role preventive approaches may play going forward.” The e-book also covers topics such as myopia, presbyopia, oxidative stress, and age-related vision changes, while describing how the global eye health market is evolving and how astaxanthin is gaining an increasingly prominent position. “Interest in vision nutrition is growing rapidly, both in research and product development. By bringing together science, market trends, and clinical data, we want to contribute to a more science-based approach to the future of eye health,” says Behnaz Shakersain, Scientific Affairs Manager at AstaReal AB. The new e-book was developed as a joint initiative by AstaReal’s global science team, bringing together researchers and experts from multiple regions, and is available for download here 

Photocure ASA to Acquire Vesica Health Inc., Strengthening Leadership in Bladder Cancer Diagnostics

Transaction Highlights ·  USD 30.5M in total cash + stock transaction · Of which USD 3.0M equity investment made during Q1 2026. · Net consideration of approx. USD 28.5M accounting for USD 2M of cash in Vesica Health · USD 13.75M due at close, comprised of USD 11.0M cash and USD 2.75M in Photocure equity. · USD 13.75M due based on two future milestones related to Medicare reimbursement, comprised of USD 5.5M cash and USD 8.25M in Photocure equity. · Advanced Diagnostic Laboratory Test (ADLT) milestone - USD 2.75M of Photocure Equity if company achieves ADLT status designation on or prior to 1 October 2026 (if this is not achieved by that date, the USD 2.75M roll into the second milestone). · Centers for Medicare and Medicaid Services (CMS) milestone - USD 5.5M of cash and USD 5.5M of Photocure equity if Vesica Health is awarded CMS reimbursement prior to end of December 2029 (assuming the ADLT milestone rolls, then the full milestone is USD 5.5M in cash and USD 8.25M in Photocure Equity). · All equity considerations will be based on Volume Weighted Average Price (VWAP) of Photocure on the Oslo Stock Exchange over the 30 trading days prior to Close, which is concurrent with this announcement. · Consideration due at Close will be funded through cash and treasury shares on hand. Consideration due for milestones will be funded with available cash and facilities. · The equity consideration due for milestones may, pursuant to the agreement with the sellers, be settled with the issuance of new shares or delivery of treasury shares to the sellers. · There are no financing conditions for the acquisition. Strategic Rationale The acquisition of Vesica Health adds a complementary noninvasive molecular diagnostic capability to Photocure’s precision diagnostics bladder cancer portfolio, extending further reach upstream in the patient evaluation pathway. Vesica Health offers AssureMDx, a multi-omic urine-based biomarker test designed to support risk stratification and identify hematuria patients at increased risk for bladder cancer to improve early detection. AssureMDx integrates six epigenetic and somatic biomarkers to help inform urologic evaluation through a urine-based testing approach. Approximately seven million patients in the U.S. present with hematuria annually, highlighting a substantial opportunity to improve patient identification and risk stratification. AssureMDx has been validated in prospective multicenter studies, including a large study of 838 hematuria patients demonstrating 96% sensitivity, 99.7% Negative Predictive Value (NPV), and 0.96 Area Under the Curve (AUC) for bladder cancer detection. The assay was recognized in American Urological Association (AUA) guidelines in September 2025 for the evaluation of microhematuria, received an American Medical Association (AMA) Proprietary Laboratory Analyses (PLA) code effective January 2026, and was granted U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (BDD) in February 2026. As of May 14, 2026, a proposed Medicare ruling may expedite future reimbursement pathway. AssureMDx’s commercialization can be significantly accelerated through Photocure’s established bladder cancer leadership, commercial infrastructure, urology footprint, and payer relationships. For Photocure, the addition of AssureMDx expands its portfolio with complementary noninvasive and procedural diagnostic technologies across the bladder cancer care pathway. The acquisition also expands Photocure’s reach into the large and rapidly growing hematuria evaluation market, supporting earlier patient risk stratification across existing urology call points. In addition, AssureMDx is expected to create meaningful operational and commercial synergies through expanded laboratory capabilities, attractive gross margins, and leverage of Photocure’s existing customer relationships and commercial organization. “This transaction represents a significant step forward in our strategy to build a comprehensive bladder cancer platform,” said Dan Schneider, Chief Executive Officer of Photocure. “We believe that Photocure can expand on progress with Blue Light Cystoscopy by building a portfolio of complementary precision diagnostics to inform physician decision-making and provide value for patients at different stages of the diagnostic pathway. By combining Vesica Health’s best-in-class hematuria early detection capabilities with our established diagnostic solution and commercial infrastructure, we are well positioned to accelerate growth and deliver improved outcomes for patients with urological cancers.” “AssureMDx represents a highly differentiated molecular assay designed to support risk stratification and earlier evaluation of hematuria patients,” said Christopher Thibodeau, Chief Executive Officer of Vesica Health. “Noninvasive genomic testing and blue light cystoscopy are highly complementary technologies within the bladder cancer care continuum, and bringing these approaches together through Photocure’s established platform has the potential to accelerate clinical adoption, support more informed clinical decision-making, and expand access to advanced noninvasive bladder cancer diagnostics.” “As the evaluation of hematuria continues to evolve, there remains a significant need for tools that can help identify patients at increased risk for bladder cancer earlier in the diagnostic pathway,” said Dr. Sam S. Chang, Professor of Urology and Chief Surgical Officer at Vanderbilt-Ingram Cancer Center. “The combination of noninvasive molecular testing such as AssureMDx with advanced visualization technologies such as Blue Light Cystoscopy has the potential to support more informed clinical decision-making and improve patient management across the bladder cancer care continuum.” Business Outlook · For full year 2026, Photocure continues to expect product revenue growth in the range of 7% to 11% on a constant currency basis, alongside continued expansion of adjusted EBITDA margins. · Assuming Medicare reimbursement by mid-2028 and positive clinical readouts supporting commercialization, Photocure expects initial AssureMDx revenues in 2027 and positive adjusted EBITDA contribution from AssureMDx operations by 2030, with market access and commercialization costs funded through free cash flow. · Modest Vesica Health operating losses expected in the near-term, quickly ramping to segment EBITDA margins north of 30%.  · The consolidated business is expected to accelerate revenue growth from a standalone mid-to-high teens CAGR to above 25% CAGR from 2026-2030, while maintaining strong profitability with consolidated adjusted EBITDA margins above 25% by 2030 and additional upside potential. · Importantly, completion of FDA down-classification, entry of additional scope manufacturers into the U.S. market including reintroduction of flexible scopes, will provide further upside to the standalone growth outlook. Conference Call and Webcast Photocure will host a conference call  on June 5, 2026 at 11.00 CEST to discuss the transaction. A company presentation is made available on the Photocure's website, www.photocure.com. Advisers DNB Carnegie, a part of DNB Bank ASA, acted as financial adviser. Morgan, Lewis & Bockius LLP is acting as US legal adviser and Advokatfirmaet Selmer is acting as Norwegian legal adviser to Photocure for this acquisition. Note to editors All trademarks mentioned in this release are protected by law and are registered trademarks of Photocure ASA.  This press release may contain product details and information which are not valid, or a product is not accessible, in your country. Please be aware that Photocure does not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or usage in the country of your origin. About Photocure ASA Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com. About Vesica Health, Inc. Vesica Health is a privately held precision diagnostics company pioneering noninvasive solutions for the early detection and management of bladder cancer. Headquartered in Irvine, California, Vesica operates a CAP-accredited, CLIA-certified laboratory and holds worldwide commercialization rights for AssureMDx. The company is led by an experienced team with a proven track record in diagnostic development, clinical evidence generation, and commercial execution. Learn more at: www.vesicahealth.com. About Bladder Cancer Bladder cancer ranks as the 8th most common cancer worldwide – the 5th most common in men – with 1 949 000 prevalent cases (5-year prevalence rate)[1a], 614 000 new cases and more than 220 000 deaths in 2022.[1b] Approx. 75% of all bladder cancer cases occur in men.1 It has a high recurrence rate with up to 61% in year one and up to 78% over five years.[2] Bladder cancer has the highest lifetime treatment costs per patient of all cancers.[3] Bladder cancer is a costly, potentially progressive disease for which patients have to undergo multiple cystoscopies due to the high risk of recurrence. There is an urgent need to improve both the diagnosis and the management of bladder cancer for the benefit of patients and healthcare systems alike. Bladder cancer is classified into two types, non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of invasion in the bladder wall. NMIBC remains in the inner layer of cells lining the bladder. These cancers are the most common (75%) of all BC cases and include the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has grown into deeper layers of the bladder wall. These cancers, including subtypes T2, T3 and T4, are more likely to spread and are harder to treat.[4] [1 ]Globocan. a) 5-year prevalence / b) incidence/mortality by population.  Available at: https://gco.iarc.fr/today, accessed [February 2024].[2 ]Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657[3 ]Sievert KD et al. World J Urol 2009;27:295–300[4 ]Bladder Cancer. American Cancer Society. https://www.cancer.org/cancer/bladder-cancer.html For more information, please contact: Dan SchneiderPresident and CEOPhotocure ASAEmail: ds@photocure.com Priyam ShahVice President Investor RelationsTel: +17176815072Email: priyam.shah@photocure.com Media and IR enquiries: Geir BjørloCorporate Communications (Norway)Tel: +47 91540000Email: geir.bjorlo@corpcom.no Important Information This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act. This stock exchange announcement was published by Dick Peters, Corporate Controller of Photocure ASA at the time and date stated above. This announcement is not and does not form a part of any offer to sell, or a solicitation of an offer to purchase, any securities. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Copies of this announcement are not being made and may not be distributed or sent into any jurisdiction in which such distribution would be unlawful or would require registration or other measures. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "strategy", "intends", "estimate", "will", "may", "continue", "should" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although Photocure believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. Photocure ASA undertakes no obligation to review, update, confirm, or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this announcement, other than as required by law. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of Photocure. Neither Photocure nor its advisors accept any liability arising from the use of this announcement. This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act.

Lundbeck presents positive Phase IIb data for bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention at the AHS congress

· The intravenous part of the Phase IIb clinical dose-finding trial PROCEED met its primary endpoint, with bocunebart demonstrating a statistically significant reduction in monthly migraine days versus placebo over Weeks 1–12 in patients with one to four prior preventive treatment failures · Bocunebart was generally well tolerated, with no new safety signals identified · The totality of the presented clinical data from the bocunebart Phase I-IIb program strengthens the evidence for PACAP pathway inhibition as a novel therapeutic approach for people severely impacted by migraine Valby, Denmark, Thursday 4 June 2026 – Lundbeck today announced the first presentation of primary data from the Phase IIb PROCEED trial evaluating bocunebart (Lu AG09222), an investigational monoclonal antibody targeting pituitary adenylate cyclase-activating polypeptide (PACAP). The data presented at the American Headache Society (AHS) Congress in Orlando, Florida, USA (4-7 June) support the potential of bocunebart as a preventive treatment in patients with one to four prior preventive migraine treatment failures, with particularly notable treatment effect in those with chronic migraine. Bocunebart is designed to bind to and inhibit PACAP, a neuropeptide implicated in migraine pathophysiology through pathways distinct from calcitonin gene-related peptide (CGRP). This differentiated mechanism positions bocunebart as a potential alternative treatment option for patients who do not achieve adequate benefit from currently available preventive therapies. “I am encouraged by the positive results from the PROCEED trial. Despite advances in migraine management, a substantial proportion of patients still do not achieve adequate disease control with currently available therapies. The clinical evidence to date highlights the potential of bocunebart as a new therapeutic approach for migraine prevention and offers hope to patients living with this debilitating condition”, said the coordinating investigator of the trial and presenting author, Dr. Jessica Ailani, certified headache specialist, Washington DC. In the intravenous (IV) dosing part of the PROCEED trial, bocunebart met the primary endpoint, demonstrating a statistically significant reduction from baseline in monthly migraine days (MMDs) over Weeks 1–12 compared with placebo. Patients treated with bocunebart experienced a mean reduction of -4.24 monthly migraine days versus -2.86 days with placebo, corresponding to a treatment difference of -1.38 days (p=0.0178). In pooled data across the Phase II program of severe, chronic migraine patients, bocunebart showed a more pronounced effect with a mean reduction of -5.94 MMDs versus -3.63 MMDs with placebo, corresponding to a treatment difference of -2.31 days (p<0.001) in patients that had experienced prior preventive treatment failures. Bocunebart was generally well tolerated, with no new safety signals identified during the treatment period. Across the Phase II program, the most commonly reported treatment-emergent adverse event (≥5%) for bocunebart was nasopharyngitis. “Today’s data mark an important milestone in our efforts to bring forward innovative treatments for people living with migraine, particularly those who continue to experience substantial disease burden despite currently available therapies” said Johan Luthman, EVP and Head of Research and Development at Lundbeck. “The PROCEED results strengthen our confidence in targeting the PACAP pathway and support continued clinical development of bocunebart.” In addition, Lundbeck presents Phase I clinical data evaluating the safety and tolerability of bocunebart when co-administered with ubrogepant in participants with migraine. Together with previously presented data on co-administration with triptans, these findings further support the safety profile of bocunebart when used alongside commonly prescribed acute migraine therapies. Based on the positive PROCEED trial, Lundbeck is advancing preparations for further clinical development of bocunebart in migraine prevention. Lundbeck will host a conference call and live webcast for investors and analysts on Friday, June 5, 2026, at 15:00 CET (09:00 a.m. ET) to discuss the announcement. The webcast can be accessed through the Investor Relations section of  Lundbecks’s website at www.lundbeck.com. A replay will be available shortly after the conclusion of the event. About Lundbeck’s bocunebart scientific presentations at the AHS congress Targeting PACAP in migraine prevention: Early outcomes from the PROCEED phase IIb trial of bocunebart (Lu AG09222) Poster presentation: Jessica Ailani Date: Thursday, June 4, 2026 Time: 6:00 pm – 7:30 pm EDT Safety and Tolerability of Anti-PACAP Monoclonal Antibody Lu AG09222 when Co-administered with Ubrogepant in Participants with Migraine. Poster presentation: Amaal Starling Date: Thursday, June 4, 2026 Time: 6:00 pm – 7:30 pm EDT About the PROCEED migraine trial The PROCEED trial assessed the efficacy, safety, and tolerability of bocunebart versus placebo when administered once monthly for three months. The Phase IIb trial was designed to establish the optimal dose and route of administration (subcutaneous and intravenous) of bocunebart. A predefined interim analysis of the subcutaneous part of the PROCEED trial demonstrated futility and triggered enrolment into the intravenous (IV) part of the trial. In the IV part of PROCEED a total of 429 patients from 14 countries (Bulgaria, Czechia, Denmark, France, Georgia, Germany, Hungary, Lithuania, Japan, Poland, Romania, Slovakia, Spain, and the United States) were treated. The primary efficacy endpoint was defined as the difference between bocunebart and placebo in mean change from baseline in the number of monthly migraine days over Weeks 1 to 12. The target population for this trial included patients diagnosed with migraine according to the International Classification of Headache Disorders, Third Edition (ICHD-3),[1] who had experienced treatment failure with one to four different preventive migraine medications within the past 10 years. About the HOPE migraine trial The HOPE trial was an interventional, multi-national, multi-site, randomized, double-blind, parallel-group, placebo-controlled Phase IIa trial designed to assess the safety, tolerability and efficacy of a single IV infusion of bocunebart for the prevention of migraine in patients that had failed prior treatments. The trial consisted of a 4-week double-blind treatment period with a follow-up period for 8 weeks. The primary endpoint was the change from baseline in the number of monthly migraine days over weeks 1 to 4, compared to placebo. Secondary endpoints were ≥50% reduction from baseline in MMDs (Weeks 1 to 4) and change from baseline in the number of monthly headache days (Weeks 1 to 4), compared to placebo. The target population for this trial was defined as patients diagnosed with migraine as outlined in the International Classification of Headache Disorders Third Edition (ICHD-3) with unsuccessful prior preventive treatments A total of 237 patients, recruited from specialist settings, were randomly allocated via a randomization system to one of three treatment groups: two doses of bocunebart or placebo. About bocunebart Bocunebart is an investigational monoclonal antibody (mAb) with a novel mechanism of action. It is designed to bind to and inhibit the signalling of pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide implicated in migraine pathophysiology.  This mechanism operates through a pathway distinct from that targeted by anti-calcitonin gene-related peptide (anti-CGRP) therapies. Bocunebart represents a potential new treatment class in migraine prevention and may provide an alternative option for people living with migraine who continue to be severely affected by the condition. Bocunebart is an investigational drug that is not approved for marketing by any regulatory authority worldwide, and the efficacy and safety of bocunebart have not been established. About migraine Migraine is a complex and disabling neurological disease characterized by recurrent attacks of severe headache typically accompanied by an array of symptoms, including nausea, vomiting, and sensitivity to light or sound.[1] Migraine is among the most prevalent neurological diseases worldwide and remains the leading cause of disability for people under the age of 50 and the 2nd leading cause of disability.[2] The disease has a profound impact on daily functioning, including relationships, social participation, household responsibilities, and work productivity. As migraine frequency and severity increase, attacks become more difficult to control, contributing to greater disease burden and can progress to chronic migraine in the absence of appropriate preventive management.[3] Contacts Anders Crillesen Jens HøyerSenior Director, Vice President, Head of Investor RelationsExternal & InternalRelationsAECE@lundbeck.com JSHR@lundbeck.com+45 27 79 12 86 +45 30 83 45 01   About H. Lundbeck A/S Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, we are committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world’s population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, we hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, we strive for our research and development programs to tackle some of the most complex neurological challenges. We develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from our strong legacy within psychiatry and neurology. We are committed to fighting stigma and we act to improve health equity. We strive to create long term value for our shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has more than 5,000 employees in more than 20 countries and our products are available in more than 80 countries. For additional information, we encourage you to visit our corporate site www.lundbeck.com  and connect with us via LinkedIn .   References: 1. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd Edition. Cephalalgia, 2018. 38(1): p. 1-211 2. Burch, R.C., D.C. Buse, and R.B. Lipton, Migraine: epidemiology, burden, and comorbidity. Neurol Clin, 2019. 37(4): p. 631-649 3. Lipton RB, Buse DC, Nahas SJ, Tietjen GE, Martin VT, Löf E, Brevig T, Cady R, Diener HC. Risk factors for migraine disease progression: a narrative review for a patient-centered approach. J Neurol. 2023 Dec;270(12):5692-5710. doi: 10.1007/s00415-023-11880-2. Epub 2023 Aug 24. PMID: 37615752; PMCID: PMC10632231 

Sectra’s year-end report 2025/2026: Long-term investments drive growth and profit

Fourth quarter: February–April 2026 · Contracted order bookings decreased 46.5% to SEK 1,551.6 million (2,900.3), of which SEK 1,322.9 million (2,382.1) pertained to guaranteed order bookings. Of the guaranteed order bookings, 13% were recognized during the quarter and a further 16–26% will pertain to revenue within 12 months after the end of the quarter. · Net sales increased 13.0% to SEK 1,033.2 million (914.1). Based on unadjusted exchange rates compared with the year-earlier quarter, the increase would have been 17.8%. Recurring revenue accounted for SEK 682.2 million (574.6) of net sales, up 18.7%. Based on unadjusted exchange rates, the increase would have been 24.1%. Cloud recurring revenue (CRR) increased 49.2% to SEK 274.7 million (184.1). · Operating profit increased 5.1% to SEK 209.1 million (198.9), corresponding to an operating margin of 20.2% (21.8). Based on unadjusted exchange rates compared with the year-earlier quarter, the increase would have been 18.0%. The outcome includes SEK 26.6 million (26.1) in costs for share-based incentive programs. · Profit for the period amounted to SEK 157.5 million (131.2). · Cash flow from operations amounted to SEK 519.7 million (222.3). This change was primarily linked to advances from customers. 2025/2026 fiscal year[1] · Contracted order bookings decreased 12.7% to SEK 7,599.5 million (8,706.1), of which SEK 5,854.5 million (7,653.0) pertained to guaranteed order bookings. The comparative figures include a very large Canadian order with a contracted order value of SEK 3.1 billion. · Net sales increased 9.3% to SEK 3,541.7 million (3,239.8). Based on unadjusted exchange rates compared with the year-earlier quarter, the increase would have been 16.5%. Recurring revenue accounted for SEK 2,451.3 million (2,067.4) of net sales, up 18.6%. Based on unadjusted exchange rates, the increase would have been 26.7%. Cloud recurring revenue (CRR) increased 54.9% to SEK 915.8 million (591.1). · Operating profit rose 15.9% to SEK 710.6 million (613.0), corresponding to an operating margin of 20.1% (18.9). Based on unadjusted exchange rates compared with the year-earlier period, operating profit would have increased 34.3%. The outcome includes SEK 80.7 million (63.5) for share-based incentive programs. The increase for incentive programs was due to a new program that started during the second half of the previous fiscal year. · Profit for the period amounted to SEK 563.8 million (475.6). · Cash flow from operations amounted to SEK 1,097.3 million (824.9). · The Board and CEO propose that the 2026 AGM resolve on an ordinary dividend of SEK 1.30 (1.10) per share and an extraordinary dividend of SEK 1.00 (1.00) per share, considering the year’s cash flow and Sectra’s financial position. In addition, it is proposed that the Board be authorized to decide on the acquisition of own shares (see the year-end report) in order to enable the repurchase of Class B shares to secure the company’s commitments under a new share-based incentive program that the Board intends to propose to the AGM.[1] Figures in parentheses pertain to the corresponding period/quarter in the preceding fiscal year. Figures for the comparative year are presented excluding the effects of a patent settlement that had a positive impact of SEK 110 million on operating profit. The business transaction was a non-recurring item and was recognized during the third quarter of 2024/2025 The patent settlement had no effect on order bookings and net sales. For further information, see the attached year-end report. Comments from Torbjörn Kronander, President and CEO of Sectra AB “Digitization, AI and increasing security requirements are drivers that are fundamentally changing how both we and our customers work. For us, this is about embracing change and converting new technologies into customer value. With a corporate culture that encourages innovation and ideas, and puts them into practice, we are continuing to strengthen Sectra’s position in medical IT and cybersecurity—areas where our solutions make a difference in people’s lives, health and safety all over the world. “The Group’s net sales exceeded SEK 1 billion for the first time in a single quarter. This positive performance was made possible as a result of satisfied and loyal customers. All of our operating areas are growing and reporting increased operating profit, despite the negative impact of currency effects and delays in product deliveries in Secure Communications. “Our ongoing transformation of the business model from software sales to service deliveries helped to increase the total share of recurring revenue by 5 percentage points to close to 70% during the fiscal year. This also led to a more even performance between quarters compared with our past seasonal trends, which is clear from our earnings outcomes for the last three quarters. “AI is an enormous wave rolling in and no one knows exactly how it will affect the future. We are choosing to ride this wave and course-correct as we go, rather than paddling behind and struggling to catch up. “At a time when politics, technology and business risks are becoming increasingly interconnected, our ability to combine innovation with high security and long-term trust is growing in importance. We will continue capitalizing on this and other strengths to make the world a healthier and safer place. Our stable financial position gives us the ability to continue investing in innovation and capacity for the future. Together with our customers, we are shaping and driving developments forward, which means that our speed is a crucial strength. The trust we receive from our customers is not something we take for granted. We must continue to earn it and build on it every day.” Read the attached financial report for further CEO comments and information. Presentation of the financial reportTorbjörn Kronander, President and CEO of Sectra AB, and Jessica Holmquist, CFO of Sectra AB, will present the financial report and answer questions. The presentation will be held in English. Time: June 5, 2026, at 10:00 a.m. (CEST) Follow live or listen to the recording afterward: https://investor.sectra.com/q4report2526 This information constitutes information that Sectra AB (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 8:15 a.m. CEST on June 5, 2026.

Hexagon Composites ASA: Approval of prospectus

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT DOES NOT CONSTITUTE AN OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN. 5 June 2026: Reference is made to the stock exchange announcement made by Hexagon Composites ASA (the "Company") on 7 May 2026 regarding the successful private placement of 68,750,000 new shares in the Company (the "Private Placement Shares") at a price of NOK 8.00 per share, raising gross proceeds of NOK 550 million (the "Private Placement"), and a potential subsequent offering (the "Subsequent Offering") of up to 15,625,000 new shares in the Company (the "Offer Shares") at the same subscription price as in the Private Placement. Reference is further made to the resolutions made by the annual general meeting of the Company held on 4 June 2026 to, inter alia, (i) issue the Private Placement Shares, and (ii) authorize the Board of Directors of the Company to issue up to 15,625,000 Offer Shares in the Subsequent Offering. Approval and publication of prospectusThe Norwegian Financial Supervisory Authority has today, 5 June 2026, approved a prospectus prepared by the Company for the Subsequent Offering and the listing of the Offer Shares and the Private Placement Shares on Euronext Oslo Børs (the "Prospectus"). The Prospectus, including the subscription form for the Subsequent Offering, will, subject to regulatory restrictions in certain jurisdictions, be made available at www.dnb.no/emisjoner. The Subsequent OfferingThe Subsequent Offering consists of an offer of up to 15,625,000 Offer Shares at a subscription price of NOK 8.00 per Offer Share (being the same subscription price as in the Private Placement), thereby raising gross proceeds of up to NOK 125 million. The Subsequent Offering will be directed towards shareholders in the Company as of 7 May 2026 (as registered in the VPS on 11 May 2026), who (i) were not included in the pre-sounding phase of the Private Placement; (ii) were not allocated shares in the Private Placement and (iii) are not resident in a jurisdiction where such offering would be unlawful, or for jurisdictions other than Norway, would require any prospectus filing, registration or similar action ("Eligible Shareholders"). Each Eligible Shareholder will receive 0.12 non-tradeable subscription right (the "Subscription Rights") for each share held by such Eligible Shareholder in the Company as of the Record Date, rounded down to the nearest whole right. Each Subscription Right will, subject to applicable securities laws, give the preferential right to subscribe for, and be allocated, one Offer Share in the Subsequent Offering. Over-subscription will be permitted, but there can be no assurance that Offer Shares will be allocated for such subscriptions. Subscription without Subscription Rights will not be permitted. The subscription period for the Subsequent Offering commences on 8 June 2026 at 09:00 (CEST) and, subject to any extension, expires on 19 June 2026 at 16:30 (CEST) (the "Subscription Period"). The Subscription Rights must be used to subscribe for Offer Shares before the end of the Subscription Period. Subscription Rights which are not exercised before the end of the Subscription Period will have no value and will lapse without compensation to the holder. Subscriptions for Offer Shares must be made by submitting a correctly completed copy of the subscription form attached to the Prospectus to the Manager during the Subscription Period. Subscribers who are residents of Norway with a Norwegian personal identification number may also subscribe for Offer Shares through the VPS online subscription system (or by following the link on www.dnb.no/emisjoner, which will redirect the subscriber to the VPS online subscription system). Complete information on the terms and conditions of the Subsequent Offering, including subscription procedures, is set out in the Prospectus. Subscriptions may only be made on the basis of the Prospectus.  AdvisorsDNB Carnegie, a part of DNB Bank ASA, is acting as manager for the Subsequent Offering (the "Manager"). Advokatfirmaet Schjødt AS is acting as legal counsel to the Company. For more informationBerit-Cathrin Høyvik, Senior Director, Communications, Hexagon CompositesTelephone: +47 988 92 161 | berit-cathrin.hoyvik@hexagongroup.com  Eirik Løhre, CFO, Hexagon CompositesTelephone: +1 704 777 5171 (US Eastern time zone) | eirik.lohre@hexagongroup.com About Hexagon Composites ASAHexagon delivers safe and innovative solutions for a cleaner energy future. Our solutions enable storage, transportation, and conversion to clean energy in a wide range of mobility and industrial applications. Learn more at www.hexagongroup.com and follow @HexagonASA on LinkedIn. IMPORTANT INFORMATIONThis announcement does not constitute or form a part of any offer of securities for sale or a solicitation of an offer to purchase securities of the Company in the United States or any other jurisdiction. The securities of the Company may not be offered or sold in the United States absent registration or an exemption from registration under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act"). The securities of the Company have not been, and will not be, registered under the U.S. Securities Act, and may not be offered or sold in the United States absent registration under the US Securities Act or an available exemption from, or transaction not subject to, the registration requirements of the US Securities Act. There will be no public offering of securities in the United States. Any sale in the United States of the securities mentioned in this communication will be made solely to "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act. No public offering of the securities will be made in the United States. The Company has not authorized any offer to the public of securities in any Member State of the European Economic Area nor elsewhere. With respect to any Member State of the European Economic Area (each an "EEA Member State"), no action has been undertaken or will be undertaken to make an offer to the public of securities requiring publication of a prospectus in any EEA Member State. In any EEA Member State, this communication is only addressed to and is only directed at qualified investors in that Member State within the meaning of the EU Prospectus Regulation, i.e., only to investors who can receive the offer without an approved prospectus in such EEA Member State. The expression "EU Prospectus Regulation" means Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (together with any applicable implementing measures in any Member State). In the United Kingdom, these materials are only being communicated to (a) persons who have professional experience, knowledge and expertise in matters relating to investments and qualifying as "investment professionals" for the purposes of article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (all such persons being referred to as "relevant persons") and (b) only in circumstances falling within the circumstances set out in Part 1 of Schedule 1 to The Public Offers and Admissions to Trading Regulations 2024. These materials are directed only at relevant persons and must not be acted on or relied on by persons who are not relevant persons. Matters discussed in this announcement may constitute forward-looking statements. Forward-looking statements are statements that are not historical facts and may be identified by words such as "anticipate", "believe", "continue", "estimate", "expect", "intend", "may", "should", "will" and similar expressions. The forward-looking statements in this release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that these assumptions were reasonable when made, these assumptions are inherently subject to significant known and unknown risks, uncertainties, contingencies and other important factors which are difficult or impossible to predict and are beyond its control. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The information, opinions and forward-looking statements contained in this announcement speak only as at its date and are subject to change without notice. This announcement is made by and is the responsibility of, the Company. The Manager is acting exclusively for the Company and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to their respective clients, or for advice in relation to the contents of this announcement or any of the matters referred to herein. Neither the Manager nor any of its affiliates make any representation as to the accuracy or completeness of this announcement and none of them accepts any responsibility for the contents of this announcement or any matters referred to herein. This announcement is not a prospectus. This announcement is for information purposes only and is not to be relied upon in substitution for the exercise of independent judgment. It is not intended as investment advice and under no circumstances is it to be used or considered as an offer to sell, or a solicitation of an offer to buy any securities or a recommendation to buy or sell any securities of the Company. Neither the Manager nor any of its affiliates accepts any liability arising from the use of this announcement. Each of the Company, the Manager and their respective affiliates expressly disclaims any obligation or undertaking to update, review or revise any statement contained in this announcement whether as a result of new information, future developments or otherwise. The distribution of this announcement and other information may be restricted by law in certain jurisdictions. Persons into whose possession this announcement or such other information should come are required to inform themselves about and to observe any such restrictions.

BTC AB resolves to carry out a rights issue of preference A shares in connection with listing on Spotlight Stock Market

The Board of Directors of B Treasury Capital AB, (“BTC AB” or the “Company”), has today resolved, pursuant to the authorisation granted by the Annual General Meeting held on 31 March 2026, to carry out a rights issue of 195,078 preference A shares (“BTC PREF”), with preferential rights for the Company's existing holders of Class B shares, (the “Rights Issue”). In connection with the Rights Issue, BTC PREF is intended to be admitted to trading on Spotlight Stock Market with first day of trading expected on 20 July 2026 (the “Listing”). The subscription price has been set at SEK 120.00 per BTC PREF. Provided that the Rights Issue is fully subscribed, the Company will receive proceeds of approximately SEK 23.4 million before issue costs. The purpose of the Rights Issue is to strengthen the Company’s capital base and support the continued execution of the Company’s Bitcoin treasury strategy. If the Rights Issue is oversubscribed, the Board of Directors may, in whole or in part, pursuant to the authorisation granted by the 2026 Annual General Meeting, resolve on an over-allotment issue of a maximum of 83,333 shares, corresponding to issue proceeds of a maximum of approximately SEK 10.0 million before issue costs (the “Over-allotment Issue”). The terms of any Over-allotment Issue will be the same as those of the Rights Issue.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES.SummaryThe purpose of the Rights Issue is to strengthen the Company’s capital base and support the continued execution of the Company’s Bitcoin treasury strategy.The Rights Issue is intended to bring capital directly onto the Company’s balance sheet without creating debt or large repayment obligations, enabling BTC AB to acquire bitcoin in a flexible and risk-efficient way.Shareholders who are registered as holders of Class B shares in the share register maintained by Euroclear Sweden AB on the record date, 12 June 2026, have preferential rights to subscribe for BTC PREF in the Rights Issue.For each existing Class B share held on the record date, one (1) subscription right will be received. Four (4) subscription rights will entitle the holder to subscribe for one (1) BTC PREF.The subscription price has been set at SEK 120.00 per BTC PREF.The subscription period in the Rights Issue runs from and including 16 June 2026 up to and including 30 June 2026. Trading in subscription rights will take place from and including 16 June 2026 up to and including 25 June 2026.BTC PREF is the Company’s preference share. According to its terms, BTC PREF carries a preferential dividend of SEK 12.00 per year per share, payable monthly in arrears.If the Rights Issue is fully subscribed, BTC AB will receive issue proceeds of approximately SEK 23.4 million before issue costs.Through the Rights Issue, a maximum of 195,078 new BTC PREF may be issued, corresponding to a dilution of approximately 0.019 percent of the share capital and approximately 0.004 percent of the votes.Subscription undertakings corresponding to approximately SEK 6.3 million, equivalent to approximately 27.1 percent of the Rights Issue, have been received. In addition, the Company has received non-binding intentions to subscribe for BTC PREF from all members of the Board of Directors and certain members of management of BTC AB, corresponding to approximately SEK 2.4 million, equivalent to approximately 10.2 percent of the Rights Issue. The intentions to subscribe are not legally binding and do not constitute formal commitments to subscribe.The estimated date for announcement of the outcome of the Rights Issue is 2 July 2026.If the Rights Issue is oversubscribed, the Board of Directors may, in whole or in part, pursuant to the authorisation granted by the 2026 Annual General Meeting, resolve on an Over-allotment Issue of a maximum of 83,333 shares, corresponding to issue proceeds of a maximum of approximately SEK 10.0 million before issue costs. The terms of any Overallotment Issue will be the same as those of the Rights Issue.Background and reasons for the Rights IssueBTC AB is a Sweden-based company with Bitcoin as its core reserve asset. The Company is a pure-play Bitcoin treasury company operating under a Swedish corporate equity structure. As a dedicated operator in Bitcoin treasury management, BTC AB focuses on acquiring, securing and maintaining Bitcoin as part of a long-term capital strategy.The Rights Issue is carried out to strengthen the Company’s capital base and support the continued execution of the Company’s Bitcoin treasury strategy. The net proceeds are intended to be used primarily for additional acquisitions of bitcoin and for liquidity reserve purposes related to the Company’s preference share structure.The preference share structure is intended to allow BTC AB to raise equity capital without creating debt or large repayment obligations. The structure is also intended to enable BTC AB to prudently increase its amplification through preferred equity, with the objective of accelerating growth in Bitcoin per Share while limiting dilution for ordinary equity shareholders.BTC PREF carries a preferential dividend and has a liquidation preference corresponding to the redemption amount. BTC AB may redeem all or some of the BTC PREF in accordance with the terms set out in the Company’s articles of association and the information document.Background and reasons for the ListingIn connection with the Rights Issue, BTC AB has applied for admission to trading of BTC PREF on Spotlight Stock Market. The first day of trading is expected to be on or around 20 July 2026.Following the directed issue of preference shares in December 2025, the Company now seeks to broaden its shareholder base through the Rights Issue, and the Listing provides an organised secondary market and transparent pricing for existing and new holders. The preference share is a key part of the Company's financing strategy, as the Board considers it an effective instrument for raising capital for its Bitcoin treasury strategy without increasing financial leverage or diluting ordinary shareholders.The Rights IssueThe Board of Directors has resolved to carry out the Rights Issue. For each existing Class B share held on the record date, one (1) subscription right will be received. Four (4) subscription rights will entitle the holder to subscribe for one (1) BTC PREF. The subscription price has been set at SEK 120.00 per BTC PREF.Provided that the Rights Issue is fully subscribed, the Company will receive approximately SEK 23.4 million before transaction related costs.Upon full subscription, 195,078 BTC PREF will be issued, and the Company’s share capital will increase by SEK 97.5390, corresponding to a dilution of approximately 0.019 percent of the share capital and approximately 0.004 percent of the votes.Shareholders who do not participate in the Rights Issue have the possibility to receive certain financial compensation by selling their subscription rights. In order not to lose the value of the subscription rights, the holder must either exercise the subscription rights to subscribe for BTC PREF or sell them during the period for trading in subscription rights.If not all BTC PREF are subscribed for with subscription rights, the Board of Directors shall, within the maximum amount of the Rights Issue, resolve on allotment of BTC PREF subscribed for without subscription rights in accordance with the following.First, allotment shall be made to those who have subscribed for BTC PREF with subscription rights, regardless of whether the subscriber was a shareholder on the record date or not, and, in the event that allotment to these subscribers cannot be made in full, allotment shall be made pro rata in relation to the number of subscription rights exercised for subscription of BTC PREF and, to the extent this cannot be done, by drawing of lots. Second, allotment shall be made to others who have subscribed for BTC PREF without subscription rights, and, in the event that allotment to these subscribers cannot be made in full, allotment shall be made pro rata in relation to the number of BTC PREF subscribed for by each person and, to the extent this cannot be done, by drawing of lots.Subscription undertakingsA number of external investors have entered into subscription undertakings to subscribe for BTC PREF in the Rights Issue, corresponding in aggregate to approximately SEK 6.3 million, equivalent to approximately 27.1 percent of the Rights Issue. The individual subscription undertakings are set out in the table below. The subscription undertakings are not secured through bank guarantees, blocked funds, pledges or similar arrangements. No remuneration is paid for the subscription undertakings. The Rights Issue is not covered by guarantee commitments.Subscriber                           I Number of BTC PREF        I Amount (SEK)Tobias Persson Rosenqvist I 50,000                                I 6,000,000Niklas Estensson                 I 2,500                                  I 300,000Mikael Koponen                   I 300                                     I 36,000Total                                     52,800                                   6,336,000In addition, all members of the Board of Directors and certain members of management of BTC AB have expressed non-binding intentions to subscribe for BTC PREF in the Rights Issue, corresponding in aggregate to approximately SEK 2.4 million, equivalent to approximately 10.2 percent of the Rights Issue. These intentions reflect the relevant persons’ current intention to participate in the Rights Issue but are not legally binding and do not constitute formal subscription commitments.Preliminary timetable for the Rights Issue, all dates refer to 2026 unless otherwise stated10 June: Last day of trading in Class B shares including the right to receive subscription rights11 June: First day of trading in Class B shares excluding the right to receive subscription rights12 June: Record date for participation in the Rights Issue15 June: Publication of the information document16 June to 25 June: Trading in subscription rights on Spotlight Stock Market16 June to 30 June: Subscription period in the Rights Issue 16 June to until the Rights Issue is registered with the Swedish Companies Registration Office (Sw. Bolagsverket): Estimated trading in paid subscribed shares on Spotlight Stock Market2 July: Estimated date for announcement of the outcome of the Rights Issue14 July: Estimated registration of the Rights Issue with the Swedish Companies Registration Office20 July: Estimated first day of trading in BTC PREF on Spotlight Stock MarketChange in share capital and number of sharesIf the Rights Issue is fully subscribed, the Company’s share capital will increase by a maximum of SEK 97.5390, from SEK 500,416.7505 to SEK 500,514.2895. The number of shares will increase by a maximum of 195,078 BTC PREF, from 1,000,833,501 shares to 1,001,028,579 shares (consisting of 499,999,900 Class A shares, 780,313 Class B shares, 499,992,888 Class C shares and 255,478 BTC PREF). This corresponds to a dilution of approximately 0.019 percent of the share capital and approximately 0.004 percent of the votes.Information documentFull terms and instructions for the Rights Issue as well as additional information about the Company will be set out in the information document, which is expected to be published on 15 June 2026. The information document and application form will be available at btc.se and at the dedicated page btc.se/pref.Over-allotment IssueIf the Rights Issue is oversubscribed, the Board of Directors may, pursuant to the authorisation granted by the 2026 Annual General Meeting, resolve in whole or in part on an Over-allotment Issue. The Over-allotment Issue may comprise up to 83,333 shares, corresponding to maximum issue proceeds of approximately SEK 10.0 million before issue costs. The terms of any Over-allotment Issue will be the same as those of the Rights Issue. When resolving on the Over-allotment Issue, the Board of Directors shall determine allotment in accordance with the principles for allotment applied in the Rights Issue. The reason for the deviation from the shareholders' preferential rights is to accommodate a higher demand than initially anticipated in the event of oversubscription in the Rights Issue, and to enable the Company to receive additional issue proceeds in such case. The right to subscribe for shares in the Over-allotment Issue shall accrue to those who have subscribed for shares in the Rights Issue without receiving full allotment.The Over-allotment Issue means that the share capital may increase by a maximum of an additional SEK 41.6665 and that the number of shares may increase by a maximum of an additional 83,333 shares, which, together with the Rights Issue, corresponds to a dilution of approximately 0.028 percent of the share capital and approximately 0.005 percent of the votes in the Company following registration of the new shares with the Swedish Companies Registration Office.AdvisorsEminova Partners acts as financial advisor in connection with the Rights Issue. Aqurat Fondkommission AB acts as issuing agent in connection with the Rights Issue.Important informationThe information in this press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, preference shares, subscription rights or other securities in BTC AB. No action has been taken, and no action will be taken, to permit a public offering in any jurisdiction other than Sweden. Invitation to eligible persons to subscribe for BTC PREF in BTC AB will only be made through the information document published by the Company.The information in this press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Switzerland, Singapore, South Africa or South Korea or any other jurisdiction where such action would be unlawful, subject to legal restrictions or require measures other than those required under Swedish law. Any action in violation of this instruction may constitute a breach of applicable securities legislation. This press release does not constitute an offer or invitation to acquire or subscribe for securities in the United States. No shares, preference shares, subscription rights or other securities issued by the Company, the “Securities”, have been or will be registered under the United States Securities Act of 1933, the “Securities Act”, or the securities legislation of any state or other jurisdiction in the United States, and no Securities may be offered, subscribed for, exercised, pledged, sold, resold, delivered or transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in accordance with the securities legislation of the relevant state or other jurisdiction in the United States. The Securities have neither been approved nor registered, and will not be approved or registered, by the United States Securities and Exchange Commission, any state securities authority or any other authority in the United States. Nor has any such authority assessed or expressed an opinion on the offering or the accuracy and reliability of the information document. To assert otherwise is a criminal offence in the United States.This press release is not a prospectus within the meaning of Regulation EU 2017/1129, the “Prospectus Regulation”, and has not been approved by any regulatory authority in any jurisdiction. In an EEA Member State other than Sweden, this communication is only intended for and directed only at “qualified investors” in the relevant Member State within the meaning of the Prospectus Regulation.In the United Kingdom, this document and other materials relating to the securities referred to herein are distributed and directed only to, and any investment or investment activity to which this document relates is available only to and will be engaged in only with, “qualified investors” within the meaning of the UK version of Regulation EU 2017/1129, which forms part of UK law by virtue of the European Union Withdrawal Act 2018, who are i persons having professional experience in matters relating to investments and who fall within the definition of “investment professionals” in article 19 5 of the Financial Services and Markets Act 2000 Financial Promotion Order 2005, the “Order”, ii “high net worth entities” etc. as referred to in article 49 2 a to d of the Order, or iii such other persons to whom such investment or investment activity may lawfully be directed under the Order, all such persons together being referred to as “relevant persons”. Any investment or investment activity to which this communication relates is available in the United Kingdom only to relevant persons and will be engaged in only with relevant persons. Persons who are not relevant persons should not take any action based on this document and should not act or rely on it.Forward-looking statementsThis press release contains certain forward-looking information that reflects the Company’s current view of future events as well as financial and operational development. Words such as “intends”, “assesses”, “expects”, “may”, “plans”, “believes”, “estimates” and other expressions that indicate predictions or indications of future development or trends, and that are not based on historical facts, constitute forward-looking information. Forward-looking information is by its nature associated with both known and unknown risks and uncertainties, since it depends on future events and circumstances. Forward-looking information does not constitute a guarantee of future results or development, and actual outcomes may differ materially from what is expressed or implied in forward-looking information.For further information, please contact:Christoffer De Geer, CEOEmail: hello@btc.seWebsite: www.btc.seAbout BTC ABBTC AB is a Sweden-based company with Bitcoin as its core reserve asset. The Company is a pure-play Bitcoin treasury company operating under a Swedish corporate equity structure. As a dedicated operator in Bitcoin treasury management, BTC AB focuses on acquiring, securing and maintaining Bitcoin as part of a long-term capital strategy. BTC AB is listed on Spotlight Stock Market.This information is information that B Treasury Capital AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication through the agency of the contact person set out above on 5 June 2026 at 12.00 CEST. 

Legato Merger Corp. III Shareholders Approve Business Combination with Einride

NEW YORK, NY & STOCKHOLM, SWEDEN — June 5, 2026 — Einride AB ("Einride" or the "Company"), a technology company driving the transition to cost-efficient electric and autonomous freight operations, and Legato Merger Corp. III (NYSE American: LEGT) ("Legato"), a publicly traded special purpose acquisition company, today announced that Legato's shareholders voted to approve the previously announced business combination  between Einride and Legato and the related matters (the "Transaction") at a special meeting of shareholders held on June 4, 2026 (the "Special Meeting"). A Current Report on Form 8-K disclosing the full voting results will be filed by Legato with the Securities and Exchange Commission. The Transaction values Einride at a pre-money equity value of $1.35 billion. As previously announced,  Einride raised $113 million through an oversubscribed PIPE financing in connection with the Transaction. The PIPE was supported by new and existing investors, including Stockholm-based EQT Ventures and a global asset management company based on the West Coast of the United States. "At Einride, we are redesigning the way freight moves. We are building the world’s most efficient freight network and going public gives us the platform to deploy our electric and autonomous technologies at the speed this market demands,” said Roozbeh Charli, Chief Executive Officer at Einride. Einride, which is driving the transition to cost-efficient electric and autonomous freight operations for large shippers across the U.S., Europe, and the Middle East, currently counts more than 30 enterprise customers across seven countries, with approximately $92 million in expected annual recurring revenue (ARR) from signed contracts and over $800 million in potential long-term ARR through joint business plans with blue-chip customers. Upon the completion of the Transaction, the combined company's ordinary shares, represented by American Depositary Shares, and warrants are expected to commence trading on the Nasdaq under the ticker symbol "ENRD" and “ENRDW,” respectively. About Einride Founded in 2016, Einride is a technology company that develops and operates digital, electric, and autonomous freight solutions, accelerating the transition to future-proofed transportation. Its technology platform includes AI-powered planning and optimization, autonomous technologies, one of the world's largest electric heavy-duty fleets, and charging infrastructure. Einride serves customers across North America, Europe, and the Middle East.  About Legato Merger Corp. III: Legato is a blank check company organized for the purpose of effecting a merger, capital stock exchange, asset acquisition or other similar business combination with one or more businesses or entities. Forward-Looking Statements This communication contains certain “forward-looking statements” within the meaning of U.S. federal securities laws including, but not limited to, statements regarding the additional investments and Transaction. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are based on current expectations and assumptions available to the Company and Legato, and, as a result, are subject to risks and uncertainties. Any such expectations and assumptions, whether or not identified in this communication, should be regarded as preliminary and for illustrative purposes only and should not be relied upon as being necessarily indicative of future results. Many factors could cause actual future events to differ materially from the forward-looking statements in this communication, including but not limited to: (1) the occurrence of any event, change or other circumstances that could give rise to the termination of definitive agreements with respect to the Transaction; (2) the outcome of any legal proceedings that may be instituted against Legato, Einride, the combined company or others following the announcement of the Transaction and any definitive agreements with respect thereto; (3) The inability to complete the Transaction due to the failure to satisfy conditions to closing the Transaction; (4) risks related to the scaling of the Company’s business and the timing of expected business milestones; (5) the ability to meet stock exchange listing standards following the consummation of the Transaction; (6) the risk that the Transaction disrupts current plans and operations of the Company as a result of the announcement and consummation of the Transaction; (7) the ability to recognize the anticipated benefits of the business combination, which may be affected by, among other things, competition, the ability of the combined company to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (8) costs related to the Transaction; (9) risks associated with changes in laws or regulations applicable to operations; (10) the possibility that the Company or the combined company may be adversely affected by other economic, geopolitical, business, and/or competitive factors; (11) supply shortages in the materials necessary for the production of Einride’s solutions; (12) negative perceptions or publicity of the Company; (13) risks related to working with third-party manufacturers for key components of Einride’s solutions; (14) the termination or suspension of any of Einride’s contracts or the reduction in counterparty spending; and (15) the ability of Einride or the combined company to issue equity or equity- linked securities in connection with the business combination or in the future. Forward-looking statements are not guarantees of future performance. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of the Company’s registration statement on Form F-4 (“Registration Statement”) filed with the U.S. Securities and Exchange Commission (the “SEC”), and other documents filed by the Company and/or Legato from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward- looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and all forward-looking statements in this communication are qualified by these cautionary statements. The Company and Legato assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except to the extent required by applicable law. Neither the Company nor Legato gives any assurance that either the Company or Legato will achieve its expectations. The inclusion of any statement in this communication does not constitute an admission by the Company or Legato or any other person that the events or circumstances described in such statement are material. Additional Information and Where to Find It In connection with the Transaction, the Company filed the Registration Statement, including a preliminary proxy statement/prospectus, which was declared effective by the SEC on May 14, 2026. This communication does not contain all the information that should be considered concerning the Transactions and is not intended to form the basis of any investment decision or any other decision in respect of the Transaction. Before making any investment decision, investors and shareholders of Legato are urged to read the Registration Statement, the proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC in connection with the Transaction as they become available because they will contain important information about the Transaction. Investors and shareholders will be able to obtain free copies of the Registration Statement, proxy statement/prospectus and all other relevant documents filed or that will be filed with the SEC by the Company or Legato through the website maintained by the SEC at www.sec.gov. In addition, the documents filed by Legato may be obtained by written request to Legato at Legato Merger Corp. III, 777 Third Avenue, 37th Floor, New York, NY 10017. No Offer or Solicitation This communication does not constitute an offer to sell or a solicitation of an offer to buy the securities of Legato, Einride or the combined company resulting from the Transaction, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of the Securities Act. This communication is restricted by law; it is not intended for distribution to, or use by any person in, any jurisdiction in where such distribution or use would be contrary to local law or regulation.

Inside information: Summa Defence Plc enters into a EUR 8 million bridge financing arrangement and updates its liquidity and working capital position

Summa Defence Plc           Company announcement, inside information          5 June 2026 at 4:30 p.m. EEST Summa Defence Plc (the “company”) has today entered into a loan agreement with Largus Holding AB concerning a bridge financing arrangement of EUR 8.0 million. Largus Holding AB is a Swedish privately owned investment company controlled by Erik Salén. Largus Holding AB forms part of the Salén investment sphere, a Swedish family-owned investment group with a long history of entrepreneurship, active ownership and long-term investments. The purpose of the financing is to strengthen the company’s short-term liquidity and working capital position and to support the stabilisation of the Group’s financing structure while the company prepares longer-term equity- and debt-based financing solutions. The loan will be made available to the company following the signing of the loan agreement. The loan carries an annual interest rate of 14 per cent, a set-up fee of 6 per cent of the principal amount and matures on 3 July 2026. The company may prepay the loan before maturity, subject to a prepayment penalty of 10 per cent of the principal amount repaid early. The loan agreement includes certain undertakings relating to the company’s use of the loan proceeds and future issuances of financial instruments. The bridge financing has been structured with the intention that it may be converted into a convertible bond. Subject to the approval of the required authorisation by the Annual General Meeting on 24 June 2026 for the Board of Directors of the company, the agreement between the parties and applicable corporate and regulatory requirements, the loan, accrued interest and set-up fee may be converted into convertible bonds or otherwise set off against shares at a subscription or conversion price of EUR 0.20 per share. If the loan is converted into a convertible bond, the maturity date would be on or about 31 March 2027. If the Annual General Meeting does not approve the required authorisation or if the Board of Directors of the company has not directed the convertible bond for subscription by Largus Holding AB by 3 July 2026, the loan principal, accrued interest and set-up fee shall be repaid in cash by 4 July 2026. As previously announced, without new financing or payment arrangements, the company’s current working capital is not sufficient for its needs for the next 12 months. Following the bridge financing, and provided that the loan is drawn down as planned, the company expects its short-term liquidity position and working capital to improve materially and estimates that the financing will cover the company’s liquidity and working capital needs for approximately three to five months, depending on delivery schedules and the implementation of payment, financing and operational measures. The bridge financing is expected to address the company’s immediate liquidity situation, but it does not remove the company’s need to complete a longer-term financing solution. As part of such longer-term financing solution, the company intends to prepare a rights issue, subject to the authorisations proposed to the Annual General Meeting, market conditions and separate resolutions by the Board of Directors of the company. The current intention of the Board of Directors is that the subscription price in the contemplated rights issue would correspond to the subscription or conversion price of EUR 0.20 per share contemplated under the possible convertible bond arrangement. If the required financing, payment arrangements and operational measures cannot be implemented as planned or to a sufficient extent, this may have a material adverse effect on the company’s business operations, financial position, liquidity and ability to continue as a going concern. The company will communicate further information as the preparations progress. SUMMA DEFENCE PLCBoard of Directors Further information:Robert Blumberg, CEOPhone: +358 40 839 7408Email: robert.blumberg@summadefence.com Summa Defence in brief Summa Defence Plc is a Finnish defence and security technology group whose mission is to create a strong industrial foundation of innovative defence and dual use SMEs for strengthening the comprehensive security of society. Summa Defence aims for both organic and inorganic growth across three focus areas: maritime technologies, land technologies and new technologies. The company’s vision is to be a forerunner in comprehensive security industry. The shares of Summa Defence Plc are listed on the Nasdaq First North Growth Market in Sweden (SUMMAS) and Finland (SUMMA). www.summadefence.fi/en/ The company’s Certified Adviser is Augment Partners AB, info@augment.se, tel. +46 8 604 2255.

Episurf Medical acquires a mixed property portfolio of 30 properties in Södermanland and Östergötland with an agreed property value of SEK 920 mn from Livi Fastigheter AB

The acquisition in brief Episurf has entered into an agreement to acquire all shares in Grännäs Fastigheter Holding AB, reg. no. 559572-2470, and Goldcup 39848 AB, reg. no. 559585-9330, from Livi Fastigheter AB. The property portfolio comprises 30 properties and constitutes a mixed portfolio of residential properties and LSS housing. The lettable area amounts to approximately 51,000 sqm. The total agreed property value amounts to SEK 920 mn, with a possible deferred consideration of SEK 25 mn based on the occupancy rate at closing. Payment of the purchase price The purchase price is financed through an issue of B-shares of SEK 200 mn at a price of SEK 0.10 per B-share, a convertible loan of SEK 66.5 mn with a 24-month maturity and interest of STIBOR + 1.75 percent, and financing from banks and credit institutions. The conversion price is determined by the time at which conversion is called: SEK 0.11 per B-share during the first six months, SEK 0.12 per B-share during the following twelve months and SEK 0.13 per B-share during the final six months. The buyer is entitled to call for conversion during the final six-month period. Dilution The issue of B-shares and conversion of the convertible loan may result in dilution for existing shareholders of up to approximately 59 percent based on the current number of registered shares. Calculated on all issued and contracted shares prior to the acquisition (fully diluted basis), the dilution amounts to approximately 7 percent. Background and rationale On 30 December 2025, Episurf's board of directors announced that the Company had decided to acquire property companies to broaden its operations and strengthen its financial position. Episurf has since entered into agreements to acquire Frusipe Intressenter Target 1 AB, KlaraBo Empire Holding AB, Mofast Invest II AB, a property portfolio from Botrygg AB, a property portfolio from Lilium, two smaller properties from HanssonGruppen and a property portfolio from Setune Assets AB in Uppsala. With the acquisition of the property portfolio from Livi Fastigheter, Episurf continues to build its Nordic property platform with a focus on cash flow and return. Based on already signed property acquisitions, the annual rental income of Episurf's property segment is expected, on a pro forma basis following the acquisition, to increase from approximately SEK 357 mn to approximately SEK 439 mn, and total property assets from approximately SEK 4,319 mn to approximately SEK 5,264 mn. Key figures for the property portfolio The property portfolio has an agreed property value of SEK 920 mn, a lettable area of approximately 51,000 sqm and net operating income (NOI) of SEK 57 mn, corresponding to an NOI yield of approximately 6.2 percent. Annual rental income amounts to approximately SEK 77.7 mn. The occupancy rate amounts to approximately 95%. For further information, please contact: Jens Andersson, CEO, Episurf Medical Email: jens.andersson@episurf.com About Episurf Medical Episurf Medical is a property company with exposure to a diversified portfolio of property assets. The Company's objective is to create value growth through the acquisition and management of Nordic properties. The Company also has a medical technology operation based on the individualized implant Episealer® and associated surgical instruments, which are used to treat cartilage injuries in joints. Episurf Medical's head office is in Stockholm, Sweden. This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation 596/2014. The information was submitted for publication, through the agency of the contact person set out above, at 16:30 CET on 5 June 2026. THIS PRESS RELEASE HAS BEEN PUBLISHED IN SWEDISH AND ENGLISH. IN THE EVENT OF ANY DISCREPANCY BETWEEN THE LANGUAGE VERSIONS, THE SWEDISH VERSION SHALL PREVAIL.

Klaria receives 25 MSEK in loan financing with the possibility of an additional 15 MSEK

The purpose of the bridge loan is to strengthen Klaria's financial flexibility during the ongoing process that the Company is conducting together with BDO London to access all available markets around the world.  Klaria would also like to highlight that the preparatory activities ahead of CNX Therapeutics' expected launch of Sumatriptan Alginate Film in Europe are progressing according to plan, including ongoing large-scale manufacturing of the product. In addition, the market for migraine treatment continues to grow, and Klaria believes that the Company's product has a good opportunity to take a very strong position in the treatment of acute migraine – completely replacing many of the existing sumatriptan products. "This financing significantly strengthens our flexibility, thus creating stability during the process we are now conducting together with BDO. At the same time, we continue to progress towards the market launch of Sumatriptan Alginate Film in Europe together with our licensing partner CNX Therapeutics. The product's unique advantages in the form of an overall lower dose and rapid and reliable delivery of the sumatriptan to the bloodstream with much lower variability mean that we see the perfect conditions to establish a very strong penetration in the large and growing worldwide market for acute migraine treatment," says Klaria's Chairman of the Board Fredrik Hübinette. The bridge loan will be disbursed immediately and runs up until May 27 2027. The loan has an arrangement fee of 1,5 MSEK, and a fixed interest rate for the loan period of 30-day Stibor +1.5 percentage points.

Nel ASA: Settlement agreement with Iwatani Corporation of America

(June 6, 2026 – Oslo, Norway) Reference is made to the press release dated February 7, 2024, in which Nel ASA (Nel, OSE: NEL) announced that Iwatani Corporation of America had filed a lawsuit against Nel and certain entities that were, at the time, part of the Nel group, in connection with agreements for the delivery of fueling equipment and services. Besides Nel, the defendants included entities that are now part of Cavendish Hydrogen ASA (Cavendish Hydrogen, OSE: CAVEN), as well as four individuals. Iwatani, Nel, and Cavendish Hydrogen have resolved their dispute, and related lawsuit, involving Iwatani’s hydrogen fueling stations in California. The dispute arose from technical and operational challenges in a developing industry and has been resolved amicably and in the best interests of all parties. With the issues now resolved to each party’s satisfaction, Iwatani, Nel, and Cavendish can confidently affirm each other’s continuing commitment to advancing the hydrogen fueling industry and remain open to future collaboration. The settlement amount for Nel ASA is USD 7.5 million. The settlement eliminates further legal costs and mitigates litigation risk in the US. ENDS  For additional information, please contact:Kjell Christian Bjørnsen, CFO, +47 917 02 097Wilhelm Flinder, Head of IR, Communications and Marketing, +47 936 11 350 About Nel ASA | www.nelhydrogen.comNel has a history tracing back to 1927 and is today a leading pure play hydrogen technology company with a global presence. The company specializes in PEM and Alkaline electrolyser technology for production of renewable hydrogen. Nel's product offerings are key enablers for a green hydrogen economy, making it possible to decarbonize various industries such as transportation, refining, steel, and ammonia. This information is subject to a duty of disclosure pursuant to Section 5-12 of the Norwegian Securities Trading Act. This information was issued as inside information pursuant to the EU Market Abuse Regulation, and was published by Wilhelm Flinder, Head of Investor Relations, Communications and Marketing, at Nel ASA on the date and time provided.